<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Beta‐blockers in patients without heart failure after myocardial infarction - Safi, S - 2021 | Cochrane Library</title> <meta content="Beta‐blockers in patients without heart failure after myocardial infarction - Safi, S - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012565.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Beta‐blockers in patients without heart failure after myocardial infarction - Safi, S - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012565.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012565.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Beta‐blockers in patients without heart failure after myocardial infarction" name="citation_title"/> <meta content="Sanam Safi" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="sanam.safi@ctu.dk" name="citation_author_email"/> <meta content="Naqash J Sethi" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Steven Kwasi Korang" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Emil Eik Nielsen" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Joshua Feinberg" name="citation_author"/> <meta content="The Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Janus C Jakobsen" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD012565.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/11/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012565.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012565.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012565.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cause of Death; *Heart Failure [drug therapy]; *Myocardial Infarction [complications, drug therapy]; Quality of Life; Stroke Volume; Ventricular Function, Left" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012565.pub2&amp;doi=10.1002/14651858.CD012565.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="PSzzz2OT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012565\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012565\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012565.pub2",title:"Beta\\u2010blockers in patients without heart failure after myocardial infarction",firstPublishedDate:"Nov 5, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012565.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012565.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012565.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012565.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012565.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012565.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012565.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012565.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012565.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012565.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4602 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012565.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-sec-0119"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-sec-0016"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-sec-0092"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/appendices#CD012565-sec-0124"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/supinfo/CD012565StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/supinfo/CD012565StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Beta‐blockers in patients without heart failure after myocardial infarction</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/information#CD012565-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Sanam Safi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/information#CD012565-cr-0005">Naqash J Sethi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/information#CD012565-cr-0006">Steven Kwasi Korang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/information#CD012565-cr-0007">Emil Eik Nielsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/information#CD012565-cr-0008">Joshua Feinberg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/information#CD012565-cr-0009">Christian Gluud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012565.pub2/information#CD012565-cr-0010">Janus C Jakobsen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/information/en#CD012565-sec-0136">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 November 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012565.pub2">https://doi.org/10.1002/14651858.CD012565.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012565-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012565-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012565-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012565-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012565-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012565-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012565-abs-0001" lang="en"> <section id="CD012565-sec-0001"> <h3 class="title" id="CD012565-sec-0001">Background</h3> <p>Cardiovascular disease is the number one cause of death globally. According to the World Health Organization (WHO), 7.4 million people died from ischaemic heart disease in 2012, constituting 15% of all deaths. Beta‐blockers are recommended and are often used in patients with heart failure after acute myocardial infarction. However, it is currently unclear whether beta‐blockers should be used in patients without heart failure after acute myocardial infarction. Previous meta‐analyses on the topic have shown conflicting results. No previous systematic review using Cochrane methods has assessed the effects of beta‐blockers in patients without heart failure after acute myocardial infarction. </p> </section> <section id="CD012565-sec-0002"> <h3 class="title" id="CD012565-sec-0002">Objectives</h3> <p>To assess the benefits and harms of beta‐blockers compared with placebo or no treatment in patients without heart failure and with left ventricular ejection fraction (LVEF) greater than 40% in the non‐acute phase after myocardial infarction. </p> </section> <section id="CD012565-sec-0003"> <h3 class="title" id="CD012565-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, LILACS, Science Citation Index ‐ Expanded, BIOSIS Citation Index, the WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, European Medicines Agency, Food and Drug Administration, Turning Research Into Practice, Google Scholar, and SciSearch from their inception to February 2021. </p> </section> <section id="CD012565-sec-0004"> <h3 class="title" id="CD012565-sec-0004">Selection criteria</h3> <p>We included all randomised clinical trials assessing effects of beta‐blockers versus control (placebo or no treatment) in patients without heart failure after myocardial infarction, irrespective of publication type and status, date, and language. We excluded trials randomising participants with diagnosed heart failure at the time of randomisation. </p> </section> <section id="CD012565-sec-0005"> <h3 class="title" id="CD012565-sec-0005">Data collection and analysis</h3> <p>We followed our published protocol, with a few changes made, and methodological recommendations provided by Cochrane and Jakobsen and colleagues. Two review authors independently extracted data. Our primary outcomes were all‐cause mortality, serious adverse events, and major cardiovascular events (composite of cardiovascular mortality and non‐fatal myocardial reinfarction). Our secondary outcomes were quality of life, angina, cardiovascular mortality, and myocardial infarction during follow‐up. We assessed all outcomes at maximum follow‐up. We systematically assessed risks of bias using seven bias domains and we assessed the certainty of evidence using the GRADE approach. </p> </section> <section id="CD012565-sec-0006"> <h3 class="title" id="CD012565-sec-0006">Main results</h3> <p>We included 25 trials randomising a total of 22,423 participants (mean age 56.9 years). All trials and outcomes were at high risk of bias. In all, 24 of 25 trials included a mixed group of participants with ST‐elevation myocardial infarction and non‐ST myocardial infarction, and no trials provided separate results for each type of infarction. One trial included participants with only ST‐elevation myocardial infarction. All trials except one included participants younger than 75 years of age. Methods used to exclude heart failure were various and were likely insufficient. A total of 21 trials used placebo, and four trials used no intervention, as the comparator. All patients received usual care; 24 of 25 trials were from the pre‐reperfusion era (published from 1974 to 1999), and only one trial was from the reperfusion era (published in 2018). The certainty of evidence was moderate to low for all outcomes. </p> <p>Our meta‐analyses show that beta‐blockers compared with placebo or no intervention probably reduce the risks of all‐cause mortality (risk ratio (RR) 0.81, 97.5% confidence interval (CI) 0.73 to 0.90; I² = 15%; 22,085 participants, 21 trials; moderate‐certainty evidence) and myocardial reinfarction (RR 0.76, 98% CI 0.69 to 0.88; I² = 0%; 19,606 participants, 19 trials; moderate‐certainty evidence). Our meta‐analyses show that beta‐blockers compared with placebo or no intervention may reduce the risks of major cardiovascular events (RR 0.72, 97.5% CI 0.69 to 0.84; 14,994 participants, 15 trials; low‐certainty evidence) and cardiovascular mortality (RR 0.73, 98% CI 0.68 to 0.85; I² = 47%; 21,763 participants, 19 trials; low‐certainty evidence). Hence, evidence seems to suggest that beta‐blockers versus placebo or no treatment may result in a minimum reduction of 10% in RR for risks of all‐cause mortality, major cardiovascular events, cardiovascular mortality, and myocardial infarction. However, beta‐blockers compared with placebo or no intervention may not affect the risk of angina (RR 1.04, 98% CI 0.93 to 1.13; I² = 0%; 7115 participants, 5 trials; low‐certainty evidence). </p> <p>No trials provided data on serious adverse events according to good clinical practice from the International Committee for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH‐GCP), nor on quality of life. </p> </section> <section id="CD012565-sec-0007"> <h3 class="title" id="CD012565-sec-0007">Authors' conclusions</h3> <p>Beta‐blockers probably reduce the risks of all‐cause mortality and myocardial reinfarction in patients younger than 75 years of age without heart failure following acute myocardial infarction. Beta‐blockers may further reduce the risks of major cardiovascular events and cardiovascular mortality compared with placebo or no intervention in patients younger than 75 years of age without heart failure following acute myocardial infarction. These effects could, however, be driven by patients with unrecognised heart failure. The effects of beta‐blockers on serious adverse events, angina, and quality of life are unclear due to sparse data or no data at all. All trials and outcomes were at high risk of bias, and incomplete outcome data bias alone could account for the effect seen when major cardiovascular events, angina, and myocardial infarction are assessed. The evidence in this review is of moderate to low certainty, and the true result may depart substantially from the results presented here. Future trials should particularly focus on patients 75 years of age and older, and on assessment of serious adverse events according to ICH‐GCP and quality of life. Newer randomised clinical trials at low risk of bias and at low risk of random errors are needed if the benefits and harms of beta‐blockers in contemporary patients without heart failure following acute myocardial infarction are to be assessed properly. Such trials ought to be designed according to the SPIRIT statement and reported according to the CONSORT statement. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012565-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012565-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012565-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012565-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012565-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012565-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012565-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012565-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012565-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012565-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012565-abs-0002" lang="en"> <h3>Benefits and harms of beta‐blockers versus placebo or no intervention in the non‐acute phase of a myocardial infarction </h3> <p><b>Background</b> </p> <p>According to the World Health Organization, 7.4 million people died from ischaemic heart disease in 2012. This represents 15% of all global deaths. Patients with a heart attack but without heart failure may receive beta‐blockers as non‐acute treatment. Beta‐blockers inhibit beta‐receptors. This can result in a reduction in oxygen needed by the heart and may reduce complications associated with a heart attack. </p> <p><b>Study characteristics</b> </p> <p>We searched scientific databases from their beginning to February 2021 and found 25 randomised clinical trials. People had the same chance to be allocated to groups receiving beta‐blockers or control. In 21 trials, the control was a placebo. In four trials, the control was no intervention. Trials included 22,423 adults with mean age of 56.9 years (range 50 to 63 years). </p> <p><b>Key results</b> </p> <p>Patients without heart failure after a heart attack receiving beta‐blockers compared with placebo or no intervention probably have lower risk of death and of a new heart attack and may have reduced risk of major cardiovascular events and death of any heart‐related cause, but likely not of angina pectoris. The effects of beta‐blockers on serious adverse events and on quality of life were uncertain due to lack of data. </p> <p><b>Certainty of evidence</b> </p> <p>The evidence should be interpreted with caution, as certainty was judged to be moderate to low for all outcomes. Reasons mainly include high risk of bias for all included trials, limitations in design and execution, and risk of random error. This means that results might overestimate the beneficial effects of beta‐blockers and underestimate the harmful effects. Therefore, the above mentioned results may change in the future, after additional well‐designed randomised clinical trials are conducted. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012565-sec-0119" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012565-sec-0119"></div> <h3 class="title" id="CD012565-sec-0120">Implications for practice</h3> <section id="CD012565-sec-0120"> <p>Beta‐blockers probably reduce risks of all‐cause mortality and myocardial reinfarction compared with placebo or no intervention in patients younger than 75 years of age without heart failure following acute myocardial infarction. Beta‐blockers may further reduce the risks of major cardiovascular events and cardiovascular mortality compared with placebo or no intervention in patients younger than 75 years of age without heart failure following acute myocardial infarction. However, these effects could be driven by patients with unrecognised heart failure. The effects of beta‐blockers on serious adverse events, angina, and quality of life are unclear due to sparse data or no data at all. All trials and outcomes were at high risk of bias, and incomplete outcome data bias alone could account for the effects seen when major cardiovascular events, angina, and myocardial infarction were assessed. The evidence in this review is of moderate to low certainty, and the true result may depart substantially from the results presented here. </p> </section> <h3 class="title" id="CD012565-sec-0121">Implications for research</h3> <section id="CD012565-sec-0121"> <p>Due to a paradigm shift in the management of acute myocardial infarction, future trials should revisit the beta‐blocker hypothesis in the post‐reperfusion era for patients without heart failure and with preserved LVEF. These trials should particularly focus on assessing serious adverse events according to ICH‐GCP and quality of life. Furthermore, future trials ought to assess effects of beta‐blockers on older patients (e.g. 75 years of age and older) and should use standard high‐quality measures to exclude participants with heart failure before randomisation. With regard to blinding, the effects of beta‐blockers on pulse rate make these trials difficult to blind, and blinded outcome assessors should therefore be widely involved. Newer randomised clinical trials at low risk of bias and at low risk of random error are needed if the benefits and harms of beta‐blockers in patients without heart failure following acute myocardial infarction are to be assessed properly. Such trials ought to be designed according to the SPIRIT statement and reported according to the CONSORT statement (<a href="./references#CD012565-bbs2-0049" title="Chan A-W, TetzlaffJM , AltmanDG , LaupacisA , GøtzschePC , Krleža-JerićK , et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Annals of Internal Medicine2013;158(3):200-7.">Chan 2013</a>; <a href="./references#CD012565-bbs2-0125" title="SchulzKF , AltmanDG , MoherD , CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Annals of Internal Medicine2010;152(11):726-32.">Schulz 2010</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012565-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012565-sec-0008"></div> <div class="table" id="CD012565-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings at maximum follow‐up</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beta‐blockers compared with placebo or no intervention for patients after an acute myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients without heart failure </p> <p><b>Settings:</b> any setting </p> <p><b>Intervention:</b> beta‐blockers </p> <p><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo or no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Beta‐blockers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality at maximum follow‐up</b> (mean follow‐up 24.9 months; range 9 to 60 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.81</b> </p> <p>97.5% CI (0.73 to 0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>22,085</p> <p>(21 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup> </sup><br/><b>Moderate</b><sup>a</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Absolute risk for mortality at maximum follow‐up was 8.7% in the beta‐blocker group compared with 10.9% in the control group, and the NNT was 46 participants </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b><br/>(81 to 97) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major cardiovascular events (cardiovascular mortality or non‐fatal myocardial infarction) at maximum follow‐up</b> (mean follow‐up 26.3 months; range 9 to 48 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.72</b> </p> <p>97.5% CI (0.62 to 0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14,994</p> <p>(15 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<sup> </sup><br/>L<b>ow</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Absolute risk for major cardiovascular events at maximum follow‐up was 10.3% in the beta‐blocker group compared with 14.0% in the control group, and the NNT was 23 participants </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>140 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>103 per 1000</b><br/>(97 to 118) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events at maximum follow‐up</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported serious adverse events according to ICH‐GCP</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported quality of life on a continuous or any other scale</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Angina pectoris at maximum follow‐up</b> (mean follow‐up 10 months; range 12 to 47 months) </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.04</b> </p> <p>98% CI (0.95 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7715</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<sup> </sup><br/>L<b>ow</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Absolute risk for angina at maximum follow‐up was 26.4% in the beta‐blocker group compared with 25.6% in the control group, and the NNT was 125 participants </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>256 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>264 per 1000</b><br/>(238 to 289) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular mortality at maximum follow‐up</b> (mean follow‐up 28.8 months; range 9 to 48 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.73</b> </p> <p>98% CI (0.61 to 0.88)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>21,763</p> <p>(19 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<sup> </sup><br/>L<b>ow</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Absolute risk for cardiovascular mortality at maximum follow‐up was 6.0% in the beta‐blocker group compared with 8.0% in the control group, and the NNT was 50 participants </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b><br/>(54 to 68) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Myocardial infarction at maximum follow‐up</b> (mean follow‐up 33.3 months; range 9 to 48 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.76</b> </p> <p>98% CI (0.67 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>19,606</p> <p>(19 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup> </sup><br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Absolute risk for myocardial infarction at maximum follow‐up was 5.9% in the beta‐blocker group compared with 7.8% in the control group, and the NNT was 53 participants </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b><br/>(54 to 69) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 97.5% or 98% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 97.5% or 98% CI).<br/><b>CI:</b> confidence interval; <b>ICH‐GCP:</b> International Committee for Harmonization of Technical Requirements for Pharmaceuticals for Human Use; <b>NNT:</b> number needed to treat; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to risk of bias. All included trials were at high risk of bias due to unclear or high risk in several bias domains. None of the included trials were at low risk of bias. </p> <p><sup>b</sup>Downgraded by one level due to risk of inconsistency based on a moderate I²(30% to 60%) with a small P value (P &lt; 0.05) when the statistical test was assessed for heterogeneity. </p> <p><sup>c</sup>Downgraded by one level due to risk of imprecision based on optimal information size not being reached, absolute and relative 98% CIs showing both appreciable benefit and harm, and sample size being small. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012565-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012565-sec-0009"></div> <section id="CD012565-sec-0010"> <h3 class="title" id="CD012565-sec-0010">Description of the condition</h3> <p>Cardiovascular disease is the number one cause of death globally (<a href="./references#CD012565-bbs2-0052" title="CooperR , CutlerJ , Desvigne-NickensP , FortmannSP , FriedmanL , HavlikR , et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation2000;102(25):3137-47. [PMID: 11120707]">Cooper 2000</a>; <a href="./references#CD012565-bbs2-0093" title="Lloyd-JonesD , AdamsRJ , BrownTM , CarnethonM , DaiS , De SimoneG , et al. Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation2010;121(7):948-54. [PMID: 20177011]">Lloyd‐Jones 2010</a>; <a href="./references#CD012565-bbs2-0105" title="NicholsM , TownsendN , ScarboroughP , RaynerM . Cardiovascular disease in Europe 2014: epidemiological update. European Heart Journal2014;35(42):2950-9. [PMID: 25139896]">Nichols 2014</a>; <a href="./references#CD012565-bbs2-0116" title="RosamondW , FlegalK , FurieK , GoA , GreenlundK , HaaseN , et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation2008;117(4):e25-146. [PMID: 18086926]">Rosamond 2008</a>; <a href="./references#CD012565-bbs2-0123" title="SchmidtM , JacobsenJB , LashTL , BotkerHE , SorensenHT . 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ (Clinical Research Ed)2012;344:e356. [PMID: 22279115]">Schmidt 2012</a>). Ischaemic heart disease accounts for almost 50% of the disease burden of the cardiovascular diseases (<a href="./references#CD012565-bbs2-0105" title="NicholsM , TownsendN , ScarboroughP , RaynerM . Cardiovascular disease in Europe 2014: epidemiological update. European Heart Journal2014;35(42):2950-9. [PMID: 25139896]">Nichols 2014</a>). According to the World Health Organization (WHO), 7.4 million people died from ischaemic heart disease in 2012 (<a href="./references#CD012565-bbs2-0145" title="World Health Organization (WHO). Cardiovascular disease. www.who.int/cardiovascular_diseases/en/ (date accessed 7 February 2017). January 2015.">WHO 2015</a>). </p> <p>Ischaemic heart disease is caused by different underlying mechanisms: (1) atherosclerotic plaque‐related obstruction of the coronary arteries; (2) focal or diffuse spasms of normal or plaque‐diseased arteries; (3) microvascular dysfunction; or (4) left ventricular dysfunction caused by acute myocardial necrosis or ischaemic cardiomyopathy (<a href="./references#CD012565-bbs2-0103" title="MontalescotG , SechtemU , AchenbachS , AndreottiF , ArdenC , BudajA . 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal2013;34(38):2949-3003.">Montalescot 2013</a>). Ischaemic heart disease increases risks of stable angina pectoris (see later) and of acute coronary syndrome (see later). </p> <p>Stable angina pectoris is defined as episodes of reversible myocardial demand or supply mismatch leading to ischaemia or hypoxia of the heart muscle. These processes lead to transient chest discomfort or pain that is precipitated by activities such as walking, or by emotion or stress, with no to minimal symptoms at rest and with beneficial effects of sublingual nitroglycerin on pain (<a href="./references#CD012565-bbs2-0103" title="MontalescotG , SechtemU , AchenbachS , AndreottiF , ArdenC , BudajA . 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal2013;34(38):2949-3003.">Montalescot 2013</a>). </p> <p>Acute coronary syndrome is a collective term for (1) unstable angina pectoris (chest pain during rest related to ischaemia or hypoxia of the heart muscle (<a href="./references#CD012565-bbs2-0115" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>)); (2) non‐ST‐elevation myocardial infarction (NSTEMI); or (3) ST‐elevation myocardial infarction (STEMI) (<a href="./references#CD012565-bbs2-0115" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>; <a href="./references#CD012565-bbs2-0129" title="StegPG , JamesSK , AtarD , BadanoLP , Blomstrom-LundqvistC , BorgerMA , et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal2012;33(20):2569-619.">Steg 2012</a>). Myocardial infarction is caused by death of cardiac myocytes (myocardial necrosis) due to ischaemia (<a href="./references#CD012565-bbs2-0108" title="O'GaraPT , KushnerFG , AscheimDD , CaseyDE , ChungMK , deLemosJA , et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology2013;61(4):104.">O'Gara 2013</a>; <a href="./references#CD012565-bbs2-0129" title="StegPG , JamesSK , AtarD , BadanoLP , Blomstrom-LundqvistC , BorgerMA , et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal2012;33(20):2569-619.">Steg 2012</a>). Myocardial infarction is clinically defined as elevated serum levels of cardiac biomarkers (cardiac‐specific troponins and the myocardial band (MB) isoenzyme of creatine kinase (CK‐MB) among others) and changes in the ST‐segment on an electrocardiogram (ECG) (STEMI and NSTEMI) or symptoms of cardiac ischaemia (<a href="./references#CD012565-bbs2-0115" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>; <a href="./references#CD012565-bbs2-0129" title="StegPG , JamesSK , AtarD , BadanoLP , Blomstrom-LundqvistC , BorgerMA , et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal2012;33(20):2569-619.">Steg 2012</a>). </p> <p>Diagnosis of myocardial infarction is dependent on elevation of serum levels of cardiac‐specific troponin I, troponin T, or CK‐MB, among others (<a href="./references#CD012565-bbs2-0115" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>; <a href="./references#CD012565-bbs2-0129" title="StegPG , JamesSK , AtarD , BadanoLP , Blomstrom-LundqvistC , BorgerMA , et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal2012;33(20):2569-619.">Steg 2012</a>). However, these enzymes often are not detectable before 8 to 24 hours after the first symptoms of myocardial infarction. Beta‐blockers accordingly may be commenced as an intervention for people with suspected myocardial infarction or may be commenced as an intervention for people with confirmed diagnosis of myocardial infarction at a later time. </p> <p>Pathologically, the classification of myocardial infarction is based on size (microscopic (focal necrosis) ‐ small (10% of the left ventricular myocardium), moderate (10% to 30% of the left ventricular myocardium), or large (&gt; 30% of the left ventricular myocardium)) ‐ and on location (anterior, lateral, inferior, posterior, septal, or a combination of locations) (<a href="./references#CD012565-bbs2-0136" title="ThygesenK , AlpertJS , WhiteHD . Universal definition of myocardial infarction. European Heart Journal2007;28(20):2525-38. [PMID: 17951287]">Thygesen 2007</a>). </p> <p>Furthermore, the pathological appearance can be used to classify the temporal development of myocardial infarction as evolving (&lt; 6 hours), acute (6 hours to 7 days), healing (7 days to 28 days), or healed (&gt; 4 weeks) (<a href="./references#CD012565-bbs2-0136" title="ThygesenK , AlpertJS , WhiteHD . Universal definition of myocardial infarction. European Heart Journal2007;28(20):2525-38. [PMID: 17951287]">Thygesen 2007</a>; <a href="./references#CD012565-bbs2-0139" title="ThygesenK , JaffeAS . Our nearly complete diagnostic trip of thousands of steps begets a new trip therapeutically. European Heart Journal2020;41(23):2217-9. [PMID: 32206809]">Thygesen 2020</a>). </p> <p>An acute myocardial infarction occurring <i>within</i> 28 days of the first episode of myocardial infarction is defined as a reinfarction; a myocardial infarction occurring <i>after</i> 28 days of the first episode of the event is defined as a recurrent myocardial infarction (<a href="./references#CD012565-bbs2-0100" title="MendisS , ThygesenK , KuulasmaaK , GiampaoliS , MähönenM , Ngu BlackettK , et al. World Health Organization definition of myocardial infarction: 2008-09 revision. International Journal of Epidemiology2011;40(1):139-46. [PMID: 20926369]">Mendis 2011</a>). </p> <p>Clinically, the causes of myocardial infarction are generally divided into five main classes based on morphological changes in the coronary arteries and/or on clinical history (<a href="./references#CD012565-bbs2-0137" title="ThygesenK , AlpertJS , JaffeAS , SimoonsML , ChaitmanBR , WhiteHD . Third universal definition of myocardial infarction. Global Heart2012;7(4):275-95. [PMID: 25689940]">Thygesen 2012</a>; <a href="./references#CD012565-bbs2-0138" title="ThygesenK , AlpertJS , JaffeAS , ChaitmanBR , BaxJJ , MorrowDA , et al. Fourth universal definition of myocardial infarction. Journal of the American College of Cardiology2018;72(18):2231-64. [PMID: 30153967]">Thygesen 2018</a>). </p> <p> <ul id="CD012565-list-0001"> <li> <p>Type 1: spontaneous myocardial infarction related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection, with resulting intraluminal thrombus in one or more of the coronary arteries, often caused by coronary artery disease. </p> </li> <li> <p>Type 2: myocardial infarction secondary to an ischaemic imbalance such as coronary artery spasm, coronary embolism, anaemia, arrhythmia, hypertension, or hypotension. </p> </li> <li> <p>Type 3: myocardial infarction with symptoms suggestive of myocardial ischaemia and resulting in sudden unexpected cardiac death when biomarker values are unavailable or could not be obtained before death. </p> </li> <li> <p>Type 4a: myocardial infarction associated with percutaneous coronary intervention (PCI). </p> </li> <li> <p>Type 4b: myocardial infarction associated with stent thrombosis as documented by angiography or at autopsy. </p> </li> <li> <p>Type 5: myocardial infarction associated with coronary artery bypass graft (CABG).</p> </li> </ul> </p> <p>Major complications associated with myocardial infarction include the following.</p> <p> <ul id="CD012565-list-0002"> <li> <p>Life‐threatening ventricular arrhythmia caused by changes in electrophysiological characteristics of the myocyte, electrolyte imbalance, continuous ischaemia, and variations in heart rate ‐ all due to obstruction and hence reduced flow to the myocardium and myocardial necrosis (<a href="./references#CD012565-bbs2-0046" title="BriegerD , FoxKA , FitzgeraldG , EagleKA , BudajA , AvezumA , et al. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart (British Cardiac Society)2009;95(11):888-94.">Brieger 2009</a>; <a href="./references#CD012565-bbs2-0132" title="StevensonWG , LinssenGC , HavenithMG , BrugadaP , WellensHJ . The spectrum of death after myocardial infarction: a necropsy study. American Heart Journal1989;118(6):1182-8.">Stevenson 1989</a>). </p> </li> <li> <p>Mechanical complications caused by necrosis of the myocardium such as ventricular wall rupture, septum rupture, and papillary muscle rupture (<a href="./references#CD012565-bbs2-0046" title="BriegerD , FoxKA , FitzgeraldG , EagleKA , BudajA , AvezumA , et al. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart (British Cardiac Society)2009;95(11):888-94.">Brieger 2009</a>; <a href="./references#CD012565-bbs2-0110" title="Pohjola-SintonenS , MullerJE , StonePH , WillichSN , AntmanEM , DavisVG , et al. Ventricular septal and free wall rupture complicating acute myocardial infarction: experience in the Multicenter Investigation of Limitation of Infarct Size. American Heart Journal1989;117(4):809-18.">Pohjola‐Sintonen 1989</a>; <a href="./references#CD012565-bbs2-0132" title="StevensonWG , LinssenGC , HavenithMG , BrugadaP , WellensHJ . The spectrum of death after myocardial infarction: a necropsy study. American Heart Journal1989;118(6):1182-8.">Stevenson 1989</a>). </p> </li> <li> <p>Cardiogenic shock caused by failure of the ventricle to pump an adequate amount of blood, leading to systemic hypotension (<a href="./references#CD012565-bbs2-0046" title="BriegerD , FoxKA , FitzgeraldG , EagleKA , BudajA , AvezumA , et al. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart (British Cardiac Society)2009;95(11):888-94.">Brieger 2009</a>; <a href="./references#CD012565-bbs2-0132" title="StevensonWG , LinssenGC , HavenithMG , BrugadaP , WellensHJ . The spectrum of death after myocardial infarction: a necropsy study. American Heart Journal1989;118(6):1182-8.">Stevenson 1989</a>). </p> </li> <li> <p>Acute decompensated heart failure caused by impairment in systolic and diastolic function due to myocardial ischaemia (<a href="./references#CD012565-bbs2-0046" title="BriegerD , FoxKA , FitzgeraldG , EagleKA , BudajA , AvezumA , et al. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart (British Cardiac Society)2009;95(11):888-94.">Brieger 2009</a>). </p> </li> <li> <p>Depression (<a href="./references#CD012565-bbs2-0135" title="ThombsBD , BassEB , FordDE , StewartKJ , TsilidisKK , PatelU , et al. Prevalence of depression in survivors of acute myocardial infarction: review of the evidence. Journal of General Internal Medicine2006;21(1):30-8.">Thombs 2006</a>). </p> </li> </ul> </p> </section> <section id="CD012565-sec-0011"> <h3 class="title" id="CD012565-sec-0011">Description of the intervention</h3> <p>The discovery of the difference between adrenergic receptors by Raymond Ahlquist in 1948 led Sir James Black to develop the first clinically useful beta‐receptor blocker (propranolol) in 1964 (<a href="./references#CD012565-bbs2-0037" title="AhlquistRP . A study of the adrenotropic receptors. American Journal of Physiology1948;153(3):586-600. [PMID: 18882199]">Ahlquist 1948</a>; <a href="./references#CD012565-bbs2-0045" title="BlackJW , CrowtherAF , ShanksRG , SmithLH , DornhorstAC . A new adrenergic beta receptor antagonist. Lancet1964;1(7342):1080-1. [PMID: 14132613]">Black 1964</a>). This discovery was awarded the Nobel Prize in 1988 (<a href="./references#CD012565-bbs2-0112" title="QuirkeV . Theory into practice: James Black, receptor theory and the development of the beta-blockers at ICI, 1958-1978. Medical History2006;50(1):69-92.">Quirke 2006</a>). Beta‐blockers are classified as non‐selective beta‐blockers or selective beta‐blockers according to their selectivity for one of the three subtypes of beta‐receptors. </p> <p> <ul id="CD012565-list-0003"> <li> <p>The beta₁‐receptor is mainly located in:</p> <ul id="CD012565-list-0004"> <li> <p>the heart, where it induces positive chronotropic effects (increases heart rate) and positive inotropic effects (increases contractility of the myocardium); and </p> </li> <li> <p>in the kidneys, where activation of the beta₁‐receptor results in increased release of renin, which in turn increases blood pressure, among other effects (<a href="./references#CD012565-bbs2-0064" title="GolanDE , Tashjian AH Jr, ArmstrongEJ , ArmstrongAW . Principles of Pharmacology - The Pathophysiologic Basis of Drug Therapy. 3rd edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2012.">Golan 2012</a>; <a href="./references#CD012565-bbs2-0099" title="MarlinGE , KumanaCR , KayeCM , SmithDM , TurnerP . An investigation into the cardiac and pulmonary beta-adrenoceptor blocking activity of ICI 66,082 in man. British Journal of Clinical Pharmacology1975;2(2):151-7. [PMID: 1234497]">Marlin 1975</a>; <a href="./references#CD012565-bbs2-0126" title="SinghBN , NisbetHE , HarrisEA , WhitlockRM . A comparison of the actions of ICI66082 and propranolol on cardiac and peripheral beta-adrenoceptors. European Journal of Pharmacology1975;34(1):75-86. [PMID: 11998]">Singh 1975</a>). </p> </li> </ul> </li> <li> <p>The beta₂‐receptor is mainly located in smooth muscle cells, where it promotes relaxation; in skeletal muscle cells, where it promotes tremor and increased glycogenolysis; and in the liver, where it increases glycogenolysis (<a href="./references#CD012565-bbs2-0064" title="GolanDE , Tashjian AH Jr, ArmstrongEJ , ArmstrongAW . Principles of Pharmacology - The Pathophysiologic Basis of Drug Therapy. 3rd edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2012.">Golan 2012</a>). </p> </li> <li> <p>The beta₃‐receptor is mainly located in adipose tissue, where it primarily induces lipolysis (<a href="./references#CD012565-bbs2-0064" title="GolanDE , Tashjian AH Jr, ArmstrongEJ , ArmstrongAW . Principles of Pharmacology - The Pathophysiologic Basis of Drug Therapy. 3rd edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2012.">Golan 2012</a>). </p> </li> </ul> </p> <p>Beta‐blockers may be administered both intravenously and orally.</p> <p>Three different classes of beta‐blockers are available.</p> <p> <ul id="CD012565-list-0005"> <li> <p>First‐generation non‐selective beta‐blockers (e.g. propranolol, oxprenolol, sotalol, timolol), affecting all beta‐receptors. </p> </li> <li> <p>Second‐generation selective beta‐blockers (e.g. metoprolol, bisoprolol, acebutolol, atenolol, esmolol), mainly affecting the heart. </p> </li> <li> <p>Third‐generation beta‐blockers, which have combined non‐selective beta‐blocking effects and alpha‐blocking effects (e.g. carvedilol), affecting all beta‐receptors plus alpha‐receptors in the vessels, lowering blood pressure. </p> </li> </ul> </p> <p>Oral beta‐blockers may be used as secondary prevention, especially in the non‐acute phase, defined as more than seven days after an acute myocardial infarction (<a href="./references#CD012565-bbs2-0127" title="SmithSCJ , BenjaminEJ , BonowRO , BraunLT , CreagerMA , Franklin BA et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation2011;124:2458–73.">Smith 2011</a>). Furthermore, over the past few decades, in the so‐called reperfusion era, reperfusion strategies have played a central role in secondary prevention after a myocardial infarction (<a href="./references#CD012565-bbs2-0081" title="IbanazB , HeuschG , OvizeM , Van de WerfF . Evolving therapies for myocardial ischemia/reperfusion injury. Journal of the American College of Cardiology2015;65(14):1454-71. [PMID: 25857912]">Ibanaz 2015</a>; <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012481.pub2/references#CD012481-bbs2-0157" target="_blank">Roffi 2016</a>). </p> </section> <section id="CD012565-sec-0012"> <h3 class="title" id="CD012565-sec-0012">How the intervention might work</h3> <p>The beta‐receptor is an adrenergic Gs heterodimeric G‐protein‐coupled receptor located throughout the body. Beta‐receptors are stimulated by the sympathetic nervous system, with catecholamines epinephrine (adrenaline) and norepinephrine (noradrenaline) as their primary endogenous agonists. The role of non‐acute treatment with beta‐blockers in people with myocardial infarction rests on their inhibition of chronotropic and inotropic effects of the beta‐receptor, leading to lowering of intracellular levels of cyclic adenosine monophosphate and calcium (<a href="./references#CD012565-bbs2-0095" title="LubbeWF , PodzuweitT , OpieLH . Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. Journal of the American College of Cardiology1992;19(7):1622-33. [PMID: 1350597]">Lubbe 1992</a>). This may result in a reduction in heart rate, in cardiac contractility, and in systemic arterial pressure, thereby decreasing the oxygen demand of the heart, and consequently reducing ischaemic chest pain and improving left ventricular compliance (<a href="./references#CD012565-bbs2-0094" title="Lopez-SendonJ , SwedbergK , McMurrayJ , TamargoJ , MaggioniAP , DargieH , et al. Expert consensus document on beta-adrenergic receptor blockers. European Heart Journal2004;25(15):1341-62. [PMID: 15288162]">Lopez‐Sendon 2004</a>). Additionally, this inhibition of the beta‐receptor is thought to decrease recurrent ischaemia and might decrease the risk of life‐threatening ventricular arrhythmias and other complications associated with myocardial infarction by prolonging the ventricular refractory period (<a href="./references#CD012565-bbs2-0065" title="GrandiE , RipplingerCM . Antiarrhythmic mechanisms of beta blocker therapy. Pharmacological Research2019;146:104274. [PMID: 31100336]">Grandi 2019</a>; <a href="./references#CD012565-bbs2-0115" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>; <a href="./references#CD012565-bbs2-0129" title="StegPG , JamesSK , AtarD , BadanoLP , Blomstrom-LundqvistC , BorgerMA , et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal2012;33(20):2569-619.">Steg 2012</a>). </p> </section> <section id="CD012565-sec-0013"> <h3 class="title" id="CD012565-sec-0013">Why it is important to do this review</h3> <p>The prevalence of ischaemic heart disease is considerable, and former meta‐analyses have shown conflicting results (see later). According to the WHO, 7.4 million people died of ischaemic heart disease in 2012 (<a href="./references#CD012565-bbs2-0093" title="Lloyd-JonesD , AdamsRJ , BrownTM , CarnethonM , DaiS , De SimoneG , et al. Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation2010;121(7):948-54. [PMID: 20177011]">Lloyd‐Jones 2010</a>; <a href="./references#CD012565-bbs2-0105" title="NicholsM , TownsendN , ScarboroughP , RaynerM . Cardiovascular disease in Europe 2014: epidemiological update. European Heart Journal2014;35(42):2950-9. [PMID: 25139896]">Nichols 2014</a>; <a href="./references#CD012565-bbs2-0116" title="RosamondW , FlegalK , FurieK , GoA , GreenlundK , HaaseN , et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation2008;117(4):e25-146. [PMID: 18086926]">Rosamond 2008</a>; <a href="./references#CD012565-bbs2-0145" title="World Health Organization (WHO). Cardiovascular disease. www.who.int/cardiovascular_diseases/en/ (date accessed 7 February 2017). January 2015.">WHO 2015</a>). Therefore, the right treatment may result in a considerable reduction in disease burden and healthcare costs. </p> <p>The role of beta‐blockers in the present as well as in other clinical settings is still debated. </p> <p>Beta‐blockers used to be contraindicated in people with congestive heart failure (<a href="./references#CD012565-bbs2-0047" title="BristowMR . Beta-adrenergic receptor blockade in chronic heart failure. Circulation2000;101(5):558-69.">Bristow 2000</a>). Non‐selective combined alpha‐ and beta‐blockers are now a part of standard treatment for congestive heart failure (<a href="./references#CD012565-bbs2-0050" title="ChatterjeeS , Biondi-ZoccaiG , AbbateA , D'AscenzoF , CastagnoD , Van TassellB , et al. Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ (Clinical Research Ed)2013;346:f55. [PMID: 23325883]">Chatterjee 2013</a>; <a href="./references#CD012565-bbs2-0148" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDEJ , DraznerMH , et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation2013;128:e240–e327.">Yancy 2013</a>). Beta‐blockers are also considered an option for treatment of hypertension but are rarely used as first‐line treatment (<a href="./references#CD012565-bbs2-0098" title="ManciaG , FagardR , NarkiewiczK , RedonJ , ZanchettiA , BöhmM , et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal2013;34(28):2159-219.">Mancia 2013</a>). A recent Cochrane Review found that beta‐blockers were inferior when compared with other antihypertensive drugs (<a href="./references#CD012565-bbs2-0146" title="WiysongeCS , BradleyHA , VolminkJ , MayosiBM , MbewuA , OpieLH , et al. Beta-blockers for hypertension. Cochrane Database of Systematic Reviews2012;11:CD002003. [PMID: 23152211]">Wiysonge 2012</a>). Non‐selective beta‐blockers are used for treatment of anxiety due to their effects on decreasing tremor and tachycardia (<a href="./references#CD012565-bbs2-0140" title="TurnerSM , BeidelDC , JacobRG . Social phobia: a comparison of behavior therapy and atenolol. Journal of Consulting and Clinical Psychology1994;62(2):350-8. [PMID: 8201073]">Turner 1994</a>). </p> <p>Perioperative beta‐blockade for major non‐cardiac surgery in people with risk factors for ischaemic heart disease has been tested in several randomised clinical trials (<a href="./references#CD012565-bbs2-0041" title="BangaloreS , WetterslevJ , PraneshS , SawhneyS , GluudC , MesserliFH . Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet2008;372(9654):1962-76. [PMID: 19012955]">Bangalore 2008</a>; <a href="./references#CD012565-bbs2-0057" title="DevereauxPJ , YangH , YusufS , GuyattG , LeslieK , VillarJC , et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet2008;371(9627):1839-47.">Devereaux 2008</a>; <a href="./references#CD012565-bbs2-0086" title="JuulAB , WetterslevJ , GluudC , Kofoed-EnevoldsenA , JensenG , CallesenT , et al. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. BMJ (Clinical Research Ed)2006;332(7556):1482. [PMID: 16793810]">Juul 2006</a>), and it seems to increase 30‐day all‐cause mortality as well as the occurrence of stroke, although non‐fatal myocardial infarction is reduced (<a href="./references#CD012565-bbs2-0041" title="BangaloreS , WetterslevJ , PraneshS , SawhneyS , GluudC , MesserliFH . Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet2008;372(9654):1962-76. [PMID: 19012955]">Bangalore 2008</a>). Perioperative usage of beta‐blockers remains a controversial topic (<a href="./references#CD012565-bbs2-0142" title="WangX , Fernandez RoblesC , KertaiMD . Perioperative β-blocker use: what is new in 2020?Current Opinion in Anaesthesiology2020;33(3):417-22. [PMID: 32324663]">Wang 2020</a>). </p> <p>Beta‐blockers may cause both cardiac adverse effects and non‐cardiac adverse effects. Among the most serious cardiac adverse effects is exacerbation of heart failure in people with acute decompensated heart failure due to the need for sympathetic activity to maintain cardiac output (<a href="./references#CD012565-bbs2-0134" title="TaylorSH , SilkeB , LeePS . Intravenous beta-blockade in coronary heart disease: is cardioselectivity or intrinsic sympathomimetic activity hemodynamically useful?New England Journal of Medicine1982;306(11):631-5. [PMID: 6120457]">Taylor 1982</a>). In addition, beta‐blocker withdrawal has been shown to cause exacerbation of ischaemic symptoms and to precipitate acute myocardial infarction in people with ischaemic heart disease (<a href="./references#CD012565-bbs2-0075" title="HoustonMC . Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. American Heart Journal1981;102(3 Pt 1):415-30. [PMID: 6115570]">Houston 1981</a>). </p> <p>Case studies have suggested that depression, fatigue, and sexual dysfunction are among beta‐blocker‐induced non‐cardiac adverse effects (<a href="./references#CD012565-bbs2-0066" title="GreenblattDJ , Koch-WeserJ . Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program. Drugs1974;7(1):118-29. [PMID: 4151696]">Greenblatt 1974</a>; <a href="./references#CD012565-bbs2-0141" title="WaalHJ . Propranolol-induced depression. British Medical Journal1967;2(5543):50. [PMID: 6021004]">Waal 1967</a>; <a href="./references#CD012565-bbs2-0144" title="WarrenSC , WarrenSG . Propranolol and sexual impotence. Annals of Internal Medicine1977;86(1):112. [PMID: 835912]">Warren 1977</a>). However, a meta‐analysis comparing beta‐blockers versus placebo showed no difference in depressive symptoms and only a minor increase in sexual dysfunction and fatigue among participants randomised to beta‐blockers compared with placebo (<a href="./references#CD012565-bbs2-0088" title="KoDT , HebertPR , CoffeyCS , SedrakyanA , CurtisJP , KrumholzHM . Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA2002;288(3):351-7. [PMID: 12117400]">Ko 2002</a>). </p> <p>Although beta‐blockers are considered standard treatment for people with diagnosed heart failure (<a href="./references#CD012565-bbs2-0050" title="ChatterjeeS , Biondi-ZoccaiG , AbbateA , D'AscenzoF , CastagnoD , Van TassellB , et al. Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ (Clinical Research Ed)2013;346:f55. [PMID: 23325883]">Chatterjee 2013</a>; <a href="./references#CD012565-bbs2-0148" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDEJ , DraznerMH , et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation2013;128:e240–e327.">Yancy 2013</a>), it remains unclear whether beta‐blockers have a beneficial effect in the non‐acute phase following acute myocardial infarction for people without heart failure (<a href="./references#CD012565-bbs2-0051" title="Collet J-P, ThieleH , BarbatoE , et al. ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal2021;42(14):1289-367.">Collet 2020</a>; <a href="./references#CD012565-bbs2-0115" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>). This Cochrane Review will be the first to specifically assess effects of treatment with beta‐blockers in the non‐acute phase after myocardial infarction. </p> <section id="CD012565-sec-0014"> <h4 class="title">Evidence on effects of beta‐blockers following acute myocardial infarction in patients without heart failure </h4> <p>Two meta‐analyses including randomised controlled trials conducted before 2000 compared the effects of any type of beta‐blocker versus no beta‐blocker on long‐term outcomes among participants with suspected or diagnosed myocardial infarction (<a href="./references#CD012565-bbs2-0061" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ (Clinical Research Ed)1999;318(7200):1730-7. [PMID: 10381708]">Freemantle 1999</a>; <a href="./references#CD012565-bbs2-0149" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335-71. [PMID: 2858114]">Yusuf 1985</a>). Both showed a beneficial effect of beta‐blockers for mortality; however, all included trials were performed before the reperfusion era, when heart failure was a common finding in these patients. A more recent meta‐analysis including randomised controlled trials from both pre‐reperfusion and reperfusion eras found a beneficial effect on mortality only in trials from the pre‐reperfusion era, in which participants had not received revascularisation (percutaneous coronary intervention or coronary artery bypass graft) nor thrombolytics (e.g. streptokinase) (<a href="./references#CD012565-bbs2-0042" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. American Journal of Medicine2014;127(10):939-53. [PMID: 24927909]">Bangalore 2014</a>). <a href="./references#CD012565-bbs2-0042" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. American Journal of Medicine2014;127(10):939-53. [PMID: 24927909]">Bangalore 2014</a> also found beneficial effects of beta‐blockers on symptoms of angina and risk of recurrent myocardial infarction regardless of whether or not participants received intervention for reperfusion. However, this study also shows that beta‐blockers seemed to increase the severity of heart failure among participants receiving intervention for reperfusion (<a href="./references#CD012565-bbs2-0042" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. American Journal of Medicine2014;127(10):939-53. [PMID: 24927909]">Bangalore 2014</a>). It must be noted that <a href="./references#CD012565-bbs2-0042" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. American Journal of Medicine2014;127(10):939-53. [PMID: 24927909]">Bangalore 2014</a> included a larger number of trials than <a href="./references#CD012565-bbs2-0061" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ (Clinical Research Ed)1999;318(7200):1730-7. [PMID: 10381708]">Freemantle 1999</a> and <a href="./references#CD012565-bbs2-0149" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335-71. [PMID: 2858114]">Yusuf 1985</a>, and only <a href="./references#CD012565-bbs2-0042" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. American Journal of Medicine2014;127(10):939-53. [PMID: 24927909]">Bangalore 2014</a> included trials after reperfusion strategies had been implemented. It is important to keep in mind that implementation of rapid reperfusion in the treatment of myocardial infarction has had beneficial effects on both survival and development of heart failure because of reduced infarct size (<a href="./references#CD012565-bbs2-0081" title="IbanazB , HeuschG , OvizeM , Van de WerfF . Evolving therapies for myocardial ischemia/reperfusion injury. Journal of the American College of Cardiology2015;65(14):1454-71. [PMID: 25857912]">Ibanaz 2015</a>). Thus, it is of utmost importance to identify the effects of beta‐blockers specifically in the modern reperfusion era. However, none of these meta‐analyses systematically assessed trials from the reperfusion era including only participants <i>without</i> heart failure and with <i>preserved left ventricular ejection fraction (LVEF)</i> in the non‐acute phase following acute myocardial infarction. </p> <p>Despite the lack of recent randomised controlled trials from the current reperfusion era assessing long‐term effects of beta‐blockers in patients without heart failure following acute myocardial infarction, a large number of recent observational and registry studies assessing this issue have been conducted. A recent meta‐analysis including 16 observational studies from 2000 to 2017 found a beneficial effect on reduction of all‐cause mortality among almost 170,000 patients without heart failure following acute myocardial infarction (rate ratio 0.74, 95% confidence interval (CI) 0.64 to 0.85) (<a href="./references#CD012565-bbs2-0053" title="Dahl AarvikM , SandvenI , DondoTB , GaleCP , RuddoxV , MunkhaugenJ , et al. Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. European Heart Journal. Cardiovascular Pharmacotherapy2019;5(1):12-20. [PMID: 30192930]">Dahl 2019</a>). However, with control for bias due to the presence of publication and small‐study effect bias, the beneficial effects of beta‐blocker therapy disappeared. Another meta‐analysis consisting of 10 observational studies with a total of 40,000 patients assessed effects of oral beta‐blocker therapy after PCI treatment for patients following acute myocardial infarction with follow‐up of at least three months; researchers found a beneficial effect on all‐cause mortality only in those with reduced LVEF (unadjusted relative risk 0.58, 95% CI 0.48 to 0.71) (<a href="./references#CD012565-bbs2-0080" title="HuangBT , HuangFY , ZuoZL , LiaoYB , HengY , WangPJ , et al. Meta-analysis of relation between oral β-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention. American Journal of Cardiology2015;115(11):1529-38. [PMID: 25862157]">Huang 2015</a>). However, no significant beneficial effects were found in the subgroup of patients with preserved LVEF (relative risk 0.79, 95% CI 0.59 to 1.07), and potential beneficial effects of beta‐blocker therapy appeared to gradually disappear after more than one year of follow‐up after myocardial infarction. These findings were further supported by a cohort study following 3145 patients for a total of one‐year follow‐up after STEMI, where patients with reduced LVEF had a better prognosis, and fewer patients reached the primary outcome of all‐cause mortality or hospital re‐admission for a cardiovascular event (hazard ratio (HR) 0.431, 95% CI 0.262 to 0.703; P = 0.001) (<a href="./references#CD012565-bbs2-0060" title="FerreiraJA , BaptistaRM , MonteiroSR , GonçalvesLM . Usefulness of universal beta-blocker therapy in patients after ST-elevation myocardial infarction. Medicine2021;100(3):e23987. [PMID: 33545989]">Ferreira 2021</a>). However, in patients with preserved (HR 0.73, 95% CI 0.51 to 1.04; P = 0.081) and mid‐range (HR 1.01, 95% CI 0.64 to 1.61; P = 0.959) LVEF, no such beneficial effect was seen compared to the non‐beta‐blocker group. In contrast to these findings, a meta‐analysis of seven observational studies totaling 11,000 patients, assessed effects of long‐term beta‐blocker therapy (&gt; 6 months) among STEMI patients with LVEF greater than 40% who underwent primary PCI and found long‐term beta‐blocker therapy to be associated with decreased all‐cause mortality (combined hazard ratio 0.79, 95% CI 0.65 to 0.97) (<a href="./references#CD012565-bbs2-0101" title="MisumidaN , HarjaiK , KernisS , KaneiY . Does oral beta-blocker therapy improve long-term survival in ST-segment elevation myocardial infarction with preserved systolic function? A meta-analysis. Journal of Cardiovascular Pharmacology and Therapeutics2016;21(3):280-5. [PMID: 26424094]">Misumida 2016</a>). </p> <section id="CD012565-sec-0015"> <h5 class="title">Guideline recommendations</h5> <p>Clear inconsistency between international guidelines is evident in their recommendations for the use of beta‐blockers in patients without heart failure and a preserved left ventricular ejection fraction after myocardial infarction (<a href="./references#CD012565-bbs2-0038" title="AmsterdamEA , WengerNK , BrindisRG , Casey DE Jr, GaniatsTG , Holmes DR Jr, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology2014;64(24):e139-228. [PMID: 25260718]">Amsterdam 2014</a>; <a href="./references#CD012565-bbs2-0040" title="AntmanEM , AnbeDT , ArmstrongPW , BatesER , GreenLA , HandM , et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Journal of the American College of Cardiology2004;44(3):671-719. [PMID: 15358045]">Antman 2004</a>; <a href="./references#CD012565-bbs2-0051" title="Collet J-P, ThieleH , BarbatoE , et al. ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal2021;42(14):1289-367.">Collet 2020</a>; <a href="./references#CD012565-bbs2-0082" title="IbanezB , JamesS , AgewallS , AntunesMJ , Bucciarelli-DucciC , BuenoH , et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal2018;39(2):119-77.">Ibanez 2017</a>; <a href="./references#CD012565-bbs2-0104" title="National Clinical Guideline Centre (UK) MI - Secondary Prevention: Secondary Prevention in Primary and Secondary Care for Patients Following a Myocardial Infarction: Partial Update of NICE CG48. London: Royal College of Physicians (UK)2013;PMID: 25340229..">NICE 2013</a>; <a href="./references#CD012565-bbs2-0108" title="O'GaraPT , KushnerFG , AscheimDD , CaseyDE , ChungMK , deLemosJA , et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology2013;61(4):104.">O'Gara 2013</a>; <a href="./references#CD012565-bbs2-0129" title="StegPG , JamesSK , AtarD , BadanoLP , Blomstrom-LundqvistC , BorgerMA , et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal2012;33(20):2569-619.">Steg 2012</a>; <a href="./references#CD012565-bbs2-0115" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>). </p> <p>According to European Society of Cardiology (ESC) guidelines, oral beta‐blocker therapy is recommended during hospital stay and should be continued thereafter for all STEMI patients without contraindications with a class IIa recommendation (level of evidence (LoE) B), with no further specification of patient group. However, for patients with heart failure and/or left ventricular ejection fraction dysfunction (LVEF &lt; 40%), oral treatment with beta‐blockers is indicated with a class I recommendation (LoE A) (<a href="./references#CD012565-bbs2-0082" title="IbanezB , JamesS , AgewallS , AntunesMJ , Bucciarelli-DucciC , BuenoH , et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal2018;39(2):119-77.">Ibanez 2017</a>; <a href="./references#CD012565-bbs2-0129" title="StegPG , JamesSK , AtarD , BadanoLP , Blomstrom-LundqvistC , BorgerMA , et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal2012;33(20):2569-619.">Steg 2012</a>). </p> <p>American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines from 2004 initially recommended beta‐blocker therapy as a class I recommendation (LoE A) for all STEMI patients except those at low risk (defined as normal or near‐normal ventricular function, successful reperfusion, absence of significant ventricular arrhythmias) and those with contraindications. Treatment was suggested to begin within a few days of the event, if not initiated acutely, and to continue indefinitely. However, it was argued that it would be reasonable to prescribe beta‐blockers for low‐risk patients after STEMI but only with a class IIa recommendation (LoE A) (<a href="./references#CD012565-bbs2-0040" title="AntmanEM , AnbeDT , ArmstrongPW , BatesER , GreenLA , HandM , et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Journal of the American College of Cardiology2004;44(3):671-719. [PMID: 15358045]">Antman 2004</a>). More recent ACCF/AHA guidelines from 2013 suggest that oral beta‐blockers should be initiated in the first 24 hours for patients with STEMI who do not have any of the following: signs of heart failure, evidence of a low‐output state, increased risk of cardiogenic shock, or other contraindications with a class I recommendation (LoE B). Furthermore, it was suggested that therapy should be continued during and after hospitalisation for all patients with STEMI with a class I recommendation (LoE B). This recommendation was further extended to suggest a three‐year treatment course for patients without heart failure while acknowledging lack of data on the long‐term effects of beta‐blocker therapy (<a href="./references#CD012565-bbs2-0108" title="O'GaraPT , KushnerFG , AscheimDD , CaseyDE , ChungMK , deLemosJA , et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology2013;61(4):104.">O'Gara 2013</a>). </p> <p>For patients with non‐ST elevation after myocardial infarction, the use of beta‐blockers is provided with a class I recommendation (LoE A), according to ESC guidelines, but only in the context of heart failure and LVEF less than 40% (<a href="./references#CD012565-bbs2-0115" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>). However, no recommendations have been made for NSTEMI patients without heart failure and normal left ventricular function, as it appears that this has not yet been investigated in contemporary randomised clinical trials according to ESC guidelines (<a href="./references#CD012565-bbs2-0115" title="RoffiM , PatronoC , ColletJP , MuellerC , ValgimigliM , AndreottiF , et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal2016;37(3):267-315.">Roffi 2016</a>). The latest ESC guidelines from 2020 further reinforce the need for studies evaluating the value of long‐term therapy with beta‐blockers for patients with LVEF 40% or greater (<a href="./references#CD012565-bbs2-0051" title="Collet J-P, ThieleH , BarbatoE , et al. ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal2021;42(14):1289-367.">Collet 2020</a>). In contrast to this, ACCF/AHA guidelines appear to be based on enough data to find it reasonable to continue beta‐blocker therapy with a class IIa recommendation (LoE C) for NSTEMI patients with normal left ventricular function (<a href="./references#CD012565-bbs2-0038" title="AmsterdamEA , WengerNK , BrindisRG , Casey DE Jr, GaniatsTG , Holmes DR Jr, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology2014;64(24):e139-228. [PMID: 25260718]">Amsterdam 2014</a>). </p> <p>Last, the 2013 National Institute for Health and Care Excellence (NICE) guideline recommends continuing beta‐blocker therapy for at least one year after myocardial infarction for patients without heart failure or reduced LVEF (<a href="./references#CD012565-bbs2-0104" title="National Clinical Guideline Centre (UK) MI - Secondary Prevention: Secondary Prevention in Primary and Secondary Care for Patients Following a Myocardial Infarction: Partial Update of NICE CG48. London: Royal College of Physicians (UK)2013;PMID: 25340229..">NICE 2013</a>). </p> <p>Hence, meta‐analyses and guidelines have shown conflicting results and recommendations, and no former reviews have used Cochrane methods to systematically assess effects of beta‐blockers among people without heart failure and with LVEF 40% or greater after myocardial infarction (<a href="./references#CD012565-bbs2-0071" title="HigginsJT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>). The present Cochrane Review will be the first to assess risk of systematic errors ('bias'), design errors, and random errors ('play of chance') (<a href="./references#CD012565-bbs2-0071" title="HigginsJT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>), including trials irrespective of outcome, duration of follow‐up, number of participants, language, and publication status. </p> </section> </section> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012565-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012565-sec-0016"></div> <p>To assess the benefits and harms of beta‐blockers compared with placebo or no treatment in patients without heart failure and with left ventricular ejection fraction (LVEF) greater than 40% in the non‐acute phase after myocardial infarction. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012565-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012565-sec-0017"></div> <section id="CD012565-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012565-sec-0019"> <h4 class="title">Types of studies</h4> <p>We included all randomised clinical trials irrespective of publication type, reported outcomes, publication status, publication date, and language. We did not include cluster randomised trials due to the inferiority of these trials compared to individually randomised clinical trials. We did not specifically search for non‐randomised studies. </p> </section> <section id="CD012565-sec-0020"> <h4 class="title">Types of participants</h4> <p>We included any participants, irrespective of age, whom trialists described as receiving a diagnosis of myocardial infarction in the non‐acute and stable phase after acute myocardial infarction. We excluded trials assessing effects of beta‐blockers among patients with post‐myocardial infarction heart failure, defined as clinically overt heart failure with New York Heart Association (NYHA) Class III/IV and LVEF less than 40% at the time of discharge from the hospital. However, we included participants with Killip class I/II and NYHA Class I/II heart failure and with acute heart failure as defined by the trialist during hospitalisation with acute myocardial infarction. </p> </section> <section id="CD012565-sec-0021"> <h4 class="title">Types of interventions</h4> <p>We included three types of trials.</p> <p> <ul id="CD012565-list-0006"> <li> <p>Beta‐blocker compared with placebo.</p> </li> <li> <p>Beta‐blocker added to a co‐intervention compared with a similar co‐intervention.</p> </li> <li> <p>Beta‐blocker compared with no treatment.</p> </li> </ul> </p> <p>We accepted any co‐intervention (any medical therapy or any revascularisation strategy) provided it was planned to be delivered similarly to experimental and control groups. We assumed that no interaction between effects of co‐interventions would ‘even out’ in both groups, so possible effects of beta‐blockers would be reflected in the results. </p> <p>We accepted any type of beta‐blocker as the experimental intervention (non‐selective beta‐blockers (e.g. propanolol, oxprenolol, sotalol, timolol), selective beta₁‐blockers (e.g. metoprolol, bisoprolol, acebutolol, atenolol, esmolol), and beta‐blockers that are combined alpha‐ and non‐selective beta‐blockers (e.g. carvedilol)). </p> <p>Our analysis included trials assessing effects of any type of secondary prevention beta‐blockers commenced in the non‐acute phase after myocardial infarction. </p> <p>We accepted trialists' definitions of whether beta‐blockers were administered in an acute/subacute phase or in a 'non‐acute phase', and we included only trials in which beta‐blockers were administered in the non‐acute phase following acute myocardial infarction. However, as a rule of thumb, we considered beta‐blockers administered more than seven days after myocardial infarction as 'administered in a non‐acute phase'. We also included trials in which beta‐blockers were administered within seven days after a myocardial infarction if trialists described participants as fully recovered after acute myocardial infarction, assuming beta‐blockers were then administered in the non‐acute phase. We assessed these trials in a post hoc subgroup analysis comparing trials in which beta‐blockers were administered more than seven days after myocardial infarction to trials in which beta‐blockers were administered within seven days after myocardial infarction (see <a href="#CD012565-sec-0046">Subgroup analysis and investigation of heterogeneity</a>). </p> <p>The effects of beta‐blockers administered in the acute/subacute phase are assessed in another review (<a href="./references#CD012565-bbs2-0119" title="SafiS , SethiNJ , NielsenEE , FeinbergJ , GluudC , JakobsenJC . Beta-blockers for suspected or diagnosed acute myocardial infarction. Cochrane Database of Systematic Reviews2019;(12). [DOI: 10.1002/14651858.CD012484.pub2] [CD012484]">Safi 2019</a>). </p> </section> <section id="CD012565-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD012565-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012565-list-0007"> <li> <p>All‐cause mortality</p> </li> <li> <p>Major cardiovascular event (MACE) defined as a composite outcome consisting of cardiovascular mortality (as defined by trialists) and non‐fatal myocardial infarction (as defined by trialists). Additionally, we assessed cardiovascular mortality and myocardial infarction separately as secondary outcomes (see later). We reported MACE (cardiovascular mortality + non‐fatal myocardial infarction) only if we were confident that there was no risk of double‐counting, and if the trialist had clearly defined and reported cardiovascular mortality and non‐fatal infarction </p> </li> <li> <p>Serious adverse event defined as any untoward medical occurrence that was life‐threatening, resulted in death, or was persistent or led to significant disability; or prolonged hospitalisation or any medical event that had jeopardised the participant or required intervention to prevent it (<a href="./references#CD012565-bbs2-0083" title="ICH harmonised guideline: integrated addemdum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2) ICH Consensus Guideline (ICH-GCP). Federal Register2015.">ICH‐GCP 2015</a>). Because we expected reporting of serious adverse events in many trials to be very heterogeneous and not done strictly according to recommendations regarding good clinical practice from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH‐GCP) (<a href="./references#CD012565-bbs2-0083" title="ICH harmonised guideline: integrated addemdum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2) ICH Consensus Guideline (ICH-GCP). Federal Register2015.">ICH‐GCP 2015</a>), we planned to include the event as a serious adverse event if trial authors used the term ‘serious adverse event' without referring to ICH‐GCP. However, no trials specifically assessed serious adverse events according to the definition provided by ICH‐GCP. Instead, trials reported one specific serious adverse event, which was already included in one of the other outcomes in this review, or a composite of several different events without referring to the actual proportions of participants </p> </li> </ul> </p> </section> <section id="CD012565-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012565-list-0008"> <li> <p>Quality of life measured on any valid scale, such as Short Form Health Survey (SF‐36) (<a href="./references#CD012565-bbs2-0143" title="WareJEJ , SherbourneCD . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care1992;30(6):473-83.">Ware 1992</a>). However, no trials reported this outcome </p> </li> <li> <p>Angina measured on any valid scale, such as Canadian Cardiovascular Society (CCS) Angina Score (<a href="./references#CD012565-bbs2-0048" title="CampeauL . Letter: grading of angina pectoris. Circulation1976;54(3):522-3. [PMID: 947585]">Campeau 1976</a>) </p> </li> <li> <p>Cardiovascular mortality</p> </li> <li> <p>Myocardial infarction</p> </li> </ul> </p> <p>We planned to narratively report adverse events, presenting them in a table. However, because most of the included trials did not extensively report adverse events, we did not do this. </p> <p>We estimated all outcomes at maximum follow‐up, which was our outcome of primary interest. When data at different time periods were presented, we included only the longest follow‐up result. Furthermore, we used a subgroup analysis to assess different follow‐up durations included in the trials (please see <a href="#CD012565-sec-0046">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD012565-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012565-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases on 23 February 2021 to identify relevant trials (<a href="./references#CD012565-bbs2-0117" title="RoyleP , MilneR . Literature searching for randomized controlled trials used in Cochrane Reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care2003;19(4):591-603.">Royle 2003</a>). </p> <p> <ul id="CD012565-list-0009"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 2 of 12), in the Cochrane Library. </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily, and MEDLINE Ovid (1946 to 22 February 2021). </p> </li> <li> <p>Embase Ovid (1974 to 22 February 2021).</p> </li> <li> <p>Latin American and Caribbean Health Science Information database (LILACS) Bireme (1982 to 22 February 2021). </p> </li> <li> <p>Science Citation Index ‐ Expanded on the Web of Science (SCI‐EXPANDED) (Clarivate Analytics, 1900 to 23 February 2021). </p> </li> <li> <p>BIOSIS on the Web of Science (Clarivate Analytics, 1926 to 23 February 2021).</p> </li> </ul> </p> <p>The preliminary search strategy for MEDLINE (Ovid) was adapted for use with the other databases (<a href="./appendices#CD012565-sec-0125">Appendix 1</a>). We applied the Cochrane sensitivity‐precision maximising randomised controlled trial filter to MEDLINE (Ovid) and adaptations of it to the other databases, except CENTRAL (<a href="./references#CD012565-bbs2-0091" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6. Searching for studies. In: Higgins JT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Lefebvre 2011</a>). </p> <p>Additionally, we searched the WHO International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>), US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), European Medicines Agency (EMA) (<a href="http://www.ema.europa.eu/ema/" target="_blank">www.ema.europa.eu/ema/</a>), Food and Drug Administration (FDA) (<a href="http://www.fda.gov/" target="_blank">www.fda.gov</a>), <a href="http://www.tripdatabase.com/" target="_blank">Turning Research Into Practice (TRIP)</a>, <a href="http://scholar.google.dk/" target="_blank">Google Scholar</a>, and <a href="http://ipscience.thomsonreuters.com/" target="_blank">SciSearch</a> on 23 February 2021 for finished trials as well as ongoing trials. </p> <p>We searched all databases from their inception to the present, and we did not impose any restriction on language of publication or publication status. If we identified any papers in a language not known by the review author group, we sought help in our network and acknowledged this in the <a href="#CD012565-sec-0122">Acknowledgements</a> section. </p> </section> <section id="CD012565-sec-0027"> <h4 class="title">Searching other resources</h4> <p>We identified additional trials by searching the bibliographies of review articles, references of papers of included studies, and any relevant retraction statements and errata for included studies and included them when relevant. </p> </section> </section> <section id="CD012565-sec-0028"> <h3 class="title" id="CD012565-sec-0028">Data collection and analysis</h3> <p>We used Review Manager 5 (RevMan 5) (<a href="./references#CD012565-bbs2-0113" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2014.">RevMan 2014</a>), and, if needed, we planned to use STATA 16.1 (<a href="./references#CD012565-bbs2-0128" title="StataCorp; Stata Statistical Software. College Station: TX: StataCorp LLC, 2016. http://www.stata.com.">STATA 2016</a>), to perform the analyses. However, we did not include any analyses for which STATA 16.1 was needed. </p> <section id="CD012565-sec-0029"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SS and NJS) assessed each identified trial independently. If a trial was identified as relevant by one review author, but not by another, we discussed the reasoning behind each decision. If no agreement could be reached, we involved a third review author (JCJ) to resolve the discussion. Included trials are reported in <a href="./references#CD012565-sec-0142" title="">Characteristics of included studies</a>. </p> <p>We reported excluded trials that a reader might feasibly have expected to see as included trials in <a href="./references#CD012565-sec-0143" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD012565-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for trial characteristics and outcome data for all 25 trials included in the review. Two review authors (SS and NJS) independently extracted trial characteristics and outcome data from included trials as follows. </p> <p> <ul id="CD012565-list-0010"> <li> <p>Methods: duration of trial, details of any 'run‐in' period, date of publication.</p> </li> <li> <p>Participants: number randomised, number analysed, mean age, sex, inclusion criteria, exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications; excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, time points reported.</p> </li> <li> <p>Notes: funding for trial, notable conflicts of interest for trial authors.</p> </li> </ul> </p> <p>We resolved disagreements by reaching consensus or by involving another review author (JCJ). One review author (SS) transferred data into the RevMan 5 file (<a href="./references#CD012565-bbs2-0113" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2014.">RevMan 2014</a>), and another (NJS) double‐checked the data entry. We double‐checked that data were entered correctly by comparing data presented in the systematic review with those provided in study reports. A second review author (NJS) spot‐checked trial characteristics for accuracy against the trial report. </p> </section> <section id="CD012565-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used instructions given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> in our evaluation of methods and of risk of bias of included trials (<a href="./references#CD012565-bbs2-0072" title="HigginsJT , AltmanDG , Sterne JAC (editors). Chapter 8. Assessing risk of bias in included studies. In: Higgins JT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011b</a>). Two review authors (SS and NJS) assessed included trials independently. We evaluated risks of bias in random sequence generation, allocation concealment, blinding of participants and treatment providers, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other sources of bias. We did this because these domains enable classification of randomised clinical trials at low risk of bias and of randomised clinical trials at unclear or high risk of bias. The latter trials often overestimate benefits and underestimate harms (<a href="./references#CD012565-bbs2-0063" title="GluudLL . Bias in clinical intervention research. American Journal of Epidemiology2006;163(6):493-501.">Gluud 2006</a>; <a href="./references#CD012565-bbs2-0087" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine2001;135(11):982-9.">Kjaergard 2001</a>; <a href="./references#CD012565-bbs2-0096" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub2]">Lundh 2012</a>; <a href="./references#CD012565-bbs2-0102" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet1998;352(9128):609-13.">Moher 1998</a>; <a href="./references#CD012565-bbs2-0120" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38.">Savovic 2012</a>; <a href="./references#CD012565-bbs2-0121" title="SavovicJ , JonesH , AltmanD , HarrisR , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assesment2012;16(35):1-82.">Savovic 2012a</a>; <a href="./references#CD012565-bbs2-0122" title="SavovicJ , TurnerRM , MawdsleyD , JonesHE , BeynonR , HigginsJT , et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES meta-epidemiologic study. American Journal of Epidemiology2018;187(5):1113-22. [PMID: 29126260]">Savovic 2018</a>; <a href="./references#CD012565-bbs2-0124" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>; <a href="./references#CD012565-bbs2-0147" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed)2008;336(7644):601-5.">Wood 2008</a>). For additional details on how risk of bias was assessed, see <a href="./appendices#CD012565-sec-0126">Appendix 2</a>. </p> <section id="CD012565-sec-0032"> <h5 class="title">Overall risk of bias</h5> <p> <ul id="CD012565-list-0011"> <li> <p>Low risk of bias: outcome result was classified at overall 'low risk of bias' only if all bias domains described in the above paragraphs were classified at low risk of bias </p> </li> <li> <p>High risk of bias: outcome result was classified at 'high risk of bias' if any of the bias risk domains described above were classified at unclear or high risk of bias. </p> </li> </ul> </p> <p>We assessed blinding of outcome assessment, incomplete outcome data, and selective outcome reporting domains for each outcome. Thus, we were able to assess bias risk for each result in addition to each trial. </p> </section> </section> <section id="CD012565-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <section id="CD012565-sec-0034"> <h5 class="title">Dichotomous outcomes</h5> <p>We calculated risk ratios (RRs) with 97.5% confidence intervals (CIs) for our primary dichotomous outcomes, and 98% CIs for our secondary dichotomous outcomes. </p> </section> <section id="CD012565-sec-0035"> <h5 class="title">Continuous outcomes</h5> <p>We planned to calculate mean differences (MDs) with 95% CIs for continuous outcomes. We planned to use standardised mean differences (SMDs) when all trials assessed the same outcome but measured it in a variety of ways, for example, when they used different scales (<a href="./references#CD012565-bbs2-0054" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 9. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Deeks 2011</a>). However, we did not include any continuous outcomes and we calculated no MD or SMD. </p> </section> </section> <section id="CD012565-sec-0036"> <h4 class="title">Unit of analysis issues</h4> <p>In the case of multi‐armed trials, we planned to split the number of participants in the control group by the number of arms to avoid double‐counting. We further planned to report the number of comparisons in addition to the number of trials when reporting results. However, none of the included trials that contributed data to our review were multi‐arm trials. </p> <p>If we found any cross‐over trials, we planned to include data only from the first treatment period (<a href="./references#CD012565-bbs2-0059" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9. [PMID: 11914310]">Elbourne 2002</a>). However, we included only one cross‐over trial that did not contribute any data to our review (<a href="./references#CD012565-bbs2-0008" title="BarvikS , DicksteinK , AarslandT , Vik-MoH . Effect of timolol on cardiopulmonary exercise performance in men after myocardial infarction. American Journal of Cardiology1982;69(3):163-8. ">Barvik 1992</a>). </p> </section> <section id="CD012565-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>We contacted all trial authors to request missing data. Many of these authors did not respond to our emails. See <a href="./references#CD012565-sec-0142" title="">Characteristics of included studies</a>. </p> <p>If included trials had used rigorous methods (i.e. reporting on outcomes for all participants or multiple imputation to deal with missing data), we used these data in our primary analysis (<a href="./references#CD012565-bbs2-0131" title="SterneJA , WhiteIR , CarlinJB , SprattM , RoystonP , KenwardMG , et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ (Clinical Research Ed)2009;338:b2393. [PMID: 19564179]">Sterne 2009</a>). We did not impute missing values for any outcomes in our primary analysis. Additionally, for continuous outcomes, if standard deviations (SDs) were not reported, we planned to calculate SDs using data from the trial when possible. However, no trials reported continuous outcomes. We did not use intention‐to‐treat data if the original report did not contain such data. </p> <p>In our sensitivity analysis for dichotomous outcomes, we imputed data (see below and <a href="#CD012565-sec-0048">Sensitivity analysis</a>). We also planned this approach for continuous outcomes; however, no trials reported any continuous outcomes. </p> <section id="CD012565-sec-0038"> <h5 class="title">Best‐worst and worst‐best case scenarios</h5> <p>To assess the potential impact of missing data for dichotomous outcomes, we performed the following sensitivity analyses. </p> <section id="CD012565-sec-0039"> <h6 class="title">'Best‐worst case' scenario</h6> <p>We assumed that all participants lost to follow‐up in the experimental group survived and had no serious adverse event, major cardiovascular event, or reinfarction, and that all those in the control group with missing outcomes did not survive or had a serious adverse event, a major cardiovascular event, or a reinfarction. </p> </section> <section id="CD012565-sec-0040"> <h6 class="title">'Worst‐best case' scenario</h6> <p>We assumed that all participants lost to follow‐up in the experimental group did not survive or had a serious adverse event, a major cardiovascular event, or a reinfarction, and that all those in the control group with missing outcomes survived and had no serious adverse event, major cardiovascular event, or reinfarction. </p> <p>We presented results from both scenarios in our publication.</p> <p>To assess the potential impact of missing SDs for continuous outcomes, we planned to perform the following sensitivity analysis. </p> <p> <ul id="CD012565-list-0012"> <li> <p>When SDs were missing and could not be calculated, we planned to impute SDs from trials with similar populations and low risk of bias. If we found no such trials, we planned to impute SDs from trials with a similar population. As the final option, we planned to impute SDs from all trials. However, no trials reported any continuous outcomes. </p> </li> </ul> </p> </section> </section> </section> <section id="CD012565-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We primarily investigated forest plots to visually assess any sign of heterogeneity. We then assessed the presence of statistical heterogeneity by performing the Chi² test (threshold P &lt; 0.10) and measured the quantities of heterogeneity by using the I² statistic (<a href="./references#CD012565-bbs2-0069" title="HigginsJT , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58.">Higgins 2002</a>; <a href="./references#CD012565-bbs2-0070" title="HigginsJT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). We followed the recommendations for threshold in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012565-bbs2-0054" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 9. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Deeks 2011</a>). </p> <p> <ul id="CD012565-list-0013"> <li> <p>0% to 40%: might not be important.</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity.</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>We investigated possible heterogeneity by performing subgroup and sensitivity analyses and determined whether a meta‐analysis should be avoided (<a href="./references#CD012565-bbs2-0054" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 9. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Deeks 2011</a>). However, we found no such meta‐analyses to be excluded. </p> </section> <section id="CD012565-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>We used a funnel plot to assess reporting bias if we included 10 or more trials. Using asymmetry of the funnel plot, we assessed risk of bias. If the funnel plot showed significant asymmetry, we planned to assess this further using the Harbord test if Tau² was less than 0.1 (<a href="./references#CD012565-bbs2-0068" title="HarbordRM , EggerM , SterneJA . A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443-57. [PMID: 16345038]">Harbord 2006</a>), or the Rücker test if Tau² was greater than 0.1 (<a href="./references#CD012565-bbs2-0074" title="HigginsJT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org (updated March 2011):10.4.3.1 Recommendations on testing for funnel plot asymmetry.">Higgins 2011d</a>; <a href="./references#CD012565-bbs2-0118" title="RückerG , SchwarzerG , CarpenterJ . Arcsine test for publication bias in meta-analyses with binary outcomes. Statistics in Medicine2008;27(5):746-63. [PMID: 17592831]">Rücker 2008</a>). We used the odds ratio when conducting the Harbord test. This was relevant only for all‐cause mortality. </p> <p>For continuous outcomes, we planned to use the regression asymmetry test (<a href="./references#CD012565-bbs2-0058" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed)1997;315(7109):629-34.">Egger 1997</a>). However, we included no continuous outcomes. </p> </section> <section id="CD012565-sec-0043"> <h4 class="title">Data synthesis</h4> <section id="CD012565-sec-0044"> <h5 class="title">Meta‐analysis</h5> <p>We planned to accept both end‐scores and change‐from‐baseline scores when analysing continuous outcomes. If both end‐scores and change‐from‐baseline scores were reported, we planned to use end‐scores. If only change‐from‐baseline scores were reported, we planned to analyse these results together with end‐scores in the same meta‐analyses (<a href="./references#CD012565-bbs2-0073" title="HigginsJT , WhiteheadA , SimmondsM . Sequential methods for random-effects meta-analysis. Statistics in Medicine2011;30(9):903-21. [PMID: 21472757]">Higgins 2011c</a>). However, we included no continuous outcomes. </p> <p>We undertook this systematic review according to recommendations stated in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012565-bbs2-0054" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 9. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Deeks 2011</a>). We used the statistical software RevMan 5 as provided by Cochrane to meta‐analyse data (<a href="./references#CD012565-bbs2-0113" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2014.">RevMan 2014</a>). We planned to use STATA in case of zero event trials (<a href="./references#CD012565-bbs2-0128" title="StataCorp; Stata Statistical Software. College Station: TX: StataCorp LLC, 2016. http://www.stata.com.">STATA 2016</a>), when RevMan 5 zero event handling (replacing zero with a constant of 0.5) was not sufficient, for example, in cases with skewed numbers of participants between groups (which we planned to handle according to <a href="./references#CD012565-bbs2-0133" title="SweetingMJ , SuttonAJ , LambertPC . What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine2004;23(9):1351-75. [PMID: 15116347]">Sweeting 2004</a> and in cases for which meta‐regression (post hoc) was needed. However, we included no zero event trials and meta‐regression was not needed. </p> </section> <section id="CD012565-sec-0045"> <h5 class="title">Assessment of significance</h5> <p>We assessed our intervention effects using both random‐effects model meta‐analyses and fixed‐effect model meta‐analyses (<a href="./references#CD012565-bbs2-0056" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88. [PMID: 3802833]">DerSimonian 1986</a>; <a href="./references#CD012565-bbs2-0055" title="DeMetsDL . Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine1987;6(3):341-50. [PMID: 3616287]">DeMets 1987</a>). We used the more conservative point estimate of the two (<a href="./references#CD012565-bbs2-0084" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). The more conservative point estimate was the estimate closest to no effect (highest P value). If the two estimates were equal, we used the estimate with the widest confidence interval. We assessed three primary outcomes, and due to the risk of multiplicity, we calculated a P value less than 0.025 and a 97.5% CI for the primary outcomes (<a href="./references#CD012565-bbs2-0084" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). We assessed four secondary outcomes and calculated a P value less than 0.02 and a 98% CI for secondary outcomes (<a href="./references#CD012565-bbs2-0084" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). We used the statistical software STATA version 16.1 (command:meta) for CI‐adjusted meta‐analyses (<a href="./references#CD012565-bbs2-0128" title="StataCorp; Stata Statistical Software. College Station: TX: StataCorp LLC, 2016. http://www.stata.com.">STATA 2016</a>). </p> <p>We included all trials in our analyses, and we planned to conduct a sensitivity analysis of trials at low risk of bias. If results were similar, we would base our primary conclusions at maximum follow‐up on the overall analysis. If they differed, we would base our primary conclusions on trials with low risk of bias. However, we did not include any trials at low risk of bias, and our primary conclusions were based on the overall analysis. </p> </section> </section> <section id="CD012565-sec-0046"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform the following subgroup analyses.</p> <p> <ul id="CD012565-list-0014"> <li> <p>Trials in which participants received intervention for reperfusion (coronary artery bypass graft, percutaneous coronary intervention, or thrombolytics) compared to trials in which participants did not receive intervention for reperfusion. Additionally, we planned to assess if there seemed to be a difference between different reperfusion strategies<i>.</i> However, no trials reported data on participants who received any intervention for reperfusion, and we could not carry out this subgroup analysis. </p> </li> <li> <p>Trials in which the experimental group received different types of beta‐blockers.</p> <ul id="CD012565-list-0015"> <li> <p>Acebutolol.</p> </li> <li> <p>Alprenolol.</p> </li> <li> <p>Atenolol.</p> </li> <li> <p>Carvedilol.</p> </li> <li> <p>Metoprolol.</p> </li> <li> <p>Oxprenolol.</p> </li> <li> <p>Pindolol.</p> </li> <li> <p>Practolol.</p> </li> <li> <p>Propranolol.</p> </li> <li> <p>Sotalol.</p> </li> <li> <p>Timolol.</p> </li> </ul> </li> <li> <p>Trials with different follow‐up.</p> <ul id="CD012565-list-0016"> <li> <p>Six months or less.</p> </li> <li> <p>Between six months and 12 months.</p> </li> <li> <p>Between one year and three years.</p> </li> <li> <p>Three years or longer.</p> </li> </ul> </li> <li> <p>Trials with different age of participants.</p> <ul id="CD012565-list-0017"> <li> <p>Aged 0 to 18 years.</p> </li> <li> <p>Aged 18 to 75 years.</p> </li> <li> <p>Aged 75 years or older. However, no trials reported data on participants aged 0 to 18 years and 75 years or older, and we could not carry out this subgroup analysis. </p> </li> </ul> </li> <li> <p>Trials that randomise men compared to trials that randomise women. However, this subgroup analysis could not be carried out due to no data. </p> </li> <li> <p>Trials with different clinical trial registration status.</p> <ul id="CD012565-list-0018"> <li> <p>Pre‐registration.</p> </li> <li> <p>Post‐registration.</p> </li> <li> <p>No registration.</p> </li> </ul> </li> <li> <p>Comparison of effects of beta‐blockers versus placebo or no intervention between trials including different types of acute myocardial infarction. </p> <ul id="CD012565-list-0019"> <li> <p>Unstable angina pectoris.</p> </li> <li> <p>NSTEMI.</p> </li> <li> <p>STEMI. However, no trials reported exact data on participants with different types of acute myocardial infarction, and we could not carry out this subgroup analysis. </p> </li> </ul> </li> </ul> </p> <section id="CD012565-sec-0047"> <h5 class="title">Post hoc subgroup analyses</h5> <p> <ul id="CD012565-list-0020"> <li> <p>Comparison of effects between trials with different funding</p> <ul id="CD012565-list-0021"> <li> <p>Industry‐funded trials or trial with unknown funding</p> </li> <li> <p>Non‐industry‐funded trials</p> </li> </ul> </li> <li> <p>Comparison of trials in which beta‐blockers were administered more than seven days after acute myocardial infarction (non‐acute phase) to trials in which beta‐blockers were administered within seven days after acute myocardial infarction (subacute phase) </p> </li> <li> <p>Comparison of trials specifically excluding heart failure participants to trials specifically excluding heart failure participants but likely not adhering to this. We had, in our protocol, planned to exclude trials specifically randomising participants with heart failure. However, several trials specifically excluded heart failure participants but reported some percentage of participants with heart failure in the baseline table. We chose to include these trials but decided to perform a post hoc subgroup analysis comparing these trials to trials without any heart failure participants </p> </li> </ul> </p> </section> </section> <section id="CD012565-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to assess the potential impact of bias by performing a sensitivity analysis from which we would exclude trials with overall high risk of bias. However, because all included trials were at high risk of bias, we did not do this. </p> <p>To assess the potential impact of missing data for dichotomous outcomes, we performed best‐worst and worst‐best case scenarios (see <a href="#CD012565-sec-0037">Dealing with missing data</a>). </p> <p>If any post hoc analysis was included, we regarded these primarily as hypothesis‐generating. A post hoc test for subgroup differences comparing trials specifically excluding heart failure participants to trials specifically excluding heart failure participants but likely not adhering to this was included in the review. </p> </section> <section id="CD012565-sec-0049"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE system to assess the certainty of the body of evidence associated with each of the primary outcomes (all‐cause mortality, major cardiovascular events, serious adverse events) and with four secondary outcomes (quality of life, angina, cardiovascular mortality, myocardial infarction) (<a href="./references#CD012565-bbs2-0067" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed)2008;336(7650):924-6. [PMID: 18436948]">Guyatt 2008</a>). We constructed a 'Summary of findings' (SoF) table using the GRADEpro Guideline Development Tool (<a href="https://gradepro.org" target="_blank">www.gradepro.org</a>). The GRADE approach appraises the certainty of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The certainty measure of a body of evidence considers within‐study risk of bias, directness of evidence, heterogeneity of data, precision of effect estimates, and risk of publication bias. Two review authors (SS and NJS) assessed the certainty of evidence independently and decided on downgrading. If no agreement could be reached, a third review author (JCJ) resolved the discussion. We justified all decisions to downgrade the certainty of trials using footnotes, and we made comments to aid the reader's understanding of the review when necessary. We included all trials in our analyses, and we planned to conduct a sensitivity analysis with trials at low risk of bias; however, we found no trials to be at low risk of bias. If results had been similar, we would base our primary SoF table and primary conclusions (from our primary time point of interest at maximum follow‐up) on the overall analysis. If results had differed, we would base our primary SoF table and primary conclusions on trials at low risk of bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012565-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012565-sec-0050"></div> <section id="CD012565-sec-0051"> <h3 class="title">Description of studies</h3> <p>We assessed all trials according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and the protocol for this review (<a href="./references#CD012565-bbs2-0071" title="HigginsJT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>; <a href="./references#CD012565-bbs2-0106" title="NielsenEE , FeinbergJ , SafiS , SethiNJ , GluudC , JakobsenJC . Beta-blockers for non-acute treatment after myocardial infarction. Cochrane Database of Systematic Reviews Feb 2017, Issue 1. Art. No: CD012565. [DOI: 10.1002/14651858.CD012565]">Nielsen 2017</a>). Characteristics of each trial can be found in <a href="./references#CD012565-sec-0142" title="">Characteristics of included studies</a>; <a href="./references#CD012565-sec-0143" title="">Characteristics of excluded studies</a>; and <a href="./references#CD012565-sec-0144" title="">Characteristics of ongoing studies</a> sections. </p> <section id="CD012565-sec-0052"> <h4 class="title">Results of the search</h4> <p>Through our initial search, we identified 19,140 references at the Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library (n = 2799), MEDLINE (n = 2471), Embase (n = 6152), Science Citation Index ‐ Expanded (n = 5008), BIOSIS (n = 2615), and the Latin American Caribbean Health Sciences Literature (LILACS) (n = 95). The search strategy is presented in <a href="./appendices#CD012565-sec-0125">Appendix 1</a>. We found five potentially relevant references when searching clinical trials registers, Google Scholar, and reference lists of included trials, as well as previous systematic reviews and other types of reviews. After removing duplicates, we screened 12,889 records. We deemed 133 records relevant and obtained full texts for further evaluation. We then excluded 72 studies based on review of titles, abstracts, or full texts (see <a href="#CD012565-fig-0001">Figure 1</a>). Five records reported ongoing trials (see <a href="./references#CD012565-sec-0144" title="">Characteristics of ongoing studies</a>). Reasons for exclusion for six studies that most closely missed our inclusion criteria are listed in the <a href="https://archie.cochrane.org/sections/documents/view?version=z1705041558487490732029961903496&amp;format=REVMAN#CHARACTERISTICS_OF_EXCLUDED_STUDIES" target="_blank">Characteristics of excluded studies</a> table. The remaining 56 full‐text articles reported on 25 completed randomised clinical trials, which we included in the review according to our pre‐defined inclusion and exclusion criteria. </p> <div class="figure" id="CD012565-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012565-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012565-sec-0053"> <h4 class="title">Included studies</h4> <p>We included 56 references reporting on 25 trials comparing beta‐blockers versus control (<a href="#CD012565-fig-0001">Figure 1</a>), as well as five ongoing trials (<a href="./references#CD012565-bbs2-0032" title="MunkhaugenJ , RuddoxV , HalvorsenS , DammenT , FagerlandMW , HernæsKH , et al. BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): rationale and design of a prospective, randomized, open, blinded end point study. American Heart Journal2019;208:37-46. [PMID: 30530121]">BETAMI 2018</a>; <a href="./references#CD012565-bbs2-0033" title="KristensenAMD , BovinA , ZwislerAD , CerquiraC , Torp-PedersenC , BøtkerHE , et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. Trials2020;21(1):415. ">DANBLOCK 2018</a>; <a href="./references#CD012565-bbs2-0034" title="NordenskjöldAM , AgewallS , AtarD , BaronT , BeltrameJ , BergströmO , et al. Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): rationale and design. American Heart Journal2021;231:96-104. [PMID: 33203618]">MINOCA‐BAT 2021</a>; <a href="./references#CD012565-bbs2-0035" title="RosselloX , Raposeiras-RoubinS , LatiniR , Dominguez-RodriguezA , BarrabésJA , SánchezPL , et al. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). European Heart Journal. Cardiovascular Pharmacotherapy2021;August:pvab060. [PMID: 34351426]">REBOOT‐CNIC2018</a>; <a href="./references#CD012565-bbs2-0036" title="Assessment of βeta-Blocker Interruption After Uncomplicated Myocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization: The AβYSS Study. Ongoing study. 29 August 2018. Contact author for more information.">The AβYSS Study 2018</a>). Most trials were conducted between 1974 and 1999, and only one trial occurred in 2018 (<a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>). These trials (often multi‐national) were conducted at sites in 19 different countries: Australia, China, Denmark, France, Germany, Holland, Hungary, Italy, Japan, New Zealand, Norway, Russia, Scotland, South Africa, Sweden, Switzerland, United Kingdom, United States, and Yugoslavia. For further details on included trials and baseline characteristics of included participants, see <a href="./references#CD012565-sec-0142" title="">Characteristics of included studies</a>. </p> <p>Only one trial exclusively included participants with STEMI (<a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>), and no included trials reported outcomes with STEMI, NSTEMI, or unstable angina status on presentation separately. Hence, determination of benefits in these subgroups could not be assessed separately. It is important to note that most trials were conducted in an era that preceded coronary reperfusion (coronary artery bypass graft, percutaneous coronary intervention, or thrombolytics). Thus, determination of benefits in these subgroups could not be sufficiently assessed separately. It is similarly important to know that a large proportion of trials did not describe the use of lipid‐lowering medication, including statins. Fifteen trials excluded participants with heart failure, and 10 trials were equivocal and specifically excluded participants with heart failure but reported some heart failure participants in the baseline table (<a href="./references#CD012565-bbs2-0003" title="AhnveS , ErhardtL , LundmanT , RehnqvistN , SjögrenA . Effect of metoprolol on QTc intervals after acute myocardial infarction. Acta Medica Scandinavica1980;208(3):223-8. ">Ahnve 1980</a>; <a href="./references#CD012565-bbs2-0005" title="BoisselJP , LeizoroviczA , PicoletH , DucruetT . Efficacy of acebutolol after acute myocardial infarction (the APSI trial). American Journal of Cardiology1990;66(9):24C-31C. BoisselJP , LeizoroviczA , PicoletH , PeyrieuxJC . Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. American Journal of Cardiology1990;66(3):251-60. CucheratM , BoisselJP , LeizoroviczA . Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. American Journal of Cardiology1997;79(5):587-9. ">APSI 1997</a>; <a href="./references#CD012565-bbs2-0006" title="Australian and Swedish Pindolol Study Group. The effect of pindolol on the two years mortality after complicated myocardial infarction. European Heart Journal1983;4(6):367-75. ">Australien &amp; Swedish 1983</a>; <a href="./references#CD012565-bbs2-0007" title="BaberNS , EvansDW , HowittG , ThomasM , WilsonC , LewisJA , et al. Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy, and Yugoslavia. British Heart Journal1980;44(1):96-100. ">Baber 1980</a>; <a href="./references#CD012565-bbs2-0010" title="Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA1983;250(20):2814-9. ByingtonRP , Beta-Blocker Heart Attack Trial Research Group. Beta-blocker heart attack trial: design, methods, and baseline results. Control Clinical Trials1984;5(4):382-437. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. American Journal of Cardiology1990;66(2):129-33. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1991;122(6):1548-53. GheorghiadeM , ShivkumarK , SchultzL , JafriS , TilleyB , GoldsteinS . Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1993;126(2):271-8. GoldsteinS , ByingtonR . The Beta Blocker Heart Attack Trial: recruitment experience. Controlled Clinical Trials1987;8(4 Suppl):79S-85S. KostisJB , ByingtonR , FriedmanLM , GoldsteinS , FurbergC . Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. Journal of the American College of Cardiology1987;10(2):231-42. National Heart, Lung, and Blood Institute. Beta-blocker heart attack trial study protocol [https://babel.hathitrust.org/cgi/pt?id=pur1.32754081210092;view=1up;seq=3]. U.S. Depeartment of Health and Human Services. Public Health Service, National Institues of Health1978;81-2209. PetersRW , ByingtonR , ArensbergD , FriedmanLM , RomhiltDW , BarkerA , et al. Mortality in the beta blocker heart attack trial: circumstances surrounding death. Journal of Chronic Diseases1987;40(1):75-82. ShivkumarK , SchultzL , GoldsteinS , GheorghiadeM . Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. American Heart Journal1998;135(2 Pt 1):261-7. The Beta-blocker Heart Attack Trial (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA1982;247(12):1707-14. The Beta Blocker Heart Attack Trial Research Group. Beta blocker heart attack trial: design features. Controlled Clinical Trials1981;2(4):275-85. ">BHAT 1982</a>; <a href="./references#CD012565-bbs2-0013" title="BethgeKP , AndresenD , BoisselJP , LeitnerER , PeyrieuxJC , SchröderR , et al. Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. Journal of the American College of Cardiology1985;6(5):963-72. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. European Heart Journal1984;5:189-202. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction. European Heart Journal1982;3:583-6. ">E.I.S. 1984</a>; <a href="./references#CD012565-bbs2-0014" title="JulianDG , PrescottRJ , JacksonFS , SzekelyP . Controlled trial of sotalol for one year after myocardial infarction. Lancet1982;1(8282):1142-7. ">Julian 1982</a>; <a href="./references#CD012565-bbs2-0015" title="Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. European Heart Journal1987;8:1056-64. ">LIT 1987</a>; <a href="./references#CD012565-bbs2-0019" title="BellinEY , The Nowergian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on timolol after myocardial infarction. 1986;314(16):1052-3. Lund-Johansen, The Norwegian Multicenter Study Group. The Norwegian multicenter study on timolol after myocardial infarction. Part II. Effect in different risk groups, causes of death, heart arrest, reinfarctions, rehospitalizations and adverse experiences. Acta Medica Scandinavica1981;651:243-52. PedersenTR , The Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. New England Journal of Medicine1985;313(17):1055-8. The Norwegian Multicenter Study Group. The Norwegian multicenter study on timolol after myocardial infarction. Acta Medica Scandinavica1981;651:235-41. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New England Journal of Medicine1981;304(14):801-7. ">NMS 1981</a>; <a href="./references#CD012565-bbs2-0020" title="HansteenV , MøinichenE , LorentsenE , AndersenA , StrømO , SøilandK , et al. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. BMJ1982;284:155-60. HansteenV . Beta blockade after myocardial infarction: the Norwegian propranolol study in high-risk patients. Circulation1983;67(Suppl 1):I57-60. HansteenV . The Norwegian propranolol trial in selected patients. British Journal of Clinical Pharmacology1982;14:9S-12S. ">NPT 1982</a>). <a href="./references#CD012565-bbs2-0017" title="MazzueroG , GaldangeloF , ZottiAM , BertolottiG , TavazziL . Effects of propranolol, atenolol, and chlordesmethyldiazepam on response to mental stress in patients with recent myocardial infarction. Clinical Cardiology1987;10(6):293-302. ">Mazzuero 1987</a> was a multi‐armed trial (see <a href="./references#CD012565-sec-0142" title="">Characteristics of included studies),</a> and four trials did not report any useful data to be extracted (<a href="./references#CD012565-bbs2-0001" title="AdesPA , ThomasJD , HansonJS , ShapiroSM , LaMountainJ . Effect of metoprolol on the submaximal stress test performed early after acute myocardial infarction. American Journal of Cardiology1987;60(13):963-6. ">Ades 1987</a>; <a href="./references#CD012565-bbs2-0008" title="BarvikS , DicksteinK , AarslandT , Vik-MoH . Effect of timolol on cardiopulmonary exercise performance in men after myocardial infarction. American Journal of Cardiology1982;69(3):163-8. ">Barvik 1992</a>; <a href="./references#CD012565-bbs2-0012" title="CurtisJL , HoughtonJL , PattersonJH , KochG , BradleyDA , Adams KF Jr. Propranolol therapy alters estimation of potential cardiovascular risk derived from submaximal postinfarction exercise testing. American Heart Journal1991;121(6 Pt 1):1655-64. ">Curtis 1991</a>; <a href="./references#CD012565-bbs2-0017" title="MazzueroG , GaldangeloF , ZottiAM , BertolottiG , TavazziL . Effects of propranolol, atenolol, and chlordesmethyldiazepam on response to mental stress in patients with recent myocardial infarction. Clinical Cardiology1987;10(6):293-302. ">Mazzuero 1987</a>); hence, available data for analysis were reported in the remaining 21 trials. </p> <p>At maximum follow‐up (median 43.3 months, range 9 to 60 months), 21 of 25 trials reported all‐cause mortality, 15 of 25 reported major cardiovascular events, 5 of 25 reported angina pectoris, 19 of 25 reported cardiovascular mortality, and 19 of 25 reported myocardial reinfarction. None of the trials reported serious adverse events according to ICH‐GCP nor quality of life. For further details, see <a href="./full#CD012565-tbl-0001">summary of findings Table 1</a>. Three trials included stabilised participants for whom administration of beta‐blockers was started within seven days following acute myocardial infarction (<a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>; <a href="./references#CD012565-bbs2-0020" title="HansteenV , MøinichenE , LorentsenE , AndersenA , StrømO , SøilandK , et al. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. BMJ1982;284:155-60. HansteenV . Beta blockade after myocardial infarction: the Norwegian propranolol study in high-risk patients. Circulation1983;67(Suppl 1):I57-60. HansteenV . The Norwegian propranolol trial in selected patients. British Journal of Clinical Pharmacology1982;14:9S-12S. ">NPT 1982</a>; <a href="./references#CD012565-bbs2-0022" title="PoulsenSH , JensenSE , EgstrupK . Effects of long-term adrenergic beta-blockade on left ventricular diastolic filling in patients with acute myocardial infarction. American Heart Journal1999;138(4 Pt 1):710-20. PoulsenSH , JensenSE , EgstrupK . Improvement of exercise capacity and left ventricular diastolic function with metoprolol XL after acute myocardial infarction. American Heart Journal2000;140(1):E6-11. ">Poulsen 1999</a>). Remaining included trials administered beta‐blockers after at least seven days following acute myocardial infarction and continued this treatment for a minimum of nine months or for years thereafter. </p> <section id="CD012565-sec-0054"> <h5 class="title">Participants</h5> <p>A total of 22,423 participants were randomised in the 25 included trials. However, given that only 21 of the included trials contributed useful data, our analyses are based on 22,085 participants. The smallest of the trials included only 28 participants (<a href="./references#CD012565-bbs2-0008" title="BarvikS , DicksteinK , AarslandT , Vik-MoH . Effect of timolol on cardiopulmonary exercise performance in men after myocardial infarction. American Journal of Cardiology1982;69(3):163-8. ">Barvik 1992</a>), and the largest trial enrolled 3837 participants (<a href="./references#CD012565-bbs2-0018" title="A Multicentre International Study Group. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. BMJ1975;3:735-40. The Multicentre International Study Group. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. BMJ1977;2:419-21. ">MIS 1975</a>). Mean age in the 25 trials reporting age was 56.9 years (range 50 to 63 years). The mean proportion of women was 17.3% (2/25 trials did not report the sex distribution). The mean proportion of participants with a former myocardial infarction was 12.6% (12/25 trials did not report previous myocardial infarctions). </p> </section> <section id="CD012565-sec-0055"> <h5 class="title">Experimental intervention</h5> <p>Eleven different beta‐blockers were assessed in the included trials: six with metoprolol, six with propranolol, three with oxprenolol, two with alprenolol, two with timolol, and one each with acebutolol, atenolol, carvedilol, pindolol, practolol, and sotalol. </p> </section> <section id="CD012565-sec-0056"> <h5 class="title">Control intervention</h5> <p>We included 21 trials in which the control group received placebo and four trials in which the control group received no intervention other than the co‐intervention or usual care (<a href="./references#CD012565-bbs2-0002" title="AhlmarkG , SaetreH , KorsgrenM . Reduction of sudden deaths after myocardial infarction. Lancet1974;2(7896):1563. AhlmarkG , SaetreH . Long-term treatment with beta-blockers after myocardial infarction. European Journal of Clinical Pharmacology1976;10(2):77-83. AhlmarkG , SaetreH . Positon of myocardial infarct and results of alprenolol treatment. BMJ1976;1(6013):837. ">Ahlmark 1976</a>; <a href="./references#CD012565-bbs2-0009" title="WuN , FanZ . Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. American Journal of Cardiology1997;110(8):602-6. ">BCSG 1997</a>; <a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>; <a href="./references#CD012565-bbs2-0016" title="MazurNA , KulginskayaIV , IvanovaLA , Ostrov SkayaTP , SmirnovaTM , SvetEA , et al. Results of long-term propranolol treatment in myocardial infarction survivors with advanced grades of ventricular extrasystoles. Cor et Vasa1984;26(4):241-7. ">Mazur 1984</a>). </p> </section> <section id="CD012565-sec-0057"> <h5 class="title">Co‐interventions</h5> <p>A total of 15 of 25 trials did not describe any co‐intervention. Seven trials received standard medical therapy as co‐intervention consisting of digitalis, diuretics, vasodilators, antiarrhythmics, anticoagulants, nitrates, and aspirin (<a href="./references#CD012565-bbs2-0001" title="AdesPA , ThomasJD , HansonJS , ShapiroSM , LaMountainJ . Effect of metoprolol on the submaximal stress test performed early after acute myocardial infarction. American Journal of Cardiology1987;60(13):963-6. ">Ades 1987</a>; <a href="./references#CD012565-bbs2-0002" title="AhlmarkG , SaetreH , KorsgrenM . Reduction of sudden deaths after myocardial infarction. Lancet1974;2(7896):1563. AhlmarkG , SaetreH . Long-term treatment with beta-blockers after myocardial infarction. European Journal of Clinical Pharmacology1976;10(2):77-83. AhlmarkG , SaetreH . Positon of myocardial infarct and results of alprenolol treatment. BMJ1976;1(6013):837. ">Ahlmark 1976</a>; <a href="./references#CD012565-bbs2-0005" title="BoisselJP , LeizoroviczA , PicoletH , DucruetT . Efficacy of acebutolol after acute myocardial infarction (the APSI trial). American Journal of Cardiology1990;66(9):24C-31C. BoisselJP , LeizoroviczA , PicoletH , PeyrieuxJC . Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. American Journal of Cardiology1990;66(3):251-60. CucheratM , BoisselJP , LeizoroviczA . Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. American Journal of Cardiology1997;79(5):587-9. ">APSI 1997</a>; <a href="./references#CD012565-bbs2-0006" title="Australian and Swedish Pindolol Study Group. The effect of pindolol on the two years mortality after complicated myocardial infarction. European Heart Journal1983;4(6):367-75. ">Australien &amp; Swedish 1983</a>; <a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>; <a href="./references#CD012565-bbs2-0013" title="BethgeKP , AndresenD , BoisselJP , LeitnerER , PeyrieuxJC , SchröderR , et al. Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. Journal of the American College of Cardiology1985;6(5):963-72. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. European Heart Journal1984;5:189-202. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction. European Heart Journal1982;3:583-6. ">E.I.S. 1984</a>; <a href="./references#CD012565-bbs2-0021" title="OlssonG , LevinLA , RehnqvistN . Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol. British Medical Journal (Clinical Research Edition)1987;294(6568):339-42. OlssonG , LubsenJ , vanEsGA , RehnqvistN . Quality of life after myocardial infarction: effect of long term metoprolol on mortality and morbidity. British Medical Journal (Clinical Research Edition)1986;292(6534):1491-3. OlssonG , OdénA , JohanssonL , SjögrenA , RehnqvistN . Prognosis after withdrawal of chronic postinfarction metoprolol treatment: a 2-7 year follow-up. European Heart Journal1988;9(4):365-72. OlssonG , RehnqvistN , LundmandT , MelcherA . Metoprolol treatment after acute myocardial infarction - Effects on ventricular arrhythmias and exercise tests during 6 months. Acta Medica Scandinavica1981;210(1-2):59-65. OlssonG , RehnqvistN , SjögrenA , ErhardtL , LundmanT . Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. Journal of the American College of Cardiology1985;5(6):1428-37. ">Olsson 1985</a>). One trial described the co‐intervention as conventional therapy without further specification (<a href="./references#CD012565-bbs2-0009" title="WuN , FanZ . Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. American Journal of Cardiology1997;110(8):602-6. ">BCSG 1997</a>); one trial added tranquilliser, potassium, antihypertensive, dipyridamole, insulin, hormonal, oral hypoglycaemic, sulphinpyrazone, and lipid‐lowering drugs to standard medical therapy as the co‐intervention (<a href="./references#CD012565-bbs2-0010" title="Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA1983;250(20):2814-9. ByingtonRP , Beta-Blocker Heart Attack Trial Research Group. Beta-blocker heart attack trial: design, methods, and baseline results. Control Clinical Trials1984;5(4):382-437. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. American Journal of Cardiology1990;66(2):129-33. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1991;122(6):1548-53. GheorghiadeM , ShivkumarK , SchultzL , JafriS , TilleyB , GoldsteinS . Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1993;126(2):271-8. GoldsteinS , ByingtonR . The Beta Blocker Heart Attack Trial: recruitment experience. Controlled Clinical Trials1987;8(4 Suppl):79S-85S. KostisJB , ByingtonR , FriedmanLM , GoldsteinS , FurbergC . Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. Journal of the American College of Cardiology1987;10(2):231-42. National Heart, Lung, and Blood Institute. Beta-blocker heart attack trial study protocol [https://babel.hathitrust.org/cgi/pt?id=pur1.32754081210092;view=1up;seq=3]. U.S. Depeartment of Health and Human Services. Public Health Service, National Institues of Health1978;81-2209. PetersRW , ByingtonR , ArensbergD , FriedmanLM , RomhiltDW , BarkerA , et al. Mortality in the beta blocker heart attack trial: circumstances surrounding death. Journal of Chronic Diseases1987;40(1):75-82. ShivkumarK , SchultzL , GoldsteinS , GheorghiadeM . Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. American Heart Journal1998;135(2 Pt 1):261-7. The Beta-blocker Heart Attack Trial (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA1982;247(12):1707-14. The Beta Blocker Heart Attack Trial Research Group. Beta blocker heart attack trial: design features. Controlled Clinical Trials1981;2(4):275-85. ">BHAT 1982</a>); and participants in one trial received long‐acting nitrates and nifedipine as co‐intervention when needed (<a href="./references#CD012565-bbs2-0023" title="SchwartzPJ , MotoleseM , PollaviniG , LottoA , RubertiU , TrazziR , et al. Prevention of sudden cardiac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. Journal of Cardiovascular Electrophysiology1992;3(1):2-16. ">Schwartz 1992</a>). As stated, only <a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a> was from the reperfusion era, and remaining included trials did not include statins or invasive cardiology interventions. For further details, see <a href="./references#CD012565-sec-0142" title="">Characteristics of included studies</a>. </p> </section> <section id="CD012565-sec-0058"> <h5 class="title">Summary of funding sources</h5> <p>Five trials did not report the source of funding (<a href="./references#CD012565-bbs2-0002" title="AhlmarkG , SaetreH , KorsgrenM . Reduction of sudden deaths after myocardial infarction. Lancet1974;2(7896):1563. AhlmarkG , SaetreH . Long-term treatment with beta-blockers after myocardial infarction. European Journal of Clinical Pharmacology1976;10(2):77-83. AhlmarkG , SaetreH . Positon of myocardial infarct and results of alprenolol treatment. BMJ1976;1(6013):837. ">Ahlmark 1976</a>; <a href="./references#CD012565-bbs2-0004" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335-71. ">Amsterdam Metoprolol Trial 1983</a>; <a href="./references#CD012565-bbs2-0008" title="BarvikS , DicksteinK , AarslandT , Vik-MoH . Effect of timolol on cardiopulmonary exercise performance in men after myocardial infarction. American Journal of Cardiology1982;69(3):163-8. ">Barvik 1992</a>; <a href="./references#CD012565-bbs2-0016" title="MazurNA , KulginskayaIV , IvanovaLA , Ostrov SkayaTP , SmirnovaTM , SvetEA , et al. Results of long-term propranolol treatment in myocardial infarction survivors with advanced grades of ventricular extrasystoles. Cor et Vasa1984;26(4):241-7. ">Mazur 1984</a>; <a href="./references#CD012565-bbs2-0017" title="MazzueroG , GaldangeloF , ZottiAM , BertolottiG , TavazziL . Effects of propranolol, atenolol, and chlordesmethyldiazepam on response to mental stress in patients with recent myocardial infarction. Clinical Cardiology1987;10(6):293-302. ">Mazzuero 1987</a>). Five trials were funded by charity or by academic institutions (<a href="./references#CD012565-bbs2-0009" title="WuN , FanZ . Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. American Journal of Cardiology1997;110(8):602-6. ">BCSG 1997</a>; <a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>; <a href="./references#CD012565-bbs2-0012" title="CurtisJL , HoughtonJL , PattersonJH , KochG , BradleyDA , Adams KF Jr. Propranolol therapy alters estimation of potential cardiovascular risk derived from submaximal postinfarction exercise testing. American Heart Journal1991;121(6 Pt 1):1655-64. ">Curtis 1991</a>; <a href="./references#CD012565-bbs2-0021" title="OlssonG , LevinLA , RehnqvistN . Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol. British Medical Journal (Clinical Research Edition)1987;294(6568):339-42. OlssonG , LubsenJ , vanEsGA , RehnqvistN . Quality of life after myocardial infarction: effect of long term metoprolol on mortality and morbidity. British Medical Journal (Clinical Research Edition)1986;292(6534):1491-3. OlssonG , OdénA , JohanssonL , SjögrenA , RehnqvistN . Prognosis after withdrawal of chronic postinfarction metoprolol treatment: a 2-7 year follow-up. European Heart Journal1988;9(4):365-72. OlssonG , RehnqvistN , LundmandT , MelcherA . Metoprolol treatment after acute myocardial infarction - Effects on ventricular arrhythmias and exercise tests during 6 months. Acta Medica Scandinavica1981;210(1-2):59-65. OlssonG , RehnqvistN , SjögrenA , ErhardtL , LundmanT . Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. Journal of the American College of Cardiology1985;5(6):1428-37. ">Olsson 1985</a>; <a href="./references#CD012565-bbs2-0022" title="PoulsenSH , JensenSE , EgstrupK . Effects of long-term adrenergic beta-blockade on left ventricular diastolic filling in patients with acute myocardial infarction. American Heart Journal1999;138(4 Pt 1):710-20. PoulsenSH , JensenSE , EgstrupK . Improvement of exercise capacity and left ventricular diastolic function with metoprolol XL after acute myocardial infarction. American Heart Journal2000;140(1):E6-11. ">Poulsen 1999</a>); 14 studies were funded by pharmaceutical companies (<a href="./references#CD012565-bbs2-0001" title="AdesPA , ThomasJD , HansonJS , ShapiroSM , LaMountainJ . Effect of metoprolol on the submaximal stress test performed early after acute myocardial infarction. American Journal of Cardiology1987;60(13):963-6. ">Ades 1987</a>; <a href="./references#CD012565-bbs2-0003" title="AhnveS , ErhardtL , LundmanT , RehnqvistN , SjögrenA . Effect of metoprolol on QTc intervals after acute myocardial infarction. Acta Medica Scandinavica1980;208(3):223-8. ">Ahnve 1980</a>; <a href="./references#CD012565-bbs2-0005" title="BoisselJP , LeizoroviczA , PicoletH , DucruetT . Efficacy of acebutolol after acute myocardial infarction (the APSI trial). American Journal of Cardiology1990;66(9):24C-31C. BoisselJP , LeizoroviczA , PicoletH , PeyrieuxJC . Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. American Journal of Cardiology1990;66(3):251-60. CucheratM , BoisselJP , LeizoroviczA . Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. American Journal of Cardiology1997;79(5):587-9. ">APSI 1997</a>; <a href="./references#CD012565-bbs2-0006" title="Australian and Swedish Pindolol Study Group. The effect of pindolol on the two years mortality after complicated myocardial infarction. European Heart Journal1983;4(6):367-75. ">Australien &amp; Swedish 1983</a>; <a href="./references#CD012565-bbs2-0007" title="BaberNS , EvansDW , HowittG , ThomasM , WilsonC , LewisJA , et al. Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy, and Yugoslavia. British Heart Journal1980;44(1):96-100. ">Baber 1980</a>; <a href="./references#CD012565-bbs2-0013" title="BethgeKP , AndresenD , BoisselJP , LeitnerER , PeyrieuxJC , SchröderR , et al. Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. Journal of the American College of Cardiology1985;6(5):963-72. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. European Heart Journal1984;5:189-202. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction. European Heart Journal1982;3:583-6. ">E.I.S. 1984</a>; <a href="./references#CD012565-bbs2-0014" title="JulianDG , PrescottRJ , JacksonFS , SzekelyP . Controlled trial of sotalol for one year after myocardial infarction. Lancet1982;1(8282):1142-7. ">Julian 1982</a>; <a href="./references#CD012565-bbs2-0015" title="Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. European Heart Journal1987;8:1056-64. ">LIT 1987</a>; <a href="./references#CD012565-bbs2-0018" title="A Multicentre International Study Group. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. BMJ1975;3:735-40. The Multicentre International Study Group. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. BMJ1977;2:419-21. ">MIS 1975</a>; <a href="./references#CD012565-bbs2-0019" title="BellinEY , The Nowergian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on timolol after myocardial infarction. 1986;314(16):1052-3. Lund-Johansen, The Norwegian Multicenter Study Group. The Norwegian multicenter study on timolol after myocardial infarction. Part II. Effect in different risk groups, causes of death, heart arrest, reinfarctions, rehospitalizations and adverse experiences. Acta Medica Scandinavica1981;651:243-52. PedersenTR , The Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. New England Journal of Medicine1985;313(17):1055-8. The Norwegian Multicenter Study Group. The Norwegian multicenter study on timolol after myocardial infarction. Acta Medica Scandinavica1981;651:235-41. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New England Journal of Medicine1981;304(14):801-7. ">NMS 1981</a>; <a href="./references#CD012565-bbs2-0020" title="HansteenV , MøinichenE , LorentsenE , AndersenA , StrømO , SøilandK , et al. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. BMJ1982;284:155-60. HansteenV . Beta blockade after myocardial infarction: the Norwegian propranolol study in high-risk patients. Circulation1983;67(Suppl 1):I57-60. HansteenV . The Norwegian propranolol trial in selected patients. British Journal of Clinical Pharmacology1982;14:9S-12S. ">NPT 1982</a>; <a href="./references#CD012565-bbs2-0023" title="SchwartzPJ , MotoleseM , PollaviniG , LottoA , RubertiU , TrazziR , et al. Prevention of sudden cardiac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. Journal of Cardiovascular Electrophysiology1992;3(1):2-16. ">Schwartz 1992</a>; <a href="./references#CD012565-bbs2-0024" title="TaylorSH , SilkeB , EbbuttA , SuttonGC , ProutBJ , BurleyDM . A long-term prevention study with oxprenolol in coronary heart disease. New England Journal of Medicine1982;307(21):1293-301. ">Taylor 1982</a>; <a href="./references#CD012565-bbs2-0025" title="VedinA , WilhelmssonC , WerköL . Chronic alprenolol treatment of patients with acute myocardial infarction after discharge from hospital. Acta Medica Scandinavica Supplementum1975;575:3-56. WihelmssonC , VedinA , WilhelmsenL , TibblinG , WerköL , WedelH . Deaths and non-fatal reinfarctions during two years' follow-up. Acta Medica Scandinavica Supplementum1975;575:19-24. WilhelmssonC , VedinJA , WilhelmsenL , TibblinG , WerköL . Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet1974;2(7890):1157-60. ">Wilhelmsson 1974</a>); and one study received free study medication for a trial that had otherwise been planned and conducted independently and was funded largely by public means (<a href="./references#CD012565-bbs2-0010" title="Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA1983;250(20):2814-9. ByingtonRP , Beta-Blocker Heart Attack Trial Research Group. Beta-blocker heart attack trial: design, methods, and baseline results. Control Clinical Trials1984;5(4):382-437. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. American Journal of Cardiology1990;66(2):129-33. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1991;122(6):1548-53. GheorghiadeM , ShivkumarK , SchultzL , JafriS , TilleyB , GoldsteinS . Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1993;126(2):271-8. GoldsteinS , ByingtonR . The Beta Blocker Heart Attack Trial: recruitment experience. Controlled Clinical Trials1987;8(4 Suppl):79S-85S. KostisJB , ByingtonR , FriedmanLM , GoldsteinS , FurbergC . Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. Journal of the American College of Cardiology1987;10(2):231-42. National Heart, Lung, and Blood Institute. Beta-blocker heart attack trial study protocol [https://babel.hathitrust.org/cgi/pt?id=pur1.32754081210092;view=1up;seq=3]. U.S. Depeartment of Health and Human Services. Public Health Service, National Institues of Health1978;81-2209. PetersRW , ByingtonR , ArensbergD , FriedmanLM , RomhiltDW , BarkerA , et al. Mortality in the beta blocker heart attack trial: circumstances surrounding death. Journal of Chronic Diseases1987;40(1):75-82. ShivkumarK , SchultzL , GoldsteinS , GheorghiadeM . Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. American Heart Journal1998;135(2 Pt 1):261-7. The Beta-blocker Heart Attack Trial (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA1982;247(12):1707-14. The Beta Blocker Heart Attack Trial Research Group. Beta blocker heart attack trial: design features. Controlled Clinical Trials1981;2(4):275-85. ">BHAT 1982</a>). For further details, see <a href="./references#CD012565-sec-0142" title="">Characteristics of included studies</a>. </p> </section> </section> <section id="CD012565-sec-0059"> <h4 class="title">Excluded studies</h4> <p>We excluded 67 trials after full‐text assessment based on our inclusion and exclusion criteria. Of these trials, 62 included only participants in the acute phase of myocardial infarction and were therefore included in <a href="./references#CD012565-bbs2-0119" title="SafiS , SethiNJ , NielsenEE , FeinbergJ , GluudC , JakobsenJC . Beta-blockers for suspected or diagnosed acute myocardial infarction. Cochrane Database of Systematic Reviews2019;(12). [DOI: 10.1002/14651858.CD012484.pub2] [CD012484]">Safi 2019</a> and were excluded from this review. Only five of these 67 trials are reported in the <a href="./references#CD012565-sec-0143" title="">Characteristics of excluded studies</a> table. One trial was excluded as it included patients with heart failure; another was excluded as patients did not receive any intervention with beta‐blockers; one was excluded as most included patients had a history of stable angina pectoris ‐ not myocardial infarction; another was excluded as it was a cluster randomised trial; and one was excluded as it was not a randomised clinical trial. For further details, see <a href="./references#CD012565-sec-0143" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD012565-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>Based on information that we collected from published reports and from study authors, we considered all 25 trials to be at high risk of bias. We judged many trials to be at unclear risk of bias in several domains when we could not obtain additional information from study authors when contacted. Additional information can be found in the risk of bias summary (<a href="#CD012565-fig-0002">Figure 2</a>), the risk of bias graph (<a href="#CD012565-fig-0003">Figure 3</a>), the 'Summary of findings' table (<a href="./full#CD012565-tbl-0001">summary of findings Table 1</a>), and the <a href="./references#CD012565-sec-0142" title="">Characteristics of included studies</a> section. </p> <div class="figure" id="CD012565-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012565-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012565-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012565-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012565-sec-0061"> <h4 class="title">Allocation</h4> <p>Generation of the random sequence was at low risk of bias in three trials (<a href="./references#CD012565-bbs2-0005" title="BoisselJP , LeizoroviczA , PicoletH , DucruetT . Efficacy of acebutolol after acute myocardial infarction (the APSI trial). American Journal of Cardiology1990;66(9):24C-31C. BoisselJP , LeizoroviczA , PicoletH , PeyrieuxJC . Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. American Journal of Cardiology1990;66(3):251-60. CucheratM , BoisselJP , LeizoroviczA . Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. American Journal of Cardiology1997;79(5):587-9. ">APSI 1997</a>; <a href="./references#CD012565-bbs2-0010" title="Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA1983;250(20):2814-9. ByingtonRP , Beta-Blocker Heart Attack Trial Research Group. Beta-blocker heart attack trial: design, methods, and baseline results. Control Clinical Trials1984;5(4):382-437. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. American Journal of Cardiology1990;66(2):129-33. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1991;122(6):1548-53. GheorghiadeM , ShivkumarK , SchultzL , JafriS , TilleyB , GoldsteinS . Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1993;126(2):271-8. GoldsteinS , ByingtonR . The Beta Blocker Heart Attack Trial: recruitment experience. Controlled Clinical Trials1987;8(4 Suppl):79S-85S. KostisJB , ByingtonR , FriedmanLM , GoldsteinS , FurbergC . Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. Journal of the American College of Cardiology1987;10(2):231-42. National Heart, Lung, and Blood Institute. Beta-blocker heart attack trial study protocol [https://babel.hathitrust.org/cgi/pt?id=pur1.32754081210092;view=1up;seq=3]. U.S. Depeartment of Health and Human Services. Public Health Service, National Institues of Health1978;81-2209. PetersRW , ByingtonR , ArensbergD , FriedmanLM , RomhiltDW , BarkerA , et al. Mortality in the beta blocker heart attack trial: circumstances surrounding death. Journal of Chronic Diseases1987;40(1):75-82. ShivkumarK , SchultzL , GoldsteinS , GheorghiadeM . Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. American Heart Journal1998;135(2 Pt 1):261-7. The Beta-blocker Heart Attack Trial (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA1982;247(12):1707-14. The Beta Blocker Heart Attack Trial Research Group. Beta blocker heart attack trial: design features. Controlled Clinical Trials1981;2(4):275-85. ">BHAT 1982</a>; <a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>). In the remaining 23 trials, the method used for allocation concealment was insufficiently described and we therefore judged these trials to be at unclear risk of bias. </p> <p>The method used to conceal allocation was at low risk of bias in four trials (<a href="./references#CD012565-bbs2-0005" title="BoisselJP , LeizoroviczA , PicoletH , DucruetT . Efficacy of acebutolol after acute myocardial infarction (the APSI trial). American Journal of Cardiology1990;66(9):24C-31C. BoisselJP , LeizoroviczA , PicoletH , PeyrieuxJC . Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. American Journal of Cardiology1990;66(3):251-60. CucheratM , BoisselJP , LeizoroviczA . Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. American Journal of Cardiology1997;79(5):587-9. ">APSI 1997</a>; <a href="./references#CD012565-bbs2-0013" title="BethgeKP , AndresenD , BoisselJP , LeitnerER , PeyrieuxJC , SchröderR , et al. Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. Journal of the American College of Cardiology1985;6(5):963-72. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. European Heart Journal1984;5:189-202. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction. European Heart Journal1982;3:583-6. ">E.I.S. 1984</a>; <a href="./references#CD012565-bbs2-0018" title="A Multicentre International Study Group. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. BMJ1975;3:735-40. The Multicentre International Study Group. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. BMJ1977;2:419-21. ">MIS 1975</a>; <a href="./references#CD012565-bbs2-0023" title="SchwartzPJ , MotoleseM , PollaviniG , LottoA , RubertiU , TrazziR , et al. Prevention of sudden cardiac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. Journal of Cardiovascular Electrophysiology1992;3(1):2-16. ">Schwartz 1992</a>). In the remaining 21 trials, the method of allocation concealment was insufficiently described and we therefore judged these trials to be at unclear risk of bias. </p> </section> <section id="CD012565-sec-0062"> <h4 class="title">Blinding</h4> <p>Blinding of participants and personnel was at low risk of bias in seven trials (<a href="./references#CD012565-bbs2-0005" title="BoisselJP , LeizoroviczA , PicoletH , DucruetT . Efficacy of acebutolol after acute myocardial infarction (the APSI trial). American Journal of Cardiology1990;66(9):24C-31C. BoisselJP , LeizoroviczA , PicoletH , PeyrieuxJC . Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. American Journal of Cardiology1990;66(3):251-60. CucheratM , BoisselJP , LeizoroviczA . Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. American Journal of Cardiology1997;79(5):587-9. ">APSI 1997</a>; <a href="./references#CD012565-bbs2-0010" title="Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA1983;250(20):2814-9. ByingtonRP , Beta-Blocker Heart Attack Trial Research Group. Beta-blocker heart attack trial: design, methods, and baseline results. Control Clinical Trials1984;5(4):382-437. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. American Journal of Cardiology1990;66(2):129-33. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1991;122(6):1548-53. GheorghiadeM , ShivkumarK , SchultzL , JafriS , TilleyB , GoldsteinS . Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1993;126(2):271-8. GoldsteinS , ByingtonR . The Beta Blocker Heart Attack Trial: recruitment experience. Controlled Clinical Trials1987;8(4 Suppl):79S-85S. KostisJB , ByingtonR , FriedmanLM , GoldsteinS , FurbergC . Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. Journal of the American College of Cardiology1987;10(2):231-42. National Heart, Lung, and Blood Institute. Beta-blocker heart attack trial study protocol [https://babel.hathitrust.org/cgi/pt?id=pur1.32754081210092;view=1up;seq=3]. U.S. Depeartment of Health and Human Services. Public Health Service, National Institues of Health1978;81-2209. PetersRW , ByingtonR , ArensbergD , FriedmanLM , RomhiltDW , BarkerA , et al. Mortality in the beta blocker heart attack trial: circumstances surrounding death. Journal of Chronic Diseases1987;40(1):75-82. ShivkumarK , SchultzL , GoldsteinS , GheorghiadeM . Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. American Heart Journal1998;135(2 Pt 1):261-7. The Beta-blocker Heart Attack Trial (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA1982;247(12):1707-14. The Beta Blocker Heart Attack Trial Research Group. Beta blocker heart attack trial: design features. Controlled Clinical Trials1981;2(4):275-85. ">BHAT 1982</a>; <a href="./references#CD012565-bbs2-0013" title="BethgeKP , AndresenD , BoisselJP , LeitnerER , PeyrieuxJC , SchröderR , et al. Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. Journal of the American College of Cardiology1985;6(5):963-72. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. European Heart Journal1984;5:189-202. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction. European Heart Journal1982;3:583-6. ">E.I.S. 1984</a>; <a href="./references#CD012565-bbs2-0018" title="A Multicentre International Study Group. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. BMJ1975;3:735-40. The Multicentre International Study Group. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. BMJ1977;2:419-21. ">MIS 1975</a>; <a href="./references#CD012565-bbs2-0021" title="OlssonG , LevinLA , RehnqvistN . Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol. British Medical Journal (Clinical Research Edition)1987;294(6568):339-42. OlssonG , LubsenJ , vanEsGA , RehnqvistN . Quality of life after myocardial infarction: effect of long term metoprolol on mortality and morbidity. British Medical Journal (Clinical Research Edition)1986;292(6534):1491-3. OlssonG , OdénA , JohanssonL , SjögrenA , RehnqvistN . Prognosis after withdrawal of chronic postinfarction metoprolol treatment: a 2-7 year follow-up. European Heart Journal1988;9(4):365-72. OlssonG , RehnqvistN , LundmandT , MelcherA . Metoprolol treatment after acute myocardial infarction - Effects on ventricular arrhythmias and exercise tests during 6 months. Acta Medica Scandinavica1981;210(1-2):59-65. OlssonG , RehnqvistN , SjögrenA , ErhardtL , LundmanT . Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. Journal of the American College of Cardiology1985;5(6):1428-37. ">Olsson 1985</a>; <a href="./references#CD012565-bbs2-0023" title="SchwartzPJ , MotoleseM , PollaviniG , LottoA , RubertiU , TrazziR , et al. Prevention of sudden cardiac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. Journal of Cardiovascular Electrophysiology1992;3(1):2-16. ">Schwartz 1992</a>; <a href="./references#CD012565-bbs2-0024" title="TaylorSH , SilkeB , EbbuttA , SuttonGC , ProutBJ , BurleyDM . A long-term prevention study with oxprenolol in coronary heart disease. New England Journal of Medicine1982;307(21):1293-301. ">Taylor 1982</a>), and it was at high risk of bias in two trials (<a href="./references#CD012565-bbs2-0002" title="AhlmarkG , SaetreH , KorsgrenM . Reduction of sudden deaths after myocardial infarction. Lancet1974;2(7896):1563. AhlmarkG , SaetreH . Long-term treatment with beta-blockers after myocardial infarction. European Journal of Clinical Pharmacology1976;10(2):77-83. AhlmarkG , SaetreH . Positon of myocardial infarct and results of alprenolol treatment. BMJ1976;1(6013):837. ">Ahlmark 1976</a>; <a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>). In the remaining 16 trials, the method for blinding of participants and personnel was insufficiently described and we therefore judged these trials to be at unclear risk of bias. </p> <p>Blinding of outcome assessors was at low risk of bias in 12 trials (<a href="./references#CD012565-bbs2-0003" title="AhnveS , ErhardtL , LundmanT , RehnqvistN , SjögrenA . Effect of metoprolol on QTc intervals after acute myocardial infarction. Acta Medica Scandinavica1980;208(3):223-8. ">Ahnve 1980</a>; <a href="./references#CD012565-bbs2-0005" title="BoisselJP , LeizoroviczA , PicoletH , DucruetT . Efficacy of acebutolol after acute myocardial infarction (the APSI trial). American Journal of Cardiology1990;66(9):24C-31C. BoisselJP , LeizoroviczA , PicoletH , PeyrieuxJC . Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. American Journal of Cardiology1990;66(3):251-60. CucheratM , BoisselJP , LeizoroviczA . Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. American Journal of Cardiology1997;79(5):587-9. ">APSI 1997</a>; <a href="./references#CD012565-bbs2-0010" title="Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA1983;250(20):2814-9. ByingtonRP , Beta-Blocker Heart Attack Trial Research Group. Beta-blocker heart attack trial: design, methods, and baseline results. Control Clinical Trials1984;5(4):382-437. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. American Journal of Cardiology1990;66(2):129-33. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1991;122(6):1548-53. GheorghiadeM , ShivkumarK , SchultzL , JafriS , TilleyB , GoldsteinS . Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1993;126(2):271-8. GoldsteinS , ByingtonR . The Beta Blocker Heart Attack Trial: recruitment experience. Controlled Clinical Trials1987;8(4 Suppl):79S-85S. KostisJB , ByingtonR , FriedmanLM , GoldsteinS , FurbergC . Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. Journal of the American College of Cardiology1987;10(2):231-42. National Heart, Lung, and Blood Institute. Beta-blocker heart attack trial study protocol [https://babel.hathitrust.org/cgi/pt?id=pur1.32754081210092;view=1up;seq=3]. U.S. Depeartment of Health and Human Services. Public Health Service, National Institues of Health1978;81-2209. PetersRW , ByingtonR , ArensbergD , FriedmanLM , RomhiltDW , BarkerA , et al. Mortality in the beta blocker heart attack trial: circumstances surrounding death. Journal of Chronic Diseases1987;40(1):75-82. ShivkumarK , SchultzL , GoldsteinS , GheorghiadeM . Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. American Heart Journal1998;135(2 Pt 1):261-7. The Beta-blocker Heart Attack Trial (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA1982;247(12):1707-14. The Beta Blocker Heart Attack Trial Research Group. Beta blocker heart attack trial: design features. Controlled Clinical Trials1981;2(4):275-85. ">BHAT 1982</a>; <a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>; <a href="./references#CD012565-bbs2-0012" title="CurtisJL , HoughtonJL , PattersonJH , KochG , BradleyDA , Adams KF Jr. Propranolol therapy alters estimation of potential cardiovascular risk derived from submaximal postinfarction exercise testing. American Heart Journal1991;121(6 Pt 1):1655-64. ">Curtis 1991</a>; <a href="./references#CD012565-bbs2-0013" title="BethgeKP , AndresenD , BoisselJP , LeitnerER , PeyrieuxJC , SchröderR , et al. Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. Journal of the American College of Cardiology1985;6(5):963-72. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. European Heart Journal1984;5:189-202. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction. European Heart Journal1982;3:583-6. ">E.I.S. 1984</a>; <a href="./references#CD012565-bbs2-0017" title="MazzueroG , GaldangeloF , ZottiAM , BertolottiG , TavazziL . Effects of propranolol, atenolol, and chlordesmethyldiazepam on response to mental stress in patients with recent myocardial infarction. Clinical Cardiology1987;10(6):293-302. ">Mazzuero 1987</a>; <a href="./references#CD012565-bbs2-0019" title="BellinEY , The Nowergian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on timolol after myocardial infarction. 1986;314(16):1052-3. Lund-Johansen, The Norwegian Multicenter Study Group. The Norwegian multicenter study on timolol after myocardial infarction. Part II. Effect in different risk groups, causes of death, heart arrest, reinfarctions, rehospitalizations and adverse experiences. Acta Medica Scandinavica1981;651:243-52. PedersenTR , The Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. New England Journal of Medicine1985;313(17):1055-8. The Norwegian Multicenter Study Group. The Norwegian multicenter study on timolol after myocardial infarction. Acta Medica Scandinavica1981;651:235-41. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New England Journal of Medicine1981;304(14):801-7. ">NMS 1981</a>; <a href="./references#CD012565-bbs2-0021" title="OlssonG , LevinLA , RehnqvistN . Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol. British Medical Journal (Clinical Research Edition)1987;294(6568):339-42. OlssonG , LubsenJ , vanEsGA , RehnqvistN . Quality of life after myocardial infarction: effect of long term metoprolol on mortality and morbidity. British Medical Journal (Clinical Research Edition)1986;292(6534):1491-3. OlssonG , OdénA , JohanssonL , SjögrenA , RehnqvistN . Prognosis after withdrawal of chronic postinfarction metoprolol treatment: a 2-7 year follow-up. European Heart Journal1988;9(4):365-72. OlssonG , RehnqvistN , LundmandT , MelcherA . Metoprolol treatment after acute myocardial infarction - Effects on ventricular arrhythmias and exercise tests during 6 months. Acta Medica Scandinavica1981;210(1-2):59-65. OlssonG , RehnqvistN , SjögrenA , ErhardtL , LundmanT . Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. Journal of the American College of Cardiology1985;5(6):1428-37. ">Olsson 1985</a>; <a href="./references#CD012565-bbs2-0023" title="SchwartzPJ , MotoleseM , PollaviniG , LottoA , RubertiU , TrazziR , et al. Prevention of sudden cardiac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. Journal of Cardiovascular Electrophysiology1992;3(1):2-16. ">Schwartz 1992</a>; <a href="./references#CD012565-bbs2-0024" title="TaylorSH , SilkeB , EbbuttA , SuttonGC , ProutBJ , BurleyDM . A long-term prevention study with oxprenolol in coronary heart disease. New England Journal of Medicine1982;307(21):1293-301. ">Taylor 1982</a>; <a href="./references#CD012565-bbs2-0025" title="VedinA , WilhelmssonC , WerköL . Chronic alprenolol treatment of patients with acute myocardial infarction after discharge from hospital. Acta Medica Scandinavica Supplementum1975;575:3-56. WihelmssonC , VedinA , WilhelmsenL , TibblinG , WerköL , WedelH . Deaths and non-fatal reinfarctions during two years' follow-up. Acta Medica Scandinavica Supplementum1975;575:19-24. WilhelmssonC , VedinJA , WilhelmsenL , TibblinG , WerköL . Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet1974;2(7890):1157-60. ">Wilhelmsson 1974</a>). In the remaining 13 trials, methods used to blind outcome assessors were insufficiently described and we therefore judged these trials to be at unclear risk of bias. </p> </section> <section id="CD012565-sec-0063"> <h4 class="title">Incomplete outcome data</h4> <p>Incomplete outcome data were at low risk of bias in eight trials (<a href="./references#CD012565-bbs2-0006" title="Australian and Swedish Pindolol Study Group. The effect of pindolol on the two years mortality after complicated myocardial infarction. European Heart Journal1983;4(6):367-75. ">Australien &amp; Swedish 1983</a>; <a href="./references#CD012565-bbs2-0007" title="BaberNS , EvansDW , HowittG , ThomasM , WilsonC , LewisJA , et al. Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy, and Yugoslavia. British Heart Journal1980;44(1):96-100. ">Baber 1980</a>; <a href="./references#CD012565-bbs2-0010" title="Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA1983;250(20):2814-9. ByingtonRP , Beta-Blocker Heart Attack Trial Research Group. Beta-blocker heart attack trial: design, methods, and baseline results. Control Clinical Trials1984;5(4):382-437. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. American Journal of Cardiology1990;66(2):129-33. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1991;122(6):1548-53. GheorghiadeM , ShivkumarK , SchultzL , JafriS , TilleyB , GoldsteinS . Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1993;126(2):271-8. GoldsteinS , ByingtonR . The Beta Blocker Heart Attack Trial: recruitment experience. Controlled Clinical Trials1987;8(4 Suppl):79S-85S. KostisJB , ByingtonR , FriedmanLM , GoldsteinS , FurbergC . Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. Journal of the American College of Cardiology1987;10(2):231-42. National Heart, Lung, and Blood Institute. Beta-blocker heart attack trial study protocol [https://babel.hathitrust.org/cgi/pt?id=pur1.32754081210092;view=1up;seq=3]. U.S. Depeartment of Health and Human Services. Public Health Service, National Institues of Health1978;81-2209. PetersRW , ByingtonR , ArensbergD , FriedmanLM , RomhiltDW , BarkerA , et al. Mortality in the beta blocker heart attack trial: circumstances surrounding death. Journal of Chronic Diseases1987;40(1):75-82. ShivkumarK , SchultzL , GoldsteinS , GheorghiadeM . Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. American Heart Journal1998;135(2 Pt 1):261-7. The Beta-blocker Heart Attack Trial (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA1982;247(12):1707-14. The Beta Blocker Heart Attack Trial Research Group. Beta blocker heart attack trial: design features. Controlled Clinical Trials1981;2(4):275-85. ">BHAT 1982</a>; <a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>; <a href="./references#CD012565-bbs2-0013" title="BethgeKP , AndresenD , BoisselJP , LeitnerER , PeyrieuxJC , SchröderR , et al. Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. Journal of the American College of Cardiology1985;6(5):963-72. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. European Heart Journal1984;5:189-202. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction. European Heart Journal1982;3:583-6. ">E.I.S. 1984</a>; <a href="./references#CD012565-bbs2-0014" title="JulianDG , PrescottRJ , JacksonFS , SzekelyP . Controlled trial of sotalol for one year after myocardial infarction. Lancet1982;1(8282):1142-7. ">Julian 1982</a>; <a href="./references#CD012565-bbs2-0021" title="OlssonG , LevinLA , RehnqvistN . Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol. British Medical Journal (Clinical Research Edition)1987;294(6568):339-42. OlssonG , LubsenJ , vanEsGA , RehnqvistN . Quality of life after myocardial infarction: effect of long term metoprolol on mortality and morbidity. British Medical Journal (Clinical Research Edition)1986;292(6534):1491-3. OlssonG , OdénA , JohanssonL , SjögrenA , RehnqvistN . Prognosis after withdrawal of chronic postinfarction metoprolol treatment: a 2-7 year follow-up. European Heart Journal1988;9(4):365-72. OlssonG , RehnqvistN , LundmandT , MelcherA . Metoprolol treatment after acute myocardial infarction - Effects on ventricular arrhythmias and exercise tests during 6 months. Acta Medica Scandinavica1981;210(1-2):59-65. OlssonG , RehnqvistN , SjögrenA , ErhardtL , LundmanT . Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. Journal of the American College of Cardiology1985;5(6):1428-37. ">Olsson 1985</a>; <a href="./references#CD012565-bbs2-0023" title="SchwartzPJ , MotoleseM , PollaviniG , LottoA , RubertiU , TrazziR , et al. Prevention of sudden cardiac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. Journal of Cardiovascular Electrophysiology1992;3(1):2-16. ">Schwartz 1992</a>). Six trials did not properly deal with incomplete outcome data and were at high risk of bias (<a href="./references#CD012565-bbs2-0002" title="AhlmarkG , SaetreH , KorsgrenM . Reduction of sudden deaths after myocardial infarction. Lancet1974;2(7896):1563. AhlmarkG , SaetreH . Long-term treatment with beta-blockers after myocardial infarction. European Journal of Clinical Pharmacology1976;10(2):77-83. AhlmarkG , SaetreH . Positon of myocardial infarct and results of alprenolol treatment. BMJ1976;1(6013):837. ">Ahlmark 1976</a>; <a href="./references#CD012565-bbs2-0005" title="BoisselJP , LeizoroviczA , PicoletH , DucruetT . Efficacy of acebutolol after acute myocardial infarction (the APSI trial). American Journal of Cardiology1990;66(9):24C-31C. BoisselJP , LeizoroviczA , PicoletH , PeyrieuxJC . Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. American Journal of Cardiology1990;66(3):251-60. CucheratM , BoisselJP , LeizoroviczA . Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. American Journal of Cardiology1997;79(5):587-9. ">APSI 1997</a>; <a href="./references#CD012565-bbs2-0008" title="BarvikS , DicksteinK , AarslandT , Vik-MoH . Effect of timolol on cardiopulmonary exercise performance in men after myocardial infarction. American Journal of Cardiology1982;69(3):163-8. ">Barvik 1992</a>; <a href="./references#CD012565-bbs2-0012" title="CurtisJL , HoughtonJL , PattersonJH , KochG , BradleyDA , Adams KF Jr. Propranolol therapy alters estimation of potential cardiovascular risk derived from submaximal postinfarction exercise testing. American Heart Journal1991;121(6 Pt 1):1655-64. ">Curtis 1991</a>; <a href="./references#CD012565-bbs2-0024" title="TaylorSH , SilkeB , EbbuttA , SuttonGC , ProutBJ , BurleyDM . A long-term prevention study with oxprenolol in coronary heart disease. New England Journal of Medicine1982;307(21):1293-301. ">Taylor 1982</a>; <a href="./references#CD012565-bbs2-0025" title="VedinA , WilhelmssonC , WerköL . Chronic alprenolol treatment of patients with acute myocardial infarction after discharge from hospital. Acta Medica Scandinavica Supplementum1975;575:3-56. WihelmssonC , VedinA , WilhelmsenL , TibblinG , WerköL , WedelH . Deaths and non-fatal reinfarctions during two years' follow-up. Acta Medica Scandinavica Supplementum1975;575:19-24. WilhelmssonC , VedinJA , WilhelmsenL , TibblinG , WerköL . Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet1974;2(7890):1157-60. ">Wilhelmsson 1974</a>). In the remaining 11 trials, incomplete outcome data were insufficiently described and we therefore judged these trials to be at unclear risk of bias. </p> </section> <section id="CD012565-sec-0064"> <h4 class="title">Selective reporting</h4> <p>Three trials reported results of outcomes stated in their respective protocols, or they reported our primary outcomes, resulting in low risk of bias (<a href="./references#CD012565-bbs2-0010" title="Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA1983;250(20):2814-9. ByingtonRP , Beta-Blocker Heart Attack Trial Research Group. Beta-blocker heart attack trial: design, methods, and baseline results. Control Clinical Trials1984;5(4):382-437. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. American Journal of Cardiology1990;66(2):129-33. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1991;122(6):1548-53. GheorghiadeM , ShivkumarK , SchultzL , JafriS , TilleyB , GoldsteinS . Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1993;126(2):271-8. GoldsteinS , ByingtonR . The Beta Blocker Heart Attack Trial: recruitment experience. Controlled Clinical Trials1987;8(4 Suppl):79S-85S. KostisJB , ByingtonR , FriedmanLM , GoldsteinS , FurbergC . Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. Journal of the American College of Cardiology1987;10(2):231-42. National Heart, Lung, and Blood Institute. Beta-blocker heart attack trial study protocol [https://babel.hathitrust.org/cgi/pt?id=pur1.32754081210092;view=1up;seq=3]. U.S. Depeartment of Health and Human Services. Public Health Service, National Institues of Health1978;81-2209. PetersRW , ByingtonR , ArensbergD , FriedmanLM , RomhiltDW , BarkerA , et al. Mortality in the beta blocker heart attack trial: circumstances surrounding death. Journal of Chronic Diseases1987;40(1):75-82. ShivkumarK , SchultzL , GoldsteinS , GheorghiadeM . Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. American Heart Journal1998;135(2 Pt 1):261-7. The Beta-blocker Heart Attack Trial (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA1982;247(12):1707-14. The Beta Blocker Heart Attack Trial Research Group. Beta blocker heart attack trial: design features. Controlled Clinical Trials1981;2(4):275-85. ">BHAT 1982</a>; <a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>; <a href="./references#CD012565-bbs2-0013" title="BethgeKP , AndresenD , BoisselJP , LeitnerER , PeyrieuxJC , SchröderR , et al. Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. Journal of the American College of Cardiology1985;6(5):963-72. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. European Heart Journal1984;5:189-202. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction. European Heart Journal1982;3:583-6. ">E.I.S. 1984</a>). Six trials had no protocol and did not report our primary outcomes sufficiently, resulting in high risk of bias (<a href="./references#CD012565-bbs2-0002" title="AhlmarkG , SaetreH , KorsgrenM . Reduction of sudden deaths after myocardial infarction. Lancet1974;2(7896):1563. AhlmarkG , SaetreH . Long-term treatment with beta-blockers after myocardial infarction. European Journal of Clinical Pharmacology1976;10(2):77-83. AhlmarkG , SaetreH . Positon of myocardial infarct and results of alprenolol treatment. BMJ1976;1(6013):837. ">Ahlmark 1976</a>; <a href="./references#CD012565-bbs2-0006" title="Australian and Swedish Pindolol Study Group. The effect of pindolol on the two years mortality after complicated myocardial infarction. European Heart Journal1983;4(6):367-75. ">Australien &amp; Swedish 1983</a>; <a href="./references#CD012565-bbs2-0007" title="BaberNS , EvansDW , HowittG , ThomasM , WilsonC , LewisJA , et al. Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy, and Yugoslavia. British Heart Journal1980;44(1):96-100. ">Baber 1980</a>; <a href="./references#CD012565-bbs2-0012" title="CurtisJL , HoughtonJL , PattersonJH , KochG , BradleyDA , Adams KF Jr. Propranolol therapy alters estimation of potential cardiovascular risk derived from submaximal postinfarction exercise testing. American Heart Journal1991;121(6 Pt 1):1655-64. ">Curtis 1991</a>; <a href="./references#CD012565-bbs2-0014" title="JulianDG , PrescottRJ , JacksonFS , SzekelyP . Controlled trial of sotalol for one year after myocardial infarction. Lancet1982;1(8282):1142-7. ">Julian 1982</a>; <a href="./references#CD012565-bbs2-0015" title="Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. European Heart Journal1987;8:1056-64. ">LIT 1987</a>). For the remaining 16 trials, no protocol could be found, but some of our primary outcomes were reported, resulting in unclear risk of bias. </p> </section> <section id="CD012565-sec-0065"> <h4 class="title">Other potential sources of bias</h4> <p>One trial was prematurely terminated and was judged to be at unclear risk of bias (<a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>); all other trials were judged to be at low risk of bias when other potential sources of bias were assessed. </p> </section> </section> <section id="CD012565-sec-0066"> <h3 class="title" id="CD012565-sec-0066">Effects of interventions</h3> <p>See: <a href="./full#CD012565-tbl-0001"><b>Summary of findings 1</b> Summary of findings at maximum follow‐up</a> </p> <section id="CD012565-sec-0067"> <h4 class="title">Primary outcomes</h4> <section id="CD012565-sec-0068"> <h5 class="title">All‐cause mortality</h5> <p>In all, 21 of 25 trials with a total of 22,085 participants and mean maximum follow‐up of 24.9 months (range 9 to 60 months) reported all‐cause mortality. A total of 976 of 11,236 participants receiving beta‐blockers died versus 1182 of 10,849 control participants. Random‐effects meta‐analysis shows that beta‐blockers probably reduce the risk of all‐cause mortality compared with placebo or no intervention (risk ratio (RR) 0.81, 97.5% confidence interval (CI) 0.73 to 0.90; I² = 15%; 22,085 participants, 21 trials; moderate‐certainty evidence; <a href="#CD012565-fig-0004">Figure 4</a>). The point estimate of the meta‐analysis result corresponds to 87 of 1000 beta‐blocker patients dying compared with 109 of 1000 control participants dying, or a number needed to treat (NNT) of 46 participants. Absolute risk for mortality at maximum follow‐up was 8.7% in the beta‐blocker group compared with 10.9% in the control group. Optimal information size according to the <i>GRADE Handbook</i> using a proportion of 10.9% in the control group, relative risk reduction (RRR) of 10%, alpha of 2.5%, and beta of 10% was estimated to be 54,272 participants, and we included only 22,085 participants (see <a href="./full#CD012565-tbl-0001">summary of findings Table 1</a>). </p> <div class="figure" id="CD012565-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 All‐cause mortality at maximum follow‐up, outcome: 1.1 All‐cause mortality." data-id="CD012565-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 All‐cause mortality at maximum follow‐up, outcome: 1.1 All‐cause mortality. </p> </div> </div> </div> <section id="CD012565-sec-0069"> <h6 class="title">Heterogeneity</h6> <p>Visual inspection of the forest plot and tests for statistical heterogeneity (I²= 15%; P = 0.27) indicated no important heterogeneity (<a href="#CD012565-fig-0004">Figure 4</a>). </p> </section> <section id="CD012565-sec-0070"> <h6 class="title">Risk of bias and sensitivity analyses</h6> <p>We assessed risk of bias of this outcome result as high.</p> <p>Best‐worst and worst‐best case meta‐analyses showed that incomplete outcome data bias alone did not have the potential to influence the meta‐analysis result (best‐worst meta‐analysis: RR 0.70, 95% CI 0.59 to 0.83; I² = 71%; 22,309 participants, 21 trials; moderate‐certainty evidence; <a href="./references#CD012565-fig-0020" title="">Analysis 1.8</a>); worst‐best meta‐analysis: RR 0.89, 95% CI 0.72 to 1.09; I² = 83%; 22,309 participants, 21 trials; moderate‐certainty evidence; <a href="./references#CD012565-fig-0021" title="">Analysis 1.9</a>). Data were imputed for four trials. </p> <p>Visual inspection of the funnel plot showed some signs of asymmetry (see <a href="#CD012565-fig-0005">Figure 5</a>). Based on visual inspection of the funnel plot, we assessed the risk of publication bias as high. However, we found no signs of small‐study effect when using the Harbord test (P = 0.46) or the Egger test (P = 0.31). </p> <div class="figure" id="CD012565-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 All‐cause mortality at maximum follow‐up, outcome: 1.1 All‐cause mortality." data-id="CD012565-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 All‐cause mortality at maximum follow‐up, outcome: 1.1 All‐cause mortality. </p> </div> </div> </div> </section> <section id="CD012565-sec-0071"> <h6 class="title">Subgroup analyses</h6> <p>Testing for subgroup differences showed no evidence of a difference in subgroup analyses according to different types of beta‐blockers administered (P = 0.89; <a href="./references#CD012565-fig-0014" title="">Analysis 1.2</a>), different follow‐up periods (P = 0.73; <a href="./references#CD012565-fig-0015" title="">Analysis 1.3</a>), and varying clinical registration status (P = 0.66; <a href="./references#CD012565-fig-0016" title="">Analysis 1.4</a>). However, due to an uneven covariate distribution between different subgroups, these analyses may not have been able to detect any subgroup differences. Remaining tests for subgroup differences were not possible due to lack of data for these subgroups: reperfusion or no reperfusion; different age of participants; men compared to women; and different types of acute coronary syndrome (NSTEMI, STEMI, or unstable angina pectoris (UAP)). </p> </section> <section id="CD012565-sec-0072"> <h6 class="title">Post hoc subgroup analyses</h6> <p>Testing for subgroup differences showed no evidence of a difference in our post hoc subgroup analyses, suggesting that whether trials received industry versus non‐industry funding (P = 1.00; <a href="./references#CD012565-fig-0017" title="">Analysis 1.5</a>), beta‐blockers were administered within or after seven days following acute myocardial infarction (P = 0.84; <a href="./references#CD012565-fig-0018" title="">Analysis 1.6</a>), or heart failure patients were specifically excluded from trials (P = 0.12; <a href="./references#CD012565-fig-0019" title="">Analysis 1.7</a>), effects of beta‐blockers on all‐cause mortality were not modified when compared to placebo or no intervention. However, due to an uneven covariate distribution between different subgroups, these analyses may not have been able to detect any subgroup differences. </p> </section> </section> <section id="CD012565-sec-0073"> <h5 class="title">Major cardiovascular events</h5> <p>In all, 15 of 25 trials with a total of 14,994 participants and mean maximum follow‐up of 26.3 months (range 9 to 48 months) reported major cardiovascular events (composite outcome of cardiovascular mortality and non‐fatal myocardial infarction). A total of 796 of 7701 participants receiving beta‐blockers had a major cardiovascular event versus 1020 of 7293 control participants. Random‐effects meta‐analysis showed that beta‐blockers may reduce the risk of major cardiovascular events compared with placebo or no intervention (RR 0.72, 97.5% CI 0.62 to 0.83; I² = 42%; 14,994 participants, 15 trials; low‐certainty evidence; <a href="#CD012565-fig-0006">Figure 6</a>). The point estimate of the meta‐analysis result corresponds to 103 of 1000 beta‐blocker patients dying compared with 140 of 1000 control participants dying, or NNT of 23 participants. Absolute risk for major cardiovascular events at maximum follow‐up was 10.3% in the beta‐blocker group compared with 14.0% in the control group. Optimal information size according to the <i>GRADE Handbook</i> using a proportion of 14.0% in the control group, RRR of 10%, alpha of 2.5%, and beta of 10% was estimated to be 62,729 participants, and we included only 14,994 participants (see <a href="./full#CD012565-tbl-0001">summary of findings Table 1</a>). </p> <div class="figure" id="CD012565-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Major adverse cardiovascular events (MACE) at maximum follow‐up, outcome: 2.1 MACE (major cardiovascular events)." data-id="CD012565-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Major adverse cardiovascular events (MACE) at maximum follow‐up, outcome: 2.1 MACE (major cardiovascular events). </p> </div> </div> </div> <section id="CD012565-sec-0074"> <h6 class="title">Heterogeneity</h6> <p>Visual inspection of the forest plot and tests for statistical heterogeneity (I²= 42%; P = 0.04) indicated moderate heterogeneity (<a href="#CD012565-fig-0006">Figure 6</a>). </p> </section> <section id="CD012565-sec-0075"> <h6 class="title">Risk of bias and sensitivity analyses</h6> <p>We assessed risk of bias of the outcome result as high.</p> <p>Best‐worst and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had the potential to influence the meta‐analysis result (best‐worst meta‐analysis: RR 0.64, 95% CI 0.50 to 0.81; I² = 76%; 15,225 participants, 15 trials; low‐certainty evidence; <a href="./references#CD012565-fig-0029" title="">Analysis 2.8</a>; worst‐best meta‐analysis: RR 0.92, 95% CI 0.68 to 1.25; I² = 87%; 15,225 participants, 15 trials; low‐certainty evidence; <a href="./references#CD012565-fig-0030" title="">Analysis 2.9</a>). Data were imputed for four trials. </p> <p>Visual inspection of the funnel plot revealed some signs of asymmetry (see <a href="#CD012565-fig-0007">Figure 7</a>). Based on visual inspection of the funnel plot, we assessed the risk of publication bias as high. However, we found no signs of small‐study effect when using the Harbord test (P = 0.10) or the Egger test (P = 0.06). </p> <div class="figure" id="CD012565-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Major adverse cardiovascular events (MACE) at maximum follow‐up, outcome: 2.1 MACE (major cardiovascular events)." data-id="CD012565-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Major adverse cardiovascular events (MACE) at maximum follow‐up, outcome: 2.1 MACE (major cardiovascular events). </p> </div> </div> </div> </section> <section id="CD012565-sec-0076"> <h6 class="title">Subgroup analyses</h6> <p>Testing for subgroup differences showed no evidence of a difference when trials were compared according to the different types of beta‐blocker administered (P = 0.46; <a href="./references#CD012565-fig-0023" title="">Analysis 2.2</a>), different follow‐up periods reported (P = 0.52; <a href="./references#CD012565-fig-0024" title="">Analysis 2.3</a>), and varying clinical registration status (P = 0.91; <a href="./references#CD012565-fig-0025" title="">Analysis 2.4</a>). However, due to an uneven covariate distribution between different subgroups, these analyses may not have been able to detect any subgroup differences. Remaining tests for subgroup differences were not possible due to lack of data for these subgroups: reperfusion or no reperfusion; different age of participants; men compared to women; and different types of acute coronary syndrome (NSTEMI, STEMI, or UAP). </p> </section> <section id="CD012565-sec-0077"> <h6 class="title">Post hoc subgroup analyses</h6> <p>Testing for subgroup differences showed no evidence of a difference in our post hoc subgroup analyses, suggesting that whether trials received industry versus non‐industry funding (P = 0.26; <a href="./references#CD012565-fig-0026" title="">Analysis 2.5</a>), beta‐blockers were administered within or after seven days following acute myocardial infarction (P = 1.00; <a href="./references#CD012565-fig-0027" title="">Analysis 2.6</a>), or heart failure patients were specifically excluded from trials (P = 0.80; <a href="./references#CD012565-fig-0028" title="">Analysis 2.7</a>), effects of beta‐blockers on major cardiovascular mortality were not modified when compared to placebo or no intervention. However, due to an uneven covariate distribution between different subgroups, these analyses may not have been able to detect any subgroup differences. </p> </section> </section> <section id="CD012565-sec-0078"> <h5 class="title">Serious adverse events</h5> <p>No trials specifically assessed or reported serious adverse events according to ICH‐GCP. Instead, trials reported one specific serious adverse event, which was already included in one of the other outcomes in this review, or a composite of several different events without referring to actual proportions of participants. </p> </section> </section> <section id="CD012565-sec-0079"> <h4 class="title">Secondary outcomes</h4> <section id="CD012565-sec-0080"> <h5 class="title">Quality of life</h5> <p>No trials reported quality of life on a continuous or any other scale at any time point. </p> </section> <section id="CD012565-sec-0081"> <h5 class="title">Angina pectoris</h5> <p>Five trials reported angina with mean maximum follow‐up of 10 months (range 12 to 47 months) (<a href="./references#CD012565-bbs2-0002" title="AhlmarkG , SaetreH , KorsgrenM . Reduction of sudden deaths after myocardial infarction. Lancet1974;2(7896):1563. AhlmarkG , SaetreH . Long-term treatment with beta-blockers after myocardial infarction. European Journal of Clinical Pharmacology1976;10(2):77-83. AhlmarkG , SaetreH . Positon of myocardial infarct and results of alprenolol treatment. BMJ1976;1(6013):837. ">Ahlmark 1976</a>; <a href="./references#CD012565-bbs2-0005" title="BoisselJP , LeizoroviczA , PicoletH , DucruetT . Efficacy of acebutolol after acute myocardial infarction (the APSI trial). American Journal of Cardiology1990;66(9):24C-31C. BoisselJP , LeizoroviczA , PicoletH , PeyrieuxJC . Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. American Journal of Cardiology1990;66(3):251-60. CucheratM , BoisselJP , LeizoroviczA . Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. American Journal of Cardiology1997;79(5):587-9. ">APSI 1997</a>; <a href="./references#CD012565-bbs2-0010" title="Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA1983;250(20):2814-9. ByingtonRP , Beta-Blocker Heart Attack Trial Research Group. Beta-blocker heart attack trial: design, methods, and baseline results. Control Clinical Trials1984;5(4):382-437. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. American Journal of Cardiology1990;66(2):129-33. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1991;122(6):1548-53. GheorghiadeM , ShivkumarK , SchultzL , JafriS , TilleyB , GoldsteinS . Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1993;126(2):271-8. GoldsteinS , ByingtonR . The Beta Blocker Heart Attack Trial: recruitment experience. Controlled Clinical Trials1987;8(4 Suppl):79S-85S. KostisJB , ByingtonR , FriedmanLM , GoldsteinS , FurbergC . Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. Journal of the American College of Cardiology1987;10(2):231-42. National Heart, Lung, and Blood Institute. Beta-blocker heart attack trial study protocol [https://babel.hathitrust.org/cgi/pt?id=pur1.32754081210092;view=1up;seq=3]. U.S. Depeartment of Health and Human Services. Public Health Service, National Institues of Health1978;81-2209. PetersRW , ByingtonR , ArensbergD , FriedmanLM , RomhiltDW , BarkerA , et al. Mortality in the beta blocker heart attack trial: circumstances surrounding death. Journal of Chronic Diseases1987;40(1):75-82. ShivkumarK , SchultzL , GoldsteinS , GheorghiadeM . Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. American Heart Journal1998;135(2 Pt 1):261-7. The Beta-blocker Heart Attack Trial (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA1982;247(12):1707-14. The Beta Blocker Heart Attack Trial Research Group. Beta blocker heart attack trial: design features. Controlled Clinical Trials1981;2(4):275-85. ">BHAT 1982</a>; <a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>; <a href="./references#CD012565-bbs2-0013" title="BethgeKP , AndresenD , BoisselJP , LeitnerER , PeyrieuxJC , SchröderR , et al. Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. Journal of the American College of Cardiology1985;6(5):963-72. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. European Heart Journal1984;5:189-202. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction. European Heart Journal1982;3:583-6. ">E.I.S. 1984</a>). Different definitions and ways of measuring angina were used: <a href="./references#CD012565-bbs2-0002" title="AhlmarkG , SaetreH , KorsgrenM . Reduction of sudden deaths after myocardial infarction. Lancet1974;2(7896):1563. AhlmarkG , SaetreH . Long-term treatment with beta-blockers after myocardial infarction. European Journal of Clinical Pharmacology1976;10(2):77-83. AhlmarkG , SaetreH . Positon of myocardial infarct and results of alprenolol treatment. BMJ1976;1(6013):837. ">Ahlmark 1976</a> and <a href="./references#CD012565-bbs2-0005" title="BoisselJP , LeizoroviczA , PicoletH , DucruetT . Efficacy of acebutolol after acute myocardial infarction (the APSI trial). American Journal of Cardiology1990;66(9):24C-31C. BoisselJP , LeizoroviczA , PicoletH , PeyrieuxJC . Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. American Journal of Cardiology1990;66(3):251-60. CucheratM , BoisselJP , LeizoroviczA . Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. American Journal of Cardiology1997;79(5):587-9. ">APSI 1997</a> reported angina without further definitions, <a href="./references#CD012565-bbs2-0010" title="Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA1983;250(20):2814-9. ByingtonRP , Beta-Blocker Heart Attack Trial Research Group. Beta-blocker heart attack trial: design, methods, and baseline results. Control Clinical Trials1984;5(4):382-437. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. American Journal of Cardiology1990;66(2):129-33. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1991;122(6):1548-53. GheorghiadeM , ShivkumarK , SchultzL , JafriS , TilleyB , GoldsteinS . Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1993;126(2):271-8. GoldsteinS , ByingtonR . The Beta Blocker Heart Attack Trial: recruitment experience. Controlled Clinical Trials1987;8(4 Suppl):79S-85S. KostisJB , ByingtonR , FriedmanLM , GoldsteinS , FurbergC . Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. Journal of the American College of Cardiology1987;10(2):231-42. National Heart, Lung, and Blood Institute. Beta-blocker heart attack trial study protocol [https://babel.hathitrust.org/cgi/pt?id=pur1.32754081210092;view=1up;seq=3]. U.S. Depeartment of Health and Human Services. Public Health Service, National Institues of Health1978;81-2209. PetersRW , ByingtonR , ArensbergD , FriedmanLM , RomhiltDW , BarkerA , et al. Mortality in the beta blocker heart attack trial: circumstances surrounding death. Journal of Chronic Diseases1987;40(1):75-82. ShivkumarK , SchultzL , GoldsteinS , GheorghiadeM . Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. American Heart Journal1998;135(2 Pt 1):261-7. The Beta-blocker Heart Attack Trial (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA1982;247(12):1707-14. The Beta Blocker Heart Attack Trial Research Group. Beta blocker heart attack trial: design features. Controlled Clinical Trials1981;2(4):275-85. ">BHAT 1982</a> reported angina by using the Rose Questionnaire, <a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a> reported 'vasospastic angina', and <a href="./references#CD012565-bbs2-0013" title="BethgeKP , AndresenD , BoisselJP , LeitnerER , PeyrieuxJC , SchröderR , et al. Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. Journal of the American College of Cardiology1985;6(5):963-72. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. European Heart Journal1984;5:189-202. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction. European Heart Journal1982;3:583-6. ">E.I.S. 1984</a> reported angina as 'angina pectoris requiring change in treatment'. </p> <p>Five trials randomising a total of 7115 participants reported on the proportion of participants with angina (<a href="./references#CD012565-bbs2-0002" title="AhlmarkG , SaetreH , KorsgrenM . Reduction of sudden deaths after myocardial infarction. Lancet1974;2(7896):1563. AhlmarkG , SaetreH . Long-term treatment with beta-blockers after myocardial infarction. European Journal of Clinical Pharmacology1976;10(2):77-83. AhlmarkG , SaetreH . Positon of myocardial infarct and results of alprenolol treatment. BMJ1976;1(6013):837. ">Ahlmark 1976</a>; <a href="./references#CD012565-bbs2-0005" title="BoisselJP , LeizoroviczA , PicoletH , DucruetT . Efficacy of acebutolol after acute myocardial infarction (the APSI trial). American Journal of Cardiology1990;66(9):24C-31C. BoisselJP , LeizoroviczA , PicoletH , PeyrieuxJC . Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. American Journal of Cardiology1990;66(3):251-60. CucheratM , BoisselJP , LeizoroviczA . Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. American Journal of Cardiology1997;79(5):587-9. ">APSI 1997</a>; <a href="./references#CD012565-bbs2-0010" title="Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA1983;250(20):2814-9. ByingtonRP , Beta-Blocker Heart Attack Trial Research Group. Beta-blocker heart attack trial: design, methods, and baseline results. Control Clinical Trials1984;5(4):382-437. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. American Journal of Cardiology1990;66(2):129-33. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1991;122(6):1548-53. GheorghiadeM , ShivkumarK , SchultzL , JafriS , TilleyB , GoldsteinS . Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1993;126(2):271-8. GoldsteinS , ByingtonR . The Beta Blocker Heart Attack Trial: recruitment experience. Controlled Clinical Trials1987;8(4 Suppl):79S-85S. KostisJB , ByingtonR , FriedmanLM , GoldsteinS , FurbergC . Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. Journal of the American College of Cardiology1987;10(2):231-42. National Heart, Lung, and Blood Institute. Beta-blocker heart attack trial study protocol [https://babel.hathitrust.org/cgi/pt?id=pur1.32754081210092;view=1up;seq=3]. U.S. Depeartment of Health and Human Services. Public Health Service, National Institues of Health1978;81-2209. PetersRW , ByingtonR , ArensbergD , FriedmanLM , RomhiltDW , BarkerA , et al. Mortality in the beta blocker heart attack trial: circumstances surrounding death. Journal of Chronic Diseases1987;40(1):75-82. ShivkumarK , SchultzL , GoldsteinS , GheorghiadeM . Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. American Heart Journal1998;135(2 Pt 1):261-7. The Beta-blocker Heart Attack Trial (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA1982;247(12):1707-14. The Beta Blocker Heart Attack Trial Research Group. Beta blocker heart attack trial: design features. Controlled Clinical Trials1981;2(4):275-85. ">BHAT 1982</a>; <a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>; <a href="./references#CD012565-bbs2-0013" title="BethgeKP , AndresenD , BoisselJP , LeitnerER , PeyrieuxJC , SchröderR , et al. Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. Journal of the American College of Cardiology1985;6(5):963-72. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. European Heart Journal1984;5:189-202. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction. European Heart Journal1982;3:583-6. ">E.I.S. 1984</a>). A total of 932 of 3526 participants receiving beta‐blockers developed angina compared with 918 of 3589 control participants. Fixed‐effect meta‐analysis showed that beta‐blockers likely may not affect the risk of angina compared with placebo or no intervention (RR 1.04, 98% CI 0.95 to 1.13; I² = 0%; 7115 participants, 5 trials; low‐certainty evidence; <a href="#CD012565-fig-0008">Figure 8</a>). The point estimate of the meta‐analysis result corresponds to 264 of 1000 beta‐blocker patients having angina pectoris compared with 255 of 1000 control participants, or NNT of 125 participants. Absolute risk for angina at maximum follow‐up was 26.4% in the beta‐blocker group compared with 25.6% in the control group. Optimal information size according to the <i>GRADE Handbook</i> using a proportion of 25.6% in the control group, RRR of 10%, alpha of 2.0%, and beta of 10% was estimated to be 14,623 participants, and we included only 7115 participants (see <a href="./full#CD012565-tbl-0001">summary of findings Table 1</a>). </p> <div class="figure" id="CD012565-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of 3.1 Angina pectoris on a dichotomous scale.*E.I.S 1984: angina defined as angina events that required a change in treatment." data-id="CD012565-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of 3.1 Angina pectoris on a dichotomous scale.</p> <p>*E.I.S 1984: angina defined as angina events that required a change in treatment.</p> </div> </div> </div> <p>Best‐worst and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had the potential to influence the meta‐analysis result (best‐worst meta‐analysis: RR 0.89, 95% CI 0.83 to 0.96; I² = 96%; 7372 participants, 5 trials; low‐certainty evidence; <a href="./references#CD012565-fig-0032" title="">Analysis 3.2</a>; worst‐best meta‐analysis: RR 1.19, 95% CI 1.11 to 1.27; I² = 96%; 7372 participants, 5 trials; low‐certainty evidence; <a href="./references#CD012565-fig-0033" title="">Analysis 3.3</a>). Data were imputed for two trials. </p> <p>No further analyses were conducted due to sparse data.</p> </section> <section id="CD012565-sec-0082"> <h5 class="title">Cardiovascular mortality</h5> <p>In all, 19 of 25 trials with a total of 21,763 participants and mean maximum follow‐up of 28.8 months (range 9 to 48 months) reported cardiovascular mortality. A total of 661 of 11,080 participants receiving beta‐blockers died because of a cardiovascular event versus 857 of 10,683 control participants. Random‐effects meta‐analysis showed that beta‐blockers may reduce the risk of cardiovascular mortality compared with placebo or no intervention (RR 0.73, 98% CI 0.61 to 0.88; I² = 47%; 21,763 participants, 19 trials; low‐certainty evidence; <a href="#CD012565-fig-0009">Figure 9</a>). The point estimate of the meta‐analysis result corresponds to 60 of 1000 beta‐blocker patients having a cardiovascular death compared with 80 of 1000 control participants, or NNT of 50 participants. Absolute risk for cardiovascular mortality at maximum follow‐up was 6.0% in the beta‐blocker group compared with 8.0% in the control group. Optimal information size according to the <i>GRADE Handbook</i> using a proportion of 8.0% in the control group, RRR of 10%, alpha of 2.0%, and beta of 10% was estimated to be 137,885 participants, and we included only 21,763 participants (see <a href="./full#CD012565-tbl-0001">summary of findings Table 1</a>). </p> <div class="figure" id="CD012565-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 Cardiovascular mortality at maximum follow‐up, outcome: 4.1 Cardiovascular mortality." data-id="CD012565-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 Cardiovascular mortality at maximum follow‐up, outcome: 4.1 Cardiovascular mortality. </p> </div> </div> </div> <section id="CD012565-sec-0083"> <h6 class="title">Heterogeneity</h6> <p>Visual inspection of the forest plot and tests for statistical heterogeneity (I²= 47%; P = 0.01) indicated moderate heterogeneity (<a href="#CD012565-fig-0009">Figure 9</a>). </p> </section> <section id="CD012565-sec-0084"> <h6 class="title">Risk of bias and sensitivity analyses</h6> <p>We assessed risk of bias of the outcome result as high.</p> <p>Best‐worst and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had no potential to influence the meta‐analysis result (best‐worst meta‐analysis: RR 0.71, 95% CI 0.60 to 0.83; I² = 50%; 21,770 participants, 19 trials; low‐certainty evidence; <a href="./references#CD012565-fig-0041" title="">Analysis 4.8</a>; worst‐best meta‐analysis: RR 0.75, 95% CI 0.63 to 0.90; I² = 61%; 21,770 participants, 19 trials; low‐certainty evidence; <a href="./references#CD012565-fig-0042" title="">Analysis 4.9</a>). Data were imputed for only two trials. </p> <p>Visual inspection of the funnel plot revealed some signs of asymmetry (see <a href="#CD012565-fig-0010">Figure 10</a>). Based on visual inspection of the funnel plot, we assessed risk of publication bias as high. However, we found no signs of small‐study effect when using the Harbord test (P = 0.13) or the Egger test (P = 0.07). </p> <div class="figure" id="CD012565-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 4 Cardiovascular mortality at maximum follow‐up, outcome: 4.1 Cardiovascular mortality." data-id="CD012565-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-10.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 4 Cardiovascular mortality at maximum follow‐up, outcome: 4.1 Cardiovascular mortality. </p> </div> </div> </div> </section> <section id="CD012565-sec-0085"> <h6 class="title">Subgroup analyses</h6> <p>Testing for subgroup differences showed no evidence of a difference in subgroup analyses according to different types of beta‐blockers administered (P = 0.14; <a href="./references#CD012565-fig-0035" title="">Analysis 4.2</a>), different follow‐up periods (P = 0.47; <a href="./references#CD012565-fig-0036" title="">Analysis 4.3</a>), and varying clinical registration status (P = 0.67; <a href="./references#CD012565-fig-0037" title="">Analysis 4.4</a>). However, due to an uneven covariate distribution between different subgroups, these analyses may not have been able to detect any subgroup differences. Remaining tests for subgroup differences were not possible due to lack of data for these subgroups: reperfusion or no reperfusion; different age of participants; men compared to women; and different types of acute coronary syndrome (NSTEMI, STEMI, or UAP). </p> </section> <section id="CD012565-sec-0086"> <h6 class="title">Post hoc subgroup analyses</h6> <p>Testing for subgroup differences showed no evidence of a difference in our post hoc subgroup analyses, suggesting that whether trials received industry versus non‐industry funding (P = 0.22; <a href="./references#CD012565-fig-0038" title="">Analysis 4.5</a>), beta‐blockers were administered within or after seven days following acute myocardial infarction (P = 0.98; <a href="./references#CD012565-fig-0039" title="">Analysis 4.6</a>), or heart failure patients were specifically excluded from trials (P = 0.20; <a href="./references#CD012565-fig-0040" title="">Analysis 4.7</a>), effects of beta‐blockers on cardiovascular mortality were not modified when compared to placebo or no intervention. However, due to an uneven covariate distribution between different subgroups, these analyses may not have been able to detect any subgroup differences. </p> </section> </section> <section id="CD012565-sec-0087"> <h5 class="title">Myocardial infarction</h5> <p>In all, 19 of 25 trials with a total of 19,606 participants and mean maximum follow‐up of 33.3 months (range 9 to 48 months) reported myocardial infarction. A total of 594 of 10,003 participants receiving beta‐blockers had a reinfarction versus 746 of 9603 control participants. Fixed‐effect meta‐analysis showed that beta‐blockers probably reduce the risk of myocardial reinfarction compared with placebo or no intervention (RR 0.76, 98% CI 0.67 to 0.86; I² = 0%; 19,606 participants, 19 trials; moderate‐certainty evidence; <a href="#CD012565-fig-0011">Figure 11</a>). The point estimate of the meta‐analysis result corresponds to 59 of 1000 beta‐blocker patients having a new myocardial infarction during follow‐up compared with 78 of 1000 control participants, or NNT of 53 participants. Absolute risk for myocardial infarction at maximum follow‐up was 5.9% in the beta‐blocker group compared with 7.8% in the control group. Optimal information size according to the <i>GRADE Handbook</i> using a proportion of 7.8% in the control group, RRR of 10%, alpha of 2.0%, and beta of 10% was estimated to be 58,717 participants, and we included only 19,606 participants (see <a href="./full#CD012565-tbl-0001">summary of findings Table 1</a>). </p> <div class="figure" id="CD012565-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 5 Myocardial reinfarction at maximum follow‐up, outcome: 5.1 Myocardial infarction." data-id="CD012565-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 5 Myocardial reinfarction at maximum follow‐up, outcome: 5.1 Myocardial infarction. </p> </div> </div> </div> <section id="CD012565-sec-0088"> <h6 class="title">Heterogeneity</h6> <p>Visual inspection of the forest plot and tests for statistical heterogeneity (I²= 0%; P = 0.62) indicated no heterogeneity (<a href="#CD012565-fig-0011">Figure 11</a>). </p> </section> <section id="CD012565-sec-0089"> <h6 class="title">Risk of bias and sensitivity analyses</h6> <p>We assessed risk of bias of the outcome result as high.</p> <p>Best‐worst and worst‐best case meta‐analyses showed that incomplete outcome data bias alone had the potential to influence the meta‐analysis result (best‐worst meta‐analysis: RR 0.67, 95% CI 0.54 to 0.84; I² = 70%; 19,837 participants, 19 trials; moderate‐certainty evidence; <a href="./references#CD012565-fig-0050" title="">Analysis 5.8</a>; worst‐best meta‐analysis: RR 0.93, 95% CI 0.71 to 1.23; I² = 84%; 19,837 participants, 19 trials; moderate‐certainty evidence; <a href="./references#CD012565-fig-0051" title="">Analysis 5.9</a>). Data were imputed for three trials. </p> <p>Visual inspection of the funnel plot revealed no signs of asymmetry (see <a href="#CD012565-fig-0012">Figure 12</a>). Based on visual inspection of the funnel plot, we assessed risk of publication bias as low. </p> <div class="figure" id="CD012565-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Myocardial reinfarction at maximum follow‐up, outcome: 5.1 Myocardial infarction." data-id="CD012565-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-12.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Myocardial reinfarction at maximum follow‐up, outcome: 5.1 Myocardial infarction. </p> </div> </div> </div> </section> <section id="CD012565-sec-0090"> <h6 class="title">Subgroup analyses</h6> <p>Testing for subgroup differences showed no evidence of a difference in subgroup analyses according to different types of beta‐blockers administered (P = 0.74; <a href="./references#CD012565-fig-0044" title="">Analysis 5.2</a>), different follow‐up periods (P = 0.63; <a href="./references#CD012565-fig-0045" title="">Analysis 5.3</a>), and varying clinical registration status (P = 0.68; <a href="./references#CD012565-fig-0046" title="">Analysis 5.4</a>). However, due to an uneven covariate distribution between different subgroups, these analyses may not have been able to detect any subgroup differences. Remaining tests for subgroup differences were not possible due to lack of data for these subgroups: reperfusion or no reperfusion; different age of participants; men compared to women; and different types of acute coronary syndrome (NSTEMI, STEMI, or UAP). </p> </section> <section id="CD012565-sec-0091"> <h6 class="title">Post hoc subgroup analyses</h6> <p>Testing for subgroup differences showed no evidence of a difference in our post hoc subgroup analyses, suggesting that whether trials received industry versus non‐industry funding (P = 0.40; <a href="./references#CD012565-fig-0047" title="">Analysis 5.5</a>), beta‐blockers were administered within or after seven days following acute myocardial infarction (P = 0.64; <a href="./references#CD012565-fig-0048" title="">Analysis 5.6</a>), or heart failure patients were specifically excluded from trials (P = 0.32; <a href="./references#CD012565-fig-0049" title="">Analysis 5.7</a>), effects of beta‐blockers on cardiovascular mortality were not modified when compared to placebo or no intervention. However, due to an uneven covariate distribution between different subgroups, these analyses may not have been able to detect any subgroup differences. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012565-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012565-sec-0092"></div> <section id="CD012565-sec-0093"> <h3 class="title" id="CD012565-sec-0093">Summary of main results</h3> <p>We included a total of 25 trials consisting of 22,423 participants (mean age 56.9 years, range 50 to 63 years). However, four trials did not contribute any useful data. All trials and outcome results were at high risk of bias. The certainty of evidence according to GRADE was moderate to low for all outcome results. Most trials included a mix of participants with ST‐elevation myocardial infarction (STEMI) and non‐ST‐elevation myocardial infarction (NSTEMI), and no trials provided separate results for each type of myocardial infarction. Only one trial specifically assessed participants with STEMI. We included 21 trials in which the control group received placebo and four trials in which the control group received no intervention. We included six trials in which participants were observed for up to 12 months, 12 trials in which participants were observed for one to three years, and three trials in which participants were observed for three years or longer. We assume that beta‐blockers were administered during these periods. Methods used to exclude heart failure were varying and likely were insufficient because they did not diagnose all degrees of heart failure. </p> <p>Our meta‐analyses show moderate‐certainty evidence that beta‐blockers compared with placebo or no intervention probably reduce the risk of all‐cause mortality and myocardial reinfarction. When major cardiovascular events and cardiovascular mortality were assessed, meta‐analyses yielded low‐certainty evidence suggesting that beta‐blockers compared with placebo or no intervention may reduce the risk. Hence, evidence seems to suggest that beta‐blockers versus placebo or no treatment may result in a minimum 10% reduction in risk ratio for all‐cause mortality, major cardiovascular events, cardiovascular mortality, and myocardial infarction. However, when angina was assessed, meta‐analysis yielded low‐certainty evidence suggesting that beta‐blockers compared with placebo or no intervention may not affect the risk. </p> <p>No data were provided on serious adverse events according to International Conference on Harmonization ‐ Good Clinical Practice Guidelines (ICH‐GCP) nor on quality of life. </p> <p>Testing for subgroup differences showed no evidence of a difference in our pre‐defined and post hoc subgroup analyses according to different types of beta‐blockers administered, different follow‐up periods provided, varying clinical registration status, differences in industry funding status, beta‐blockers administered within or after seven days following acute myocardial infarction, or heart failure patients specifically excluded from trials, for any of these outcomes. However, due to an uneven covariate distribution between different subgroups, these analyses may not have been able to detect any subgroup differences. Tests for subgroup differences were not possible for reperfusion or no reperfusion; different age of participants; men compared to women; and different types of acute coronary syndrome (NSTEMI, STEMI, or unstable angina pectoris (UAP)) due to lack of data. </p> </section> <section id="CD012565-sec-0094"> <h3 class="title" id="CD012565-sec-0094">Overall completeness and applicability of evidence</h3> <p>This review provides the most contemporary appraisal of evidence to date on beta‐blockers for patients without heart failure and with left ventricular ejection fraction (LVEF) greater than 40% following acute myocardial infarction. We searched for published and unpublished trials, irrespective of publication type, publication status, publication date, and language. We also searched for trials in bibliographies of both Cochrane and non‐Cochrane reviews. All trials and results were at high risk of bias. Hence, there is a risk that our results may overestimate benefits and underestimate harms of beta‐blockers. </p> <p>We included all participants without heart failure after myocardial infarction, irrespective of age, sex, type of beta‐blocker used, and type of control group intervention received (placebo or no intervention). However, because methods used to exclude heart failure varied and were likely insufficient, we cannot exclude the possibility that any benefits could have been driven by such participants (<a href="./references#CD012565-bbs2-0043" title="BhattAS , DeVoreAD , DeWaldTA , SwedbergK , MentzRJ . Achieving a maximally tolerated beta-blocker dose in heart failure patients: is there room for improvement?Journal of the American College of Cardiology2017;69(20):2542-50. [PMID: 28521892]">Bhatt 2017</a>; <a href="./references#CD012565-bbs2-0044" title="BiglaneJB , BecnelMF , VenturaHO , KrimSR . Pharmacologic therapy for heart failure with reduced ejection fraction: closing the gap between clinical guidelines and practice. Progress in Cardiovascular Diseases2017;60(2):187-97. [PMID: 28847619]">Biglane 2017</a>; <a href="./references#CD012565-bbs2-0089" title="KotechaD , FlatherMD , AltmanDG , HolmesJ , RosanoG , WikstrandJ , et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. Journal of the American College of Cardiology2017;69(24):2885-96. [PMID: 28467883]">Kotecha 2017</a>). We found no to moderate signs of statistical heterogeneity, which indicates that pooling of these diverse participants and interventions was appropriate. </p> <p>All trials except one included participants younger than 75 years of age. All patients received usual care, but 24 of 25 trials were from the pre‐reperfusion era (published from 1974 to 1999) and only one trial was from the reperfusion era (published in 2018). Therefore, we are dealing with a select group of participants, which potentially limits the generalisability of our findings to present‐day patients (please see later). </p> <p>We found no data on effects of beta‐blockers versus placebo or no intervention on serious adverse events according to ICH‐GCP or quality of life. Therefore, effects of beta‐blockers on serious adverse events and quality of life remain unclear. </p> </section> <section id="CD012565-sec-0095"> <h3 class="title" id="CD012565-sec-0095">Quality of the evidence</h3> <p>We assessed the certainty of evidence for results of each outcome using GRADE. Our GRADE assessment generally showed that evidence was of moderate to low certainty for all outcomes (see <a href="./full#CD012565-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD012565-sec-0096"> <h4 class="title">Risk of systematic error ('bias')</h4> <p>We found no trials and no outcome results at low risk of bias. All included trials were at high risk of bias due to unclear or high risk in several bias domains (see <a href="#CD012565-fig-0003">Figure 3</a>). Therefore, the risk that our results may overestimate the beneficial effects and underestimate the harmful effects of beta‐blockers is high (<a href="./references#CD012565-bbs2-0063" title="GluudLL . Bias in clinical intervention research. American Journal of Epidemiology2006;163(6):493-501.">Gluud 2006</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1705041558487490732029961903496&amp;format=REVMAN#REF-Hrobjartsson-2012" target="_blank">Hrobjartsson 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1705041558487490732029961903496&amp;format=REVMAN#REF-Hrobjartsson-2013" target="_blank">Hrobjartsson 2013</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1705041558487490732029961903496&amp;format=REVMAN#REF-Hrobjartsson-2014" target="_blank">Hrobjartsson 2014</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1705041558487490732029961903496&amp;format=REVMAN#REF-Hrobjartsson-2014a" target="_blank">Hrobjartsson 2014a</a>; <a href="./references#CD012565-bbs2-0087" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine2001;135(11):982-9.">Kjaergard 2001</a>; <a href="./references#CD012565-bbs2-0102" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet1998;352(9128):609-13.">Moher 1998</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1705041558487490732029961903496&amp;format=REVMAN#REF-Savovic-2012" target="_blank">Savovic 2012</a>; <a href="./references#CD012565-bbs2-0122" title="SavovicJ , TurnerRM , MawdsleyD , JonesHE , BeynonR , HigginsJT , et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES meta-epidemiologic study. American Journal of Epidemiology2018;187(5):1113-22. [PMID: 29126260]">Savovic 2018</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1705041558487490732029961903496&amp;format=REVMAN#REF-Schulz-1995" target="_blank">Schulz 1995</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1705041558487490732029961903496&amp;format=REVMAN#REF-Wood-2008" target="_blank">Wood 2008</a>). Hence, we downgraded all outcomes by one level due to risk of bias. </p> </section> <section id="CD012565-sec-0097"> <h4 class="title">Imprecision</h4> <p>We further downgraded angina by one level due to risk of imprecision because the optimal information size (OIS) was not reached, absolute and relative 98% confidence intervals (CIs) showed both appreciable benefit and harm, and sample size was small. However, we downgraded none of the other outcomes for imprecision, although the OIS was not reached, large numbers of events were reported, sample sizes were large, and 97.5% or 98% CIs were fairly narrow. </p> </section> <section id="CD012565-sec-0098"> <h4 class="title">Inconsistency</h4> <p>We assessed statistical heterogeneity in our primary analyses to be of no to moderate importance. We downgraded major cardiovascular events (MACE) and cardiovascular mortality by one level due to risk of inconsistency based on a moderate I² (30% to 60%) and a small P value (P &lt; 0.05) when the statistical test for heterogeneity was used for assessment. </p> </section> <section id="CD012565-sec-0099"> <h4 class="title">Indirectness</h4> <p>We downgraded no outcomes for indirectness.</p> </section> <section id="CD012565-sec-0100"> <h4 class="title">Publication bias</h4> <p>Funnel plots assessing all‐cause mortality, MACE, and myocardial infarction at maximum follow‐up showed some signs of asymmetry. However, we detected no signs of small‐study effect when we used the Harbord test or the Egger test (<a href="./references#CD012565-bbs2-0068" title="HarbordRM , EggerM , SterneJA . A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443-57. [PMID: 16345038]">Harbord 2006</a>). Hence, there was no strong suspicion of small‐study or publication bias, and we downgraded none of the outcomes. </p> </section> </section> <section id="CD012565-sec-0101"> <h3 class="title" id="CD012565-sec-0101">Potential biases in the review process</h3> <section id="CD012565-sec-0102"> <h4 class="title">Strengths</h4> <p>Our review has several strengths. None of the review authors had any conflicts of interests. We conducted this review according to the methods outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and by Jakobsen and colleagues (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009182.pub2/references#CD009182-bbs2-0056" target="_blank">Higgins 2011</a>; <a href="./references#CD012565-bbs2-0084" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). We followed our peer‐reviewed protocol, which was published before the literature search began (<a href="./references#CD012565-bbs2-0106" title="NielsenEE , FeinbergJ , SafiS , SethiNJ , GluudC , JakobsenJC . Beta-blockers for non-acute treatment after myocardial infarction. Cochrane Database of Systematic Reviews Feb 2017, Issue 1. Art. No: CD012565. [DOI: 10.1002/14651858.CD012565]">Nielsen 2017</a>), and we described a few exceptions under <a href="#CD012565-sec-0140">Differences between protocol and review</a>. We included trials regardless of language of publication and whether they reported data on the outcomes we had planned to assess. Two independent review authors double‐extracted data, minimising the risk of inaccurate data extraction; we assessed risk of bias in all trials according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and risk of industry influence according to <a href="./references#CD012565-bbs2-0097" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL , SismondoS , et al. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3]">Lundh 2017</a><i>.</i> We contacted all relevant trial authors if we needed additional information. However, only one trial author replied and provided us with relevant information on our pre‐defined outcome measures. We included more participants than were included in any previous systematic review on this topic, which gives us increased power and precision to detect any significant differences between intervention and control groups. We tested the robustness of our results by using GRADE to assess the certainty of evidence and sensitivity analyses (best‐worst and worst‐best) to test the potential impact of incomplete outcome data bias. Hence, this review considered both risks of random errors and risks of systematic errors, which adds robustness to our results and conclusions. </p> </section> <section id="CD012565-sec-0103"> <h4 class="title">Limitations</h4> <p>Our systematic review has several limitations. Our findings, interpretations, and conclusions are affected by the quality and quantity of the trials included in this review. </p> <p>Furthermore, by including only randomised clinical trials and ignoring harms assessed in quasi‐randomised studies and observational studies, we run the risk of focusing overly on potential benefits at the cost of overlooking late and rare harms. </p> <section id="CD012565-sec-0104"> <h5 class="title">Risk of bias assessment</h5> <p>Our risk of bias assessment shows that all trials were at high risk of bias. Therefore, it is highly probable that our review results are also biased (i.e. there is great risk that our results overestimate benefit and underestimate harms) (<a href="./references#CD012565-bbs2-0063" title="GluudLL . Bias in clinical intervention research. American Journal of Epidemiology2006;163(6):493-501.">Gluud 2006</a>; <a href="./references#CD012565-bbs2-0076" title="HrobjartssonA , ThomsenAS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ (Clinical Research Ed.)2012;344:e1119.">Hrobjartsson 2012</a>; <a href="./references#CD012565-bbs2-0077" title="HrobjartssonA , ThomsenASS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal2013;185(4):E201-11.">Hrobjartsson 2013</a>; <a href="./references#CD012565-bbs2-0078" title="HrobjartssonA , EmanuelssonF , Skou ThomsenAS , HildenJ , BrorsonS . Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. International Journal of Epidemiology2014;43(4):1272-83. [PMID: 24881045]">Hrobjartsson 2014</a>; <a href="./references#CD012565-bbs2-0079" title="HrobjartssonA , ThomsenAS , EmanuelssonF , TendalB , RasmussenJV , HildenJ , et al. Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. International Journal of Epidemiology2014;43(3):937-48.">Hrobjartsson 2014a</a>; <a href="./references#CD012565-bbs2-0087" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine2001;135(11):982-9.">Kjaergard 2001</a>; <a href="./references#CD012565-bbs2-0102" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet1998;352(9128):609-13.">Moher 1998</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1705041558487490732029961903496&amp;format=REVMAN#REF-Savovic-2012" target="_blank">Savovic 2012</a>; <a href="./references#CD012565-bbs2-0121" title="SavovicJ , JonesH , AltmanD , HarrisR , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assesment2012;16(35):1-82.">Savovic 2012a</a>; <a href="./references#CD012565-bbs2-0122" title="SavovicJ , TurnerRM , MawdsleyD , JonesHE , BeynonR , HigginsJT , et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES meta-epidemiologic study. American Journal of Epidemiology2018;187(5):1113-22. [PMID: 29126260]">Savovic 2018</a>; <a href="./references#CD012565-bbs2-0124" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1705041558487490732029961903496&amp;format=REVMAN#REF-Wood-2008" target="_blank">Wood 2008</a>). This is the primary limitation of our review. </p> </section> <section id="CD012565-sec-0105"> <h5 class="title">Incomplete outcome data</h5> <p>Incomplete outcome data were at low risk of bias in eight trials. Six trials did not properly deal with incomplete outcome data and were at high risk of bias. In the remaining 11 trials, incomplete outcome data were insufficiently described; we therefore judged these trials to be at unclear risk of bias. However, our best‐worst and worst‐best analyses show that risk of incomplete outcome data bias was high when major cardiovascular mortality, myocardial infarction, and angina were assessed. </p> <p><a href="./references#CD012565-bbs2-0002" title="AhlmarkG , SaetreH , KorsgrenM . Reduction of sudden deaths after myocardial infarction. Lancet1974;2(7896):1563. AhlmarkG , SaetreH . Long-term treatment with beta-blockers after myocardial infarction. European Journal of Clinical Pharmacology1976;10(2):77-83. AhlmarkG , SaetreH . Positon of myocardial infarct and results of alprenolol treatment. BMJ1976;1(6013):837. ">Ahlmark 1976</a> included 393 participants in the original round of randomisation but followed up on only 162 of these participants and included them in one of two groups. Participants were excluded from the trial if, after randomisation, they were found not to have acute infarction, to have died in the hospital, to not belong to the hospital's catchment area, or to have persisting contraindications to beta‐blockade. This gives rise to high incomplete outcome data bias. Given that a large proportion of trials were performed more than 30 years ago, one might argue that trialists may not have properly approached or reported incomplete outcome data, and our best‐worst and worst‐best sensitivity analyses might highly underestimate the potential impact of missing data because we used available trial data even if the number of participants included in the assessment was unclear based on the publication. Incomplete outcome data bias might have greater bias impact than our best‐worst and worst‐best case scenarios show (i.e. the ’true’ difference between actually observed cases and the intention‐to‐treat population might be greater than our data suggest). </p> </section> <section id="CD012565-sec-0106"> <h5 class="title">Assessed time points</h5> <p>In our protocol, we pre‐defined the time point closest to 12 months (range 6 to 18 months) as our primary assessment time point, and maximum follow‐up as a secondary time point of interest. However, after further consideration, we decided to change our primary assessment time point to maximum follow‐up to achieve more power and precision, and, because we already had conducted a pre‐defined subgroup analysis looking at different follow‐up time points, we did not find it necessary to also assess outcomes at a secondary time point. </p> </section> <section id="CD012565-sec-0107"> <h5 class="title">Continuous outcomes</h5> <p>We included quality of life and angina on any valid scale. However, none of the included trials reported data on quality of life, and trials provided only limited dichotomous data on angina. This is a great limitation, as we found insufficient information on important subjective patient‐relevant outcomes. </p> </section> <section id="CD012565-sec-0108"> <h5 class="title">Clinical heterogeneity</h5> <p>Beta‐blockers used in the experimental group and co‐interventions used in different trials differed. Our results show no to moderate signs of statistical heterogeneity; this is a limitation of our review because subsequent transferability into a specific clinical context may be impaired. </p> </section> <section id="CD012565-sec-0109"> <h5 class="title">Indirectness of evidence</h5> <p>It is important to note that less than 20% of participants included in this review were women, indicating the risk for evidence being indirect. However, when we considered the overall certainty of evidence, we did not find further indications suggesting significant variation in the study population. Hence, we did not find it necessary to decrease certainty for indirectness. </p> </section> <section id="CD012565-sec-0110"> <h5 class="title">Assessed age range</h5> <p>In all, 17 of 25 studies included only participants younger than 70 years of age, six studies included participants between 70 and 75 years of age, and only one study included participants older than 75 years of age (<a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>). The limited age range of patients included in this review and absence of data on the elderly, for whom risk‐benefit ratios may differ substantially, are important limitations that ought to be taken under serious consideration when our results are viewed, because we lack any evidence on effects of beta‐blockers for patients older than 75 years of age without heart failure and with preserved ejection fraction. This is especially of concern when it is considered how patients have gotten older in the past few decades, and how the number of older patients and especially of cardiac patients will continue to increase (<a href="./references#CD012565-bbs2-0114" title="RodgersJL , JonesJ , BolledduSI , VanthenapalliS , RodgersLE , ShahK , et al. Cardiovascular risks associated with gender and aging. Journal of Cardiovascular Development and Disease2019;6(2):19. [PMID: 31035613]">Rodgers 2019</a>). Therefore, it is of utmost importance to uncover in future clinical and research studies the impact of beta‐blockers for patients older than 75 years of age without heart failure and with preserved ejection fraction after myocardial infarction, to improve outcomes for the older population. </p> </section> <section id="CD012565-sec-0111"> <h5 class="title">Composite outcome</h5> <p>We included two composite outcomes ‐ 'major cardiovascular events' (MACE) (defined as a composite outcome of cardiovascular mortality and non‐fatal myocardial infarction) and 'serious adverse events' according to ICH‐GCP. A potential limitation when composite outcomes are used is that each component of the composite outcome will not necessarily have similar degrees of severity (<a href="./references#CD012565-bbs2-0062" title="GarattiniS , JakobsenJC , WetterslevJ , BerteleV , BanziR , RathA , et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13-21.">Garattini 2016</a>). This might bias results for these outcomes (<a href="./references#CD012565-bbs2-0062" title="GarattiniS , JakobsenJC , WetterslevJ , BerteleV , BanziR , RathA , et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13-21.">Garattini 2016</a>). For example, if certain more severe serious adverse events occur in one of the intervention groups and other less severe serious adverse events occur in another intervention group, there is a risk of overlooking actual severity differences between compared groups on these composite outcomes (<a href="./references#CD012565-bbs2-0062" title="GarattiniS , JakobsenJC , WetterslevJ , BerteleV , BanziR , RathA , et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13-21.">Garattini 2016</a>). Furthermore, a potential limitation of a composite outcome as 'serious adverse events' is that heterogeneity arises when different events are compared. However, none of the included trials specifically assessed serious adverse events according to the recommendations of ICH‐GCP. Instead, trials reported one specific serious adverse event, which was already included in one of the other outcomes in this review, or a composite of several different events without referring to actual proportions of participants. When MACE was assessed, most trials successfully managed to report both cardiovascular mortality and non‐fatal myocardial infarction. Three trials did not differentiate between non‐fatal and fatal myocardial infarction when reporting data for myocardial infarction (<a href="./references#CD012565-bbs2-0009" title="WuN , FanZ . Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. American Journal of Cardiology1997;110(8):602-6. ">BCSG 1997</a>; <a href="./references#CD012565-bbs2-0013" title="BethgeKP , AndresenD , BoisselJP , LeitnerER , PeyrieuxJC , SchröderR , et al. Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. Journal of the American College of Cardiology1985;6(5):963-72. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. European Heart Journal1984;5:189-202. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction. European Heart Journal1982;3:583-6. ">E.I.S. 1984</a>; <a href="./references#CD012565-bbs2-0019" title="BellinEY , The Nowergian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on timolol after myocardial infarction. 1986;314(16):1052-3. Lund-Johansen, The Norwegian Multicenter Study Group. The Norwegian multicenter study on timolol after myocardial infarction. Part II. Effect in different risk groups, causes of death, heart arrest, reinfarctions, rehospitalizations and adverse experiences. Acta Medica Scandinavica1981;651:243-52. PedersenTR , The Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. New England Journal of Medicine1985;313(17):1055-8. The Norwegian Multicenter Study Group. The Norwegian multicenter study on timolol after myocardial infarction. Acta Medica Scandinavica1981;651:235-41. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New England Journal of Medicine1981;304(14):801-7. ">NMS 1981</a>), and two trials reported only cardiovascular mortality or myocardial infarction (<a href="./references#CD012565-bbs2-0015" title="Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. European Heart Journal1987;8:1056-64. ">LIT 1987</a>; <a href="./references#CD012565-bbs2-0025" title="VedinA , WilhelmssonC , WerköL . Chronic alprenolol treatment of patients with acute myocardial infarction after discharge from hospital. Acta Medica Scandinavica Supplementum1975;575:3-56. WihelmssonC , VedinA , WilhelmsenL , TibblinG , WerköL , WedelH . Deaths and non-fatal reinfarctions during two years' follow-up. Acta Medica Scandinavica Supplementum1975;575:19-24. WilhelmssonC , VedinJA , WilhelmsenL , TibblinG , WerköL . Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet1974;2(7890):1157-60. ">Wilhelmsson 1974</a>). One trial did not specify the definition of myocardial infarction used in the trial, but we contacted the trial author, who clarified that only non‐fatal myocardial infarctions were reported (<a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>). Hence, when possible, and when there was no risk of double‐counting patients, we calculated MACE as a composite of cardiovascular mortality and non‐fatal myocardial infarction. We believe that the clinical relevance of composite outcomes such as 'major cardiovascular events' and ‘serious adverse events’ and the resulting increased statistical power justify use of these composite outcomes as a primary outcome. However, the interpretative limitations ought to be considered. </p> </section> <section id="CD012565-sec-0112"> <h5 class="title">External validity</h5> <p>Management of myocardial infarction has been evolving greatly in the past two decades with the introduction of early coronary reperfusion strategies leading to reduced mortality and improved LVEF by immediate restoration of myocardial blood flow and lowering of sympathetic activation following acute myocardial infarction. Since the 1980s, survival from myocardial infarction has improved by approximately 25% in Western countries ‐ an effect attributable not only to the introduction of reperfusion strategies but also to major advancements in medical therapy consisting of antiplatelet therapies, angiotensin‐converting enzyme (ACE) inhibitors/angiotensin‐receptor blockers (ARBs), and statins substantially improving the prognosis for patients following acute myocardial infarction (<a href="./references#CD012565-bbs2-0107" title="NobleS , RoffiM . Routine beta-blocker administration following acute myocardial infarction: why still an unsolved issue?Journal of Thoracic Disease2017;9(11):4191-4. [PMID: 29268468]">Noble 2017</a>). Antiplatelets and statins have been shown to reduce the risk of reinfarction by reducing atherothrombosis, and ACE inhibitors and ARBs have been found to prevent adverse ventricular remodelling and development of severe heart failure (<a href="./references#CD012565-bbs2-0039" title="Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (Clinical research ed.)2002;324(7329):71-86. [PMID: 11786451]">Antithrombotic Trialists' Collaboration 2002</a>; <a href="./references#CD012565-bbs2-0090" title="KøberL , Torp-PedersenC , CarlsenJE , BaggerH , EliasenP , LyngborgK , et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. New England Journal of Medicine1995;333(25):1670-6. [PMID: 7477219]">Køber 1995</a>; <a href="./references#CD012565-bbs2-0109" title="PfefferMA , GreavesSC , ArnoldJM , GlynnRJ , LaMotteFS , LeeRT , et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation1997;95(12):2643-51. [PMID: 9193433]">Pfeffer 1997</a>; <a href="./references#CD012565-bbs2-0130" title="SteinhublSR , BhattDL , BrennanDM , MontalescotG , HankeyGJ , EikelboomJW , et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Annals of Internal Medicine2009;150(6):379-86. [PMID: 19293071]">Steinhubl 2009</a>). Hence, these therapies, which currently constitute standard care for myocardial infarction, have been shown to have the same positive effects as beta‐blockers on pathophysiological consequences following a myocardial infarction (<a href="./references#CD012565-bbs2-0111" title="QamarA , BangaloreS . Beta-blocker therapy after myocardial infarction: is there an expiry date?Canadian Journal of Cardiology2020;36(10):1577-9. [PMID: 32634390]">Qamar 2020</a>). However, most of the trials included in this review were conducted between 1974 and 1999 ‐ an era in which the above mentioned therapies were not available or were routinely practiced, and only one trial was from 2018 (<a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>). Therefore, the findings of this review may not be compatible with the present management of myocardial infarction in the non‐acute phase following acute myocardial infarction. Furthermore, conduct and reporting of trials have immensely improved over the last two decades, which may have influenced the results of this review. This emphasises the importance of the five ongoing trials assessing long‐term effects of beta‐blockers for patients without heart failure and with preserved LVEF following acute myocardial infarction (see <a href="./references#CD012565-sec-0144" title="">Characteristics of ongoing studies</a>). </p> </section> <section id="CD012565-sec-0113"> <h5 class="title">Definition of included patients</h5> <p>One important limitation of our review is that most of the included trials were conducted in an era in which the definition of heart failure and assessment and differentiation of STEMI/NSTEMI patients and LVEF differed from the current clinical approach. Most trials included a mix of participants with STEMI and NSTEMI, and no trials provided separate results for each type of myocardial infarction, except one trial, which specifically assessed participants with STEMI (<a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>). Only three trials assessed LVEF and specifically included patients with preserved LVEF greater than 40% (<a href="./references#CD012565-bbs2-0009" title="WuN , FanZ . Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. American Journal of Cardiology1997;110(8):602-6. ">BCSG 1997</a>; <a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a>; <a href="./references#CD012565-bbs2-0022" title="PoulsenSH , JensenSE , EgstrupK . Effects of long-term adrenergic beta-blockade on left ventricular diastolic filling in patients with acute myocardial infarction. American Heart Journal1999;138(4 Pt 1):710-20. PoulsenSH , JensenSE , EgstrupK . Improvement of exercise capacity and left ventricular diastolic function with metoprolol XL after acute myocardial infarction. American Heart Journal2000;140(1):E6-11. ">Poulsen 1999</a>). Most of the included trials stated that heart failure participants were excluded but provided no further specification on the diagnosis nor on the definition of heart failure. Some trials might have included participants with reduced LVEF but without clinical overt heart failure; other trials might have included participants with clinical overt heart failure but with estimated preserved LVEF, etc. Based on these trials, European Society of Cardiology (ESC) guidelines recommend the use of beta‐blockers for both STEMI and NSTEMI patients with heart failure and LVEF less than 40% with a class I recommendation. However, the newest ESC guidelines (from 2020) highlight the need for studies evaluating the value of long‐term therapy with beta‐blockers for patients with LVEF greater than 40%, and American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines recommend beta‐blockers for patients with both STEMI and NSTEMI following acute myocardial infarction. </p> <p>In our protocol, we planned to exclude trials specifically randomising participants with post‐myocardial infarction heart failure, defined as clinically overt New York Heart Association (NYHA) Class III/IV heart failure and LVEF less than 40% at the time of discharge from the hospital. Several trials specifically excluded heart failure participants but reported some percentage of patients with heart failure in the baseline table or some percentage of patients discharged on digitalis and diuretics (for a detailed description, see <a href="#CD012565-tbl-0002">Table 1</a>). We chose to include these trials but decided to perform a post hoc subgroup analysis comparing trials specifically excluding heart failure participants to trials specifically excluding heart failure participants but likely not adhering to this. Testing for subgroup differences showed no evidence of a difference when these two subgroups were compared. However, because most trials did not specifically assess LVEF, the results of this review might be overestimated by potential inclusion of patients with reduced LVEF. Hence, the external validity of our results may refer only to patients post myocardial infarction and without severe heart failure, covering 70% to 80% of the heart failure patient group. Results may not reflect true intervention effects for the last 20% to 30% of patients with some degree of mild heart failure that was not detectable when trials were conducted but that would have been excluded today based on newer diagnostic techniques. Future trials ought to assess the effects of beta‐blockers separately in STEMI and NSTEMI patients while using a clear definition of no heart failure with preserved LVEF greater than 40%. </p> <div class="table" id="CD012565-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Detailed description of heart failure in the included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition of heart failure in the exclusion criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Digitalis and diuretics at discharge</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients with HF included</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0001" title="AdesPA , ThomasJD , HansonJS , ShapiroSM , LaMountainJ . Effect of metoprolol on the submaximal stress test performed early after acute myocardial infarction. American Journal of Cardiology1987;60(13):963-6. ">Ades 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically overt heart failure (raies, third heart sound)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 patients on digitalis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0002" title="AhlmarkG , SaetreH , KorsgrenM . Reduction of sudden deaths after myocardial infarction. Lancet1974;2(7896):1563. AhlmarkG , SaetreH . Long-term treatment with beta-blockers after myocardial infarction. European Journal of Clinical Pharmacology1976;10(2):77-83. AhlmarkG , SaetreH . Positon of myocardial infarct and results of alprenolol treatment. BMJ1976;1(6013):837. ">Ahlmark 1976</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac decompensation despite adequate therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>On discharge, 50% in the alprenolol group and 46% in the control group were receiving digitalis, and 26% in the </p> <p>alprenolol group and 31% in the control group were taking diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0003" title="AhnveS , ErhardtL , LundmanT , RehnqvistN , SjögrenA . Effect of metoprolol on QTc intervals after acute myocardial infarction. Acta Medica Scandinavica1980;208(3):223-8. ">Ahnve 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe heart failure (no further description given)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 patients from the experimental group and 11 patients from the control group were on digitalis at discharge or during follow‐up </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0004" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335-71. ">Amsterdam Metoprolol Trial 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded patients with NYHA Class III/IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0005" title="BoisselJP , LeizoroviczA , PicoletH , DucruetT . Efficacy of acebutolol after acute myocardial infarction (the APSI trial). American Journal of Cardiology1990;66(9):24C-31C. BoisselJP , LeizoroviczA , PicoletH , PeyrieuxJC . Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. American Journal of Cardiology1990;66(3):251-60. CucheratM , BoisselJP , LeizoroviczA . Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. American Journal of Cardiology1997;79(5):587-9. ">APSI 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute heart failure that required treatment with &gt; 2 drugs of different classes (e.g. diuretics, vasodilators). If the condition disappeared before the twenty‐second day, the patient could be included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No description of patients taking diuretics and digitalis; only nifedipine was allowed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 50% of patients had acute heart failure at the time of inclusion in the study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0006" title="Australian and Swedish Pindolol Study Group. The effect of pindolol on the two years mortality after complicated myocardial infarction. European Heart Journal1983;4(6):367-75. ">Australien &amp; Swedish 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled heart failure (no further description given)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86/266 from the control group and 81/263 from the experimental group were on digitalis at discharge. 111/266 from the control group and 120/263 from the experimental group were on diuretics at the time of discharge </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160/266 from the control group and 162/263 from the experimental group had left ventricular failure during hospitalisation and before randomisation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0007" title="BaberNS , EvansDW , HowittG , ThomasM , WilsonC , LewisJA , et al. Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy, and Yugoslavia. British Heart Journal1980;44(1):96-100. ">Baber 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent heart failure (no further description given)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 20% of patients in both groups had cardiac failure in the acute phase. Patients with heart failure were withdrawn from the study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0008" title="BarvikS , DicksteinK , AarslandT , Vik-MoH . Effect of timolol on cardiopulmonary exercise performance in men after myocardial infarction. American Journal of Cardiology1982;69(3):163-8. ">Barvik 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical signs of congestive heart failure. Included patients with NYHA Class I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0009" title="WuN , FanZ . Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. American Journal of Cardiology1997;110(8):602-6. ">BCSG 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients with contraindications to beta‐blockers. However, all patients had LVEF &gt; 40% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0010" title="Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA1983;250(20):2814-9. ByingtonRP , Beta-Blocker Heart Attack Trial Research Group. Beta-blocker heart attack trial: design, methods, and baseline results. Control Clinical Trials1984;5(4):382-437. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. American Journal of Cardiology1990;66(2):129-33. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1991;122(6):1548-53. GheorghiadeM , ShivkumarK , SchultzL , JafriS , TilleyB , GoldsteinS . Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1993;126(2):271-8. GoldsteinS , ByingtonR . The Beta Blocker Heart Attack Trial: recruitment experience. Controlled Clinical Trials1987;8(4 Suppl):79S-85S. KostisJB , ByingtonR , FriedmanLM , GoldsteinS , FurbergC . Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. Journal of the American College of Cardiology1987;10(2):231-42. National Heart, Lung, and Blood Institute. Beta-blocker heart attack trial study protocol [https://babel.hathitrust.org/cgi/pt?id=pur1.32754081210092;view=1up;seq=3]. U.S. Depeartment of Health and Human Services. Public Health Service, National Institues of Health1978;81-2209. PetersRW , ByingtonR , ArensbergD , FriedmanLM , RomhiltDW , BarkerA , et al. Mortality in the beta blocker heart attack trial: circumstances surrounding death. Journal of Chronic Diseases1987;40(1):75-82. ShivkumarK , SchultzL , GoldsteinS , GheorghiadeM . Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. American Heart Journal1998;135(2 Pt 1):261-7. The Beta-blocker Heart Attack Trial (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA1982;247(12):1707-14. The Beta Blocker Heart Attack Trial Research Group. Beta blocker heart attack trial: design features. Controlled Clinical Trials1981;2(4):275-85. ">BHAT 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>History of severe congestive heart failure (no further description given)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 17% of patients were on diuretics and 12.5% were on digitalis on the time of randomisation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 14.5% of patients in each group had congestive heart failure during hospitalisation and before randomisation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduced LVEF (LVEF &lt; 40%), symptomatic HF. Included Killip class I/II with preserved ejection fraction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No patients received digitalis or diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0012" title="CurtisJL , HoughtonJL , PattersonJH , KochG , BradleyDA , Adams KF Jr. Propranolol therapy alters estimation of potential cardiovascular risk derived from submaximal postinfarction exercise testing. American Heart Journal1991;121(6 Pt 1):1655-64. ">Curtis 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients were excluded if they could not safely undergo exercise testing due to persistent heart failure </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0013" title="BethgeKP , AndresenD , BoisselJP , LeitnerER , PeyrieuxJC , SchröderR , et al. Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. Journal of the American College of Cardiology1985;6(5):963-72. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. European Heart Journal1984;5:189-202. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction. European Heart Journal1982;3:583-6. ">E.I.S. 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heart failure (no further description given)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13% of patients in each group had left heart failure during the acute myocardial infarction, but none were noted to have heart failure at the time of randomisation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0014" title="JulianDG , PrescottRJ , JacksonFS , SzekelyP . Controlled trial of sotalol for one year after myocardial infarction. Lancet1982;1(8282):1142-7. ">Julian 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical evidence of heart failure at the 12th post‐infarction day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 21.5% in each group had heart failure during the acute phase</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0015" title="Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. European Heart Journal1987;8:1056-64. ">LIT 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Congestive heart failure (no further description given)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 6% in each group had moderate to severe CHF between admission and pre‐entry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0016" title="MazurNA , KulginskayaIV , IvanovaLA , Ostrov SkayaTP , SmirnovaTM , SvetEA , et al. Results of long-term propranolol treatment in myocardial infarction survivors with advanced grades of ventricular extrasystoles. Cor et Vasa1984;26(4):241-7. ">Mazur 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Contraindications to beta‐blockers. No further definition given. However, <a href="./references#CD012565-bbs2-0042" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. American Journal of Medicine2014;127(10):939-53. [PMID: 24927909]">Bangalore 2014</a>, which excluded trials with post‐myocardial infarction heart failure or left ventricular systolic dysfunction, included this trial </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0017" title="MazzueroG , GaldangeloF , ZottiAM , BertolottiG , TavazziL . Effects of propranolol, atenolol, and chlordesmethyldiazepam on response to mental stress in patients with recent myocardial infarction. Clinical Cardiology1987;10(6):293-302. ">Mazzuero 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded patients treated with digitalis and NYHA III/IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0018" title="A Multicentre International Study Group. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. BMJ1975;3:735-40. The Multicentre International Study Group. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. BMJ1977;2:419-21. ">MIS 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence of congestive heart failure at proposed date of entry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients with cardiac failure during follow‐up were withdrawn from trial medication</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0019" title="BellinEY , The Nowergian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on timolol after myocardial infarction. 1986;314(16):1052-3. Lund-Johansen, The Norwegian Multicenter Study Group. The Norwegian multicenter study on timolol after myocardial infarction. Part II. Effect in different risk groups, causes of death, heart arrest, reinfarctions, rehospitalizations and adverse experiences. Acta Medica Scandinavica1981;651:243-52. PedersenTR , The Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. New England Journal of Medicine1985;313(17):1055-8. The Norwegian Multicenter Study Group. The Norwegian multicenter study on timolol after myocardial infarction. Acta Medica Scandinavica1981;651:235-41. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New England Journal of Medicine1981;304(14):801-7. ">NMS 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled cardiac failure. Included Killip class I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 33% of patients in each group had heart failure at randomisation and before treatment initiation. </p> <p>Heart failure and pulmonary oedema were reasons for withdrawal only if treatment with digitalis and diuretics did not effect satisfactory improvement </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0020" title="HansteenV , MøinichenE , LorentsenE , AndersenA , StrømO , SøilandK , et al. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. BMJ1982;284:155-60. HansteenV . Beta blockade after myocardial infarction: the Norwegian propranolol study in high-risk patients. Circulation1983;67(Suppl 1):I57-60. HansteenV . The Norwegian propranolol trial in selected patients. British Journal of Clinical Pharmacology1982;14:9S-12S. ">NPT 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who presented with heart failure on admission or during the initial phase of infarction were included if signs of failure had disappeared at the time of randomisation. Patients with severe heart failure ‐ that is, cardiogenic shock or pulmonary oedema ‐ and patients who still presented with signs of heart failure at the time of randomisation, although treated with digitalis and furosemide 40 to 80 mg/d, were excluded </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 40% in each group presented with left ventricular failure in the acute phase</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0021" title="OlssonG , LevinLA , RehnqvistN . Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol. British Medical Journal (Clinical Research Edition)1987;294(6568):339-42. OlssonG , LubsenJ , vanEsGA , RehnqvistN . Quality of life after myocardial infarction: effect of long term metoprolol on mortality and morbidity. British Medical Journal (Clinical Research Edition)1986;292(6534):1491-3. OlssonG , OdénA , JohanssonL , SjögrenA , RehnqvistN . Prognosis after withdrawal of chronic postinfarction metoprolol treatment: a 2-7 year follow-up. European Heart Journal1988;9(4):365-72. OlssonG , RehnqvistN , LundmandT , MelcherA . Metoprolol treatment after acute myocardial infarction - Effects on ventricular arrhythmias and exercise tests during 6 months. Acta Medica Scandinavica1981;210(1-2):59-65. OlssonG , RehnqvistN , SjögrenA , ErhardtL , LundmanT . Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. Journal of the American College of Cardiology1985;5(6):1428-37. ">Olsson 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe cardiac failure not responding to conventional treatment with digitalis and diuretic drugs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 23.5% in each group were on digitalis at discharge. Around 45% in each group were on diuretics at discharge </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0022" title="PoulsenSH , JensenSE , EgstrupK . Effects of long-term adrenergic beta-blockade on left ventricular diastolic filling in patients with acute myocardial infarction. American Heart Journal1999;138(4 Pt 1):710-20. PoulsenSH , JensenSE , EgstrupK . Improvement of exercise capacity and left ventricular diastolic function with metoprolol XL after acute myocardial infarction. American Heart Journal2000;140(1):E6-11. ">Poulsen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe uncontrolled congestive heart failure. LVEF &lt; 40%, because it appears that all patients had LVEF &gt; 40% at baseline </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0023" title="SchwartzPJ , MotoleseM , PollaviniG , LottoA , RubertiU , TrazziR , et al. Prevention of sudden cardiac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. Journal of Cardiovascular Electrophysiology1992;3(1):2-16. ">Schwartz 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically overt heart failure (NYHA III and IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0024" title="TaylorSH , SilkeB , EbbuttA , SuttonGC , ProutBJ , BurleyDM . A long-term prevention study with oxprenolol in coronary heart disease. New England Journal of Medicine1982;307(21):1293-301. ">Taylor 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac contraindications to beta‐blockade ‐ i.e. radiographic evidence of heart failure (cardiothoracic ratio &gt; 0.50) or pulmonary venous congestion, resting heart rate &lt; 50 beats per minute, or any grade of heart block </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0025" title="VedinA , WilhelmssonC , WerköL . Chronic alprenolol treatment of patients with acute myocardial infarction after discharge from hospital. Acta Medica Scandinavica Supplementum1975;575:3-56. WihelmssonC , VedinA , WilhelmsenL , TibblinG , WerköL , WedelH . Deaths and non-fatal reinfarctions during two years' follow-up. Acta Medica Scandinavica Supplementum1975;575:19-24. WilhelmssonC , VedinJA , WilhelmsenL , TibblinG , WerköL . Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet1974;2(7890):1157-60. ">Wilhelmsson 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac decompensation despite treatment with optimum doses of digitalis and diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LVEF: left ventricular ejection fraction.</p> <p>NR: not reported.</p> <p>NYHA: New York Heart Association.</p> </div> </div> </section> </section> <section id="CD012565-sec-0114"> <h4 class="title">Subgroup analyses</h4> <p>We planned a large number of subgroup analyses, and this may significantly increase the risk of type I errors (<a href="./references#CD012565-bbs2-0084" title="JakobsenJC , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [PMID: 25416419]">Jakobsen 2014</a>). </p> </section> <section id="CD012565-sec-0115"> <h4 class="title">Post hoc analyses</h4> <p>After completing the protocol, we added three important post hoc subgroup analyses to assess differences in effect in: </p> <p> <ul id="CD012565-list-0022"> <li> <p>trials funded by industry compared to non‐industry‐funded trials;</p> </li> <li> <p>trials that administered beta‐blockers within compared to after seven days following acute myocardial infarction (subacute compared to non‐acute phase); and </p> </li> <li> <p>trials specifically excluding heart failure participants compared to trials specifically excluding heart failure participants but likely not adhering to this. </p> </li> </ul> </p> </section> <section id="CD012565-sec-0116"> <h4 class="title">Different types of beta‐blockers</h4> <p>We accepted any type of beta‐blocker as an experimental intervention (non‐selective beta‐blockers, selective beta₁‐blockers, and combined non‐selective alpha‐ and beta‐blockers). Theoretically, these different types of beta‐blockers have different effects. We systematically assessed the degree of heterogeneity in all meta‐analyses, and we carefully planned subgroup analyses comparing effects of different types of beta‐blockers. None of the subgroup analyses comparing different types of beta‐blockers at maximum follow‐up showed any evidence of a difference when different types of beta‐blockers were compared. However, it is a potential limitation that the different types of beta‐blockers included might have different effects, and that these different effects might bias our results. </p> </section> <section id="CD012565-sec-0117"> <h4 class="title">Cluster randomised trials</h4> <p>We did not include cluster randomised trials because such results will never have the same validity as results from individually randomised clinical trials. However, it is a limitation of our review that we did not include cluster randomised trials because if such trials exist at low risk of bias, it would have been important to include these results in our review. Therefore, in future updates of our review, we will include cluster randomised trials. </p> </section> </section> <section id="CD012565-sec-0118"> <h3 class="title" id="CD012565-sec-0118">Agreements and disagreements with other studies or reviews</h3> <p>We have identified several reviews assessing the effects of beta‐blockers versus control in patients without heart failure after myocardial infarction. Only one of these reviews systematically assessed risks of random errors and employed adequate assessments of risks of bias using some of the Cochrane domains (<a href="./references#CD012565-bbs2-0042" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. American Journal of Medicine2014;127(10):939-53. [PMID: 24927909]">Bangalore 2014</a>); the rest performed no risk of bias assessment ‐ <a href="./references#CD012565-bbs2-0092" title="LewisJA . Beta-blockade after myocardial infarction - a statistical view. British Journal of Clinical Pharmacology1982;14 Suppl 1:15S-21S. [PMID: 6126204]">Lewis 1982</a>; <a href="./references#CD012565-bbs2-0149" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335-71. [PMID: 2858114]">Yusuf 1985</a> ‐ or only a limited risk of bias assessment (<a href="./references#CD012565-bbs2-0061" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ (Clinical Research Ed)1999;318(7200):1730-7. [PMID: 10381708]">Freemantle 1999</a>). </p> <p><a href="./references#CD012565-bbs2-0092" title="LewisJA . Beta-blockade after myocardial infarction - a statistical view. British Journal of Clinical Pharmacology1982;14 Suppl 1:15S-21S. [PMID: 6126204]">Lewis 1982</a> assessed patients with myocardial infarction and without heart failure and distinguished between early (within 48 hours) and late intervention. This review showed evidence of a highly beneficial effect of beta‐blockade on all‐cause mortality when late‐entry trials were assessed (risk ratio (RR) 0.74, 95% confidence interval (CI) 0.65 to 0.83; P &lt; 0.00001). Review authors did not control for risks of random error. </p> <p><a href="./references#CD012565-bbs2-0149" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335-71. [PMID: 2858114]">Yusuf 1985</a> assessed effects of beta‐blockers on all‐cause mortality at short‐term and long‐term treatment with beta‐blockers for patients without heart failure. However, two trials in which participants had heart failure were included in the short‐term treatment. This review showed evidence of a beneficial effect of long‐term treatment with beta‐blockers on total mortality and sudden death. Furthermore, a reduction in non‐fatal reinfarction was found at long‐term treatment with beta‐blockers (odds ratio (OR) 0.74, 95% CI 0.66 to 0.83; P &lt; 0.0001). Review authors did not control for risks of random error. </p> <p><a href="./references#CD012565-bbs2-0061" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ (Clinical Research Ed)1999;318(7200):1730-7. [PMID: 10381708]">Freemantle 1999</a> assessed patients who had had a myocardial infarction with or without heart failure for whom treatment with any type of beta‐blocker was started at any stage before or after the myocardial infarction. This review found evidence of a beneficial effect on mortality (OR 0.77, 95% CI 0.69 to 0.85) and reinfarction at long‐term treatment with beta‐blockers. Review authors did not control for risks of random error. </p> <p><a href="./references#CD012565-bbs2-0042" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. American Journal of Medicine2014;127(10):939-53. [PMID: 24927909]">Bangalore 2014</a> assessed participants with myocardial infarction and without heart failure in the acute and subacute phases of a myocardial infarction. This review distinguished between pre‐reperfusion and reperfusion eras (when &gt; 50% of patients received reperfusion with thrombolytics or with revascularisation or aspirin/statin), and all included trials conducted in the reperfusion era included participants in the acute phase of a myocardial infarction. In the pre‐reperfusion era, beta‐blockers were associated with a statistically significant reduction in mortality (incidence rate ratio (IRR) 0.79, 95% CI 0.70 to 0.89), cardiovascular mortality, and myocardial infarction in post‐myocardial infarction trials. In the reperfusion era, beta‐blockers were associated with no beneficial effect except for myocardial infarction. However, a significant increase in heart failure and drug discontinuation was found in both eras in post‐myocardial infarction trials. </p> <p>Our present review results, when all‐cause mortality was assessed, are in agreement with those of <a href="./references#CD012565-bbs2-0092" title="LewisJA . Beta-blockade after myocardial infarction - a statistical view. British Journal of Clinical Pharmacology1982;14 Suppl 1:15S-21S. [PMID: 6126204]">Lewis 1982</a>, <a href="./references#CD012565-bbs2-0149" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335-71. [PMID: 2858114]">Yusuf 1985</a>, and <a href="./references#CD012565-bbs2-0061" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ (Clinical Research Ed)1999;318(7200):1730-7. [PMID: 10381708]">Freemantle 1999</a> ‐ all showing that beta‐blockers seem to have a beneficial effect on the risk of all‐cause mortality. The same is seen in <a href="./references#CD012565-bbs2-0042" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. American Journal of Medicine2014;127(10):939-53. [PMID: 24927909]">Bangalore 2014</a> for the pre‐reperfusion era, where a beneficial effect on all‐cause mortality was found when post‐myocardial infarction trials were assessed. As only one of the included trials was conducted in the reperfusion era and included participants undergoing percutaneous coronary intervention (PCI), we could not assess the effects of beta‐blockers in the reperfusion era. </p> <p>No other review assessed our composite outcome 'major cardiovascular events'. However, when we assessed each component separately, our review result was in agreement with those of <a href="./references#CD012565-bbs2-0149" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335-71. [PMID: 2858114]">Yusuf 1985</a>, <a href="./references#CD012565-bbs2-0061" title="FreemantleN , ClelandJ , YoungP , MasonJ , HarrisonJ . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ (Clinical Research Ed)1999;318(7200):1730-7. [PMID: 10381708]">Freemantle 1999</a>, and <a href="./references#CD012565-bbs2-0042" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. American Journal of Medicine2014;127(10):939-53. [PMID: 24927909]">Bangalore 2014</a> ‐ all showing that beta‐blockers seem to have beneficial effects on cardiovascular mortality and myocardial infarction. However, <a href="./references#CD012565-bbs2-0042" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. American Journal of Medicine2014;127(10):939-53. [PMID: 24927909]">Bangalore 2014</a> did not find this beneficial effect in the reperfusion era. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012565-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012565-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012565-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012565-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 All‐cause mortality at maximum follow‐up, outcome: 1.1 All‐cause mortality." data-id="CD012565-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 All‐cause mortality at maximum follow‐up, outcome: 1.1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 All‐cause mortality at maximum follow‐up, outcome: 1.1 All‐cause mortality." data-id="CD012565-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 All‐cause mortality at maximum follow‐up, outcome: 1.1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Major adverse cardiovascular events (MACE) at maximum follow‐up, outcome: 2.1 MACE (major cardiovascular events)." data-id="CD012565-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Major adverse cardiovascular events (MACE) at maximum follow‐up, outcome: 2.1 MACE (major cardiovascular events). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Major adverse cardiovascular events (MACE) at maximum follow‐up, outcome: 2.1 MACE (major cardiovascular events)." data-id="CD012565-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Major adverse cardiovascular events (MACE) at maximum follow‐up, outcome: 2.1 MACE (major cardiovascular events). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Forest plot of 3.1 Angina pectoris on a dichotomous scale.*E.I.S 1984: angina defined as angina events that required a change in treatment." data-id="CD012565-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-08.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of 3.1 Angina pectoris on a dichotomous scale.</p> <p>*E.I.S 1984: angina defined as angina events that required a change in treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 Cardiovascular mortality at maximum follow‐up, outcome: 4.1 Cardiovascular mortality." data-id="CD012565-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-09.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 Cardiovascular mortality at maximum follow‐up, outcome: 4.1 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 4 Cardiovascular mortality at maximum follow‐up, outcome: 4.1 Cardiovascular mortality." data-id="CD012565-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Funnel plot of comparison: 4 Cardiovascular mortality at maximum follow‐up, outcome: 4.1 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 5 Myocardial reinfarction at maximum follow‐up, outcome: 5.1 Myocardial infarction." data-id="CD012565-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-11.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Forest plot of comparison: 5 Myocardial reinfarction at maximum follow‐up, outcome: 5.1 Myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Myocardial reinfarction at maximum follow‐up, outcome: 5.1 Myocardial infarction." data-id="CD012565-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-FIG-12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Myocardial reinfarction at maximum follow‐up, outcome: 5.1 Myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-FIG-12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 1: All‐cause mortality" data-id="CD012565-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 1: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 2: All‐cause mortality ‐ Type of beta‐blocker" data-id="CD012565-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 2: All‐cause mortality ‐ Type of beta‐blocker </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 3: All‐cause mortality ‐ Different follow‐up" data-id="CD012565-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 3: All‐cause mortality ‐ Different follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 4: All‐cause mortality ‐ Registration status" data-id="CD012565-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 4: All‐cause mortality ‐ Registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 5: All‐cause mortality ‐ Industry vs non‐industry funding" data-id="CD012565-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 5: All‐cause mortality ‐ Industry vs non‐industry funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 6: All‐cause mortality ‐ Subacute vs non‐acute phase" data-id="CD012565-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 6: All‐cause mortality ‐ Subacute vs non‐acute phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 7: All‐cause mortality ‐ Heart failure vs no heart failure" data-id="CD012565-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 7: All‐cause mortality ‐ Heart failure vs no heart failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 8: All‐cause mortality ‐ 'Best‐worst case scenario'" data-id="CD012565-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 8: All‐cause mortality ‐ 'Best‐worst case scenario' </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 9: All‐cause mortality ‐ 'Worst‐best case scenario'" data-id="CD012565-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: All‐cause mortality at maximum follow‐up, Outcome 9: All‐cause mortality ‐ 'Worst‐best case scenario' </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 1: MACE (major cardiovascular events)" data-id="CD012565-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 1: MACE (major cardiovascular events) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 2: MACE (major cardiovascular events) ‐ Type of beta‐blocker" data-id="CD012565-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 2: MACE (major cardiovascular events) ‐ Type of beta‐blocker </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 3: MACE (major cardiovascular events) ‐ Different follow‐up" data-id="CD012565-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 3: MACE (major cardiovascular events) ‐ Different follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 4: MACE (major cardiovascular events) ‐ Registration status" data-id="CD012565-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 4: MACE (major cardiovascular events) ‐ Registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 5: MACE (major cardiovascular events) ‐ Industry vs non‐industry funding" data-id="CD012565-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 5: MACE (major cardiovascular events) ‐ Industry vs non‐industry funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 6: MACE (major cardiovascular events) ‐ Subacute vs non‐acute phase" data-id="CD012565-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 6: MACE (major cardiovascular events) ‐ Subacute vs non‐acute phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 7: MACE (major cardiovascular events) ‐ Heart failure vs no heart failure" data-id="CD012565-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 7: MACE (major cardiovascular events) ‐ Heart failure vs no heart failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 8: MACE (major cardiovascular events) ‐ 'Best‐worst case scenario'" data-id="CD012565-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 8: MACE (major cardiovascular events) ‐ 'Best‐worst case scenario' </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 9: MACE (major cardiovascular events) ‐ 'Worst‐best case scenario'" data-id="CD012565-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Major adverse cardiovascular events (MACE) at maximum follow‐up, Outcome 9: MACE (major cardiovascular events) ‐ 'Worst‐best case scenario' </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Angina pectoris at maximum follow‐up, Outcome 1: Angina pectoris on a dichotomous scale" data-id="CD012565-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Angina pectoris at maximum follow‐up, Outcome 1: Angina pectoris on a dichotomous scale </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Angina pectoris at maximum follow‐up, Outcome 2: Angina pectoris on a dichotomous scale ‐ 'Best‐worst case scenario'" data-id="CD012565-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Angina pectoris at maximum follow‐up, Outcome 2: Angina pectoris on a dichotomous scale ‐ 'Best‐worst case scenario' </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Angina pectoris at maximum follow‐up, Outcome 3: Angina pectoris on a dichotomous scale ‐ 'Worst‐best case scenario'" data-id="CD012565-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Angina pectoris at maximum follow‐up, Outcome 3: Angina pectoris on a dichotomous scale ‐ 'Worst‐best case scenario' </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 1: Cardiovascular mortality" data-id="CD012565-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 1: Cardiovascular mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 2: Cardiovascular mortality ‐ Type of beta‐blocker" data-id="CD012565-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 2: Cardiovascular mortality ‐ Type of beta‐blocker </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 3: Cardiovascular mortality ‐ Different follow‐up" data-id="CD012565-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 3: Cardiovascular mortality ‐ Different follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 4: Cardiovascular mortality ‐ Registration status" data-id="CD012565-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 4: Cardiovascular mortality ‐ Registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 5: Cardiovascular mortality ‐ Industry vs non‐industry funding" data-id="CD012565-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 5: Cardiovascular mortality ‐ Industry vs non‐industry funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 6: Cardiovascular mortality ‐ Subacute vs non‐acute phase" data-id="CD012565-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 6: Cardiovascular mortality ‐ Subacute vs non‐acute phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 7: Cardiovascular mortality ‐ Heart failure vs no heart failure" data-id="CD012565-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 7: Cardiovascular mortality ‐ Heart failure vs no heart failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 8: Cardiovascular mortality ‐ 'Best‐worst case scenario'" data-id="CD012565-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 8: Cardiovascular mortality ‐ 'Best‐worst case scenario' </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 9: Cardiovascular mortality ‐ 'Worst‐best case scenario'" data-id="CD012565-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Cardiovascular mortality at maximum follow‐up, Outcome 9: Cardiovascular mortality ‐ 'Worst‐best case scenario' </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 1: Myocardial infarction" data-id="CD012565-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 1: Myocardial infarction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 2: Myocardial infarction ‐ Type of beta‐blocker" data-id="CD012565-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 2: Myocardial infarction ‐ Type of beta‐blocker </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 3: Myocardial infarction ‐ Different follow‐up" data-id="CD012565-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 3: Myocardial infarction ‐ Different follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 4: Myocardial infarction ‐ Registration status" data-id="CD012565-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 4: Myocardial infarction ‐ Registration status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 5: Myocardial infarction ‐ Industry vs non‐industry funding" data-id="CD012565-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 5: Myocardial infarction ‐ Industry vs non‐industry funding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 6: Myocardial infarction ‐ Subacute vs non‐acute phase" data-id="CD012565-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 6: Myocardial infarction ‐ Subacute vs non‐acute phase </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 7: Myocardial reinfarction ‐ Heart failure vs no heart failure" data-id="CD012565-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 7: Myocardial reinfarction ‐ Heart failure vs no heart failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 8: Myocardial infarction ‐ 'Best‐worst case scenario'" data-id="CD012565-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 8: Myocardial infarction ‐ 'Best‐worst case scenario' </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012565-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/urn:x-wiley:14651858:media:CD012565:CD012565-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 9: Myocardial infarction ‐ 'Worst‐best case scenario'" data-id="CD012565-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_t/tCD012565-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Myocardial reinfarction at maximum follow‐up, Outcome 9: Myocardial infarction ‐ 'Worst‐best case scenario' </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/media/CDSR/CD012565/image_n/nCD012565-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012565-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings at maximum follow‐up</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beta‐blockers compared with placebo or no intervention for patients after an acute myocardial infarction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients without heart failure </p> <p><b>Settings:</b> any setting </p> <p><b>Intervention:</b> beta‐blockers </p> <p><b>Comparison:</b> placebo or no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo or no intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Beta‐blockers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality at maximum follow‐up</b> (mean follow‐up 24.9 months; range 9 to 60 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.81</b> </p> <p>97.5% CI (0.73 to 0.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>22,085</p> <p>(21 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup> </sup><br/><b>Moderate</b><sup>a</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Absolute risk for mortality at maximum follow‐up was 8.7% in the beta‐blocker group compared with 10.9% in the control group, and the NNT was 46 participants </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b><br/>(81 to 97) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major cardiovascular events (cardiovascular mortality or non‐fatal myocardial infarction) at maximum follow‐up</b> (mean follow‐up 26.3 months; range 9 to 48 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.72</b> </p> <p>97.5% CI (0.62 to 0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14,994</p> <p>(15 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<sup> </sup><br/>L<b>ow</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Absolute risk for major cardiovascular events at maximum follow‐up was 10.3% in the beta‐blocker group compared with 14.0% in the control group, and the NNT was 23 participants </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>140 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>103 per 1000</b><br/>(97 to 118) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events at maximum follow‐up</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>No trials reported serious adverse events according to ICH‐GCP</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>No trials reported quality of life on a continuous or any other scale</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Angina pectoris at maximum follow‐up</b> (mean follow‐up 10 months; range 12 to 47 months) </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.04</b> </p> <p>98% CI (0.95 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7715</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<sup> </sup><br/>L<b>ow</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Absolute risk for angina at maximum follow‐up was 26.4% in the beta‐blocker group compared with 25.6% in the control group, and the NNT was 125 participants </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>256 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>264 per 1000</b><br/>(238 to 289) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular mortality at maximum follow‐up</b> (mean follow‐up 28.8 months; range 9 to 48 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.73</b> </p> <p>98% CI (0.61 to 0.88)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>21,763</p> <p>(19 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<sup> </sup><br/>L<b>ow</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Absolute risk for cardiovascular mortality at maximum follow‐up was 6.0% in the beta‐blocker group compared with 8.0% in the control group, and the NNT was 50 participants </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b><br/>(54 to 68) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Myocardial infarction at maximum follow‐up</b> (mean follow‐up 33.3 months; range 9 to 48 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.76</b> </p> <p>98% CI (0.67 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>19,606</p> <p>(19 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<sup> </sup><br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Absolute risk for myocardial infarction at maximum follow‐up was 5.9% in the beta‐blocker group compared with 7.8% in the control group, and the NNT was 53 participants </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>59 per 1000</b><br/>(54 to 69) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 97.5% or 98% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 97.5% or 98% CI).<br/><b>CI:</b> confidence interval; <b>ICH‐GCP:</b> International Committee for Harmonization of Technical Requirements for Pharmaceuticals for Human Use; <b>NNT:</b> number needed to treat; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to risk of bias. All included trials were at high risk of bias due to unclear or high risk in several bias domains. None of the included trials were at low risk of bias. </p> <p><sup>b</sup>Downgraded by one level due to risk of inconsistency based on a moderate I²(30% to 60%) with a small P value (P &lt; 0.05) when the statistical test was assessed for heterogeneity. </p> <p><sup>c</sup>Downgraded by one level due to risk of imprecision based on optimal information size not being reached, absolute and relative 98% CIs showing both appreciable benefit and harm, and sample size being small. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings at maximum follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012565-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Detailed description of heart failure in the included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition of heart failure in the exclusion criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Digitalis and diuretics at discharge</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of patients with HF included</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0001" title="AdesPA , ThomasJD , HansonJS , ShapiroSM , LaMountainJ . Effect of metoprolol on the submaximal stress test performed early after acute myocardial infarction. American Journal of Cardiology1987;60(13):963-6. ">Ades 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically overt heart failure (raies, third heart sound)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 patients on digitalis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0002" title="AhlmarkG , SaetreH , KorsgrenM . Reduction of sudden deaths after myocardial infarction. Lancet1974;2(7896):1563. AhlmarkG , SaetreH . Long-term treatment with beta-blockers after myocardial infarction. European Journal of Clinical Pharmacology1976;10(2):77-83. AhlmarkG , SaetreH . Positon of myocardial infarct and results of alprenolol treatment. BMJ1976;1(6013):837. ">Ahlmark 1976</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac decompensation despite adequate therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>On discharge, 50% in the alprenolol group and 46% in the control group were receiving digitalis, and 26% in the </p> <p>alprenolol group and 31% in the control group were taking diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0003" title="AhnveS , ErhardtL , LundmanT , RehnqvistN , SjögrenA . Effect of metoprolol on QTc intervals after acute myocardial infarction. Acta Medica Scandinavica1980;208(3):223-8. ">Ahnve 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe heart failure (no further description given)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 patients from the experimental group and 11 patients from the control group were on digitalis at discharge or during follow‐up </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0004" title="YusufS , PetoR , LewisJ , CollinsR , SleightP . Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases1985;27(5):335-71. ">Amsterdam Metoprolol Trial 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded patients with NYHA Class III/IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0005" title="BoisselJP , LeizoroviczA , PicoletH , DucruetT . Efficacy of acebutolol after acute myocardial infarction (the APSI trial). American Journal of Cardiology1990;66(9):24C-31C. BoisselJP , LeizoroviczA , PicoletH , PeyrieuxJC . Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. American Journal of Cardiology1990;66(3):251-60. CucheratM , BoisselJP , LeizoroviczA . Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction. American Journal of Cardiology1997;79(5):587-9. ">APSI 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute heart failure that required treatment with &gt; 2 drugs of different classes (e.g. diuretics, vasodilators). If the condition disappeared before the twenty‐second day, the patient could be included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No description of patients taking diuretics and digitalis; only nifedipine was allowed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 50% of patients had acute heart failure at the time of inclusion in the study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0006" title="Australian and Swedish Pindolol Study Group. The effect of pindolol on the two years mortality after complicated myocardial infarction. European Heart Journal1983;4(6):367-75. ">Australien &amp; Swedish 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled heart failure (no further description given)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86/266 from the control group and 81/263 from the experimental group were on digitalis at discharge. 111/266 from the control group and 120/263 from the experimental group were on diuretics at the time of discharge </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160/266 from the control group and 162/263 from the experimental group had left ventricular failure during hospitalisation and before randomisation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0007" title="BaberNS , EvansDW , HowittG , ThomasM , WilsonC , LewisJA , et al. Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy, and Yugoslavia. British Heart Journal1980;44(1):96-100. ">Baber 1980</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Persistent heart failure (no further description given)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 20% of patients in both groups had cardiac failure in the acute phase. Patients with heart failure were withdrawn from the study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0008" title="BarvikS , DicksteinK , AarslandT , Vik-MoH . Effect of timolol on cardiopulmonary exercise performance in men after myocardial infarction. American Journal of Cardiology1982;69(3):163-8. ">Barvik 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical signs of congestive heart failure. Included patients with NYHA Class I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0009" title="WuN , FanZ . Secondary prevention of cardiac events following myocardial infarction: effects of atenolol and enalapril. American Journal of Cardiology1997;110(8):602-6. ">BCSG 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients with contraindications to beta‐blockers. However, all patients had LVEF &gt; 40% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0010" title="Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA1983;250(20):2814-9. ByingtonRP , Beta-Blocker Heart Attack Trial Research Group. Beta-blocker heart attack trial: design, methods, and baseline results. Control Clinical Trials1984;5(4):382-437. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. American Journal of Cardiology1990;66(2):129-33. GheorghiadeM , SchultzL , TilleyB , KaoW , GoldsteinS . Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1991;122(6):1548-53. GheorghiadeM , ShivkumarK , SchultzL , JafriS , TilleyB , GoldsteinS . Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. American Heart Journal1993;126(2):271-8. GoldsteinS , ByingtonR . The Beta Blocker Heart Attack Trial: recruitment experience. Controlled Clinical Trials1987;8(4 Suppl):79S-85S. KostisJB , ByingtonR , FriedmanLM , GoldsteinS , FurbergC . Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. Journal of the American College of Cardiology1987;10(2):231-42. National Heart, Lung, and Blood Institute. Beta-blocker heart attack trial study protocol [https://babel.hathitrust.org/cgi/pt?id=pur1.32754081210092;view=1up;seq=3]. U.S. Depeartment of Health and Human Services. Public Health Service, National Institues of Health1978;81-2209. PetersRW , ByingtonR , ArensbergD , FriedmanLM , RomhiltDW , BarkerA , et al. Mortality in the beta blocker heart attack trial: circumstances surrounding death. Journal of Chronic Diseases1987;40(1):75-82. ShivkumarK , SchultzL , GoldsteinS , GheorghiadeM . Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. American Heart Journal1998;135(2 Pt 1):261-7. The Beta-blocker Heart Attack Trial (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. JAMA1982;247(12):1707-14. The Beta Blocker Heart Attack Trial Research Group. Beta blocker heart attack trial: design features. Controlled Clinical Trials1981;2(4):275-85. ">BHAT 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>History of severe congestive heart failure (no further description given)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 17% of patients were on diuretics and 12.5% were on digitalis on the time of randomisation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 14.5% of patients in each group had congestive heart failure during hospitalisation and before randomisation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0011" title="WatanabeH , OzasaN , MorimotoT , ShiomiH , BingyuanB , SuwaS , et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PloS One2018;13(8):e0199347. [PMID: 30153268]">Capital‐RCT 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduced LVEF (LVEF &lt; 40%), symptomatic HF. Included Killip class I/II with preserved ejection fraction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No patients received digitalis or diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0012" title="CurtisJL , HoughtonJL , PattersonJH , KochG , BradleyDA , Adams KF Jr. Propranolol therapy alters estimation of potential cardiovascular risk derived from submaximal postinfarction exercise testing. American Heart Journal1991;121(6 Pt 1):1655-64. ">Curtis 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients were excluded if they could not safely undergo exercise testing due to persistent heart failure </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0013" title="BethgeKP , AndresenD , BoisselJP , LeitnerER , PeyrieuxJC , SchröderR , et al. Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. Journal of the American College of Cardiology1985;6(5):963-72. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. European Heart Journal1984;5:189-202. The European Infarction Study Group. A secondary prevention study with slow release oxprenolol after myocardial infarction. European Heart Journal1982;3:583-6. ">E.I.S. 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heart failure (no further description given)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13% of patients in each group had left heart failure during the acute myocardial infarction, but none were noted to have heart failure at the time of randomisation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0014" title="JulianDG , PrescottRJ , JacksonFS , SzekelyP . Controlled trial of sotalol for one year after myocardial infarction. Lancet1982;1(8282):1142-7. ">Julian 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical evidence of heart failure at the 12th post‐infarction day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 21.5% in each group had heart failure during the acute phase</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0015" title="Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. European Heart Journal1987;8:1056-64. ">LIT 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Congestive heart failure (no further description given)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 6% in each group had moderate to severe CHF between admission and pre‐entry</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0016" title="MazurNA , KulginskayaIV , IvanovaLA , Ostrov SkayaTP , SmirnovaTM , SvetEA , et al. Results of long-term propranolol treatment in myocardial infarction survivors with advanced grades of ventricular extrasystoles. Cor et Vasa1984;26(4):241-7. ">Mazur 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Contraindications to beta‐blockers. No further definition given. However, <a href="./references#CD012565-bbs2-0042" title="BangaloreS , MakaniH , RadfordM , ThakurK , TokluB , KatzSD , et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials. American Journal of Medicine2014;127(10):939-53. [PMID: 24927909]">Bangalore 2014</a>, which excluded trials with post‐myocardial infarction heart failure or left ventricular systolic dysfunction, included this trial </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0017" title="MazzueroG , GaldangeloF , ZottiAM , BertolottiG , TavazziL . Effects of propranolol, atenolol, and chlordesmethyldiazepam on response to mental stress in patients with recent myocardial infarction. Clinical Cardiology1987;10(6):293-302. ">Mazzuero 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded patients treated with digitalis and NYHA III/IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0018" title="A Multicentre International Study Group. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. BMJ1975;3:735-40. The Multicentre International Study Group. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. BMJ1977;2:419-21. ">MIS 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence of congestive heart failure at proposed date of entry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients with cardiac failure during follow‐up were withdrawn from trial medication</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0019" title="BellinEY , The Nowergian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on timolol after myocardial infarction. 1986;314(16):1052-3. Lund-Johansen, The Norwegian Multicenter Study Group. The Norwegian multicenter study on timolol after myocardial infarction. Part II. Effect in different risk groups, causes of death, heart arrest, reinfarctions, rehospitalizations and adverse experiences. Acta Medica Scandinavica1981;651:243-52. PedersenTR , The Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. New England Journal of Medicine1985;313(17):1055-8. The Norwegian Multicenter Study Group. The Norwegian multicenter study on timolol after myocardial infarction. Acta Medica Scandinavica1981;651:235-41. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New England Journal of Medicine1981;304(14):801-7. ">NMS 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uncontrolled cardiac failure. Included Killip class I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 33% of patients in each group had heart failure at randomisation and before treatment initiation. </p> <p>Heart failure and pulmonary oedema were reasons for withdrawal only if treatment with digitalis and diuretics did not effect satisfactory improvement </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0020" title="HansteenV , MøinichenE , LorentsenE , AndersenA , StrømO , SøilandK , et al. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. BMJ1982;284:155-60. HansteenV . Beta blockade after myocardial infarction: the Norwegian propranolol study in high-risk patients. Circulation1983;67(Suppl 1):I57-60. HansteenV . The Norwegian propranolol trial in selected patients. British Journal of Clinical Pharmacology1982;14:9S-12S. ">NPT 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who presented with heart failure on admission or during the initial phase of infarction were included if signs of failure had disappeared at the time of randomisation. Patients with severe heart failure ‐ that is, cardiogenic shock or pulmonary oedema ‐ and patients who still presented with signs of heart failure at the time of randomisation, although treated with digitalis and furosemide 40 to 80 mg/d, were excluded </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 40% in each group presented with left ventricular failure in the acute phase</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0021" title="OlssonG , LevinLA , RehnqvistN . Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol. British Medical Journal (Clinical Research Edition)1987;294(6568):339-42. OlssonG , LubsenJ , vanEsGA , RehnqvistN . Quality of life after myocardial infarction: effect of long term metoprolol on mortality and morbidity. British Medical Journal (Clinical Research Edition)1986;292(6534):1491-3. OlssonG , OdénA , JohanssonL , SjögrenA , RehnqvistN . Prognosis after withdrawal of chronic postinfarction metoprolol treatment: a 2-7 year follow-up. European Heart Journal1988;9(4):365-72. OlssonG , RehnqvistN , LundmandT , MelcherA . Metoprolol treatment after acute myocardial infarction - Effects on ventricular arrhythmias and exercise tests during 6 months. Acta Medica Scandinavica1981;210(1-2):59-65. OlssonG , RehnqvistN , SjögrenA , ErhardtL , LundmanT . Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. Journal of the American College of Cardiology1985;5(6):1428-37. ">Olsson 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe cardiac failure not responding to conventional treatment with digitalis and diuretic drugs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Around 23.5% in each group were on digitalis at discharge. Around 45% in each group were on diuretics at discharge </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0022" title="PoulsenSH , JensenSE , EgstrupK . Effects of long-term adrenergic beta-blockade on left ventricular diastolic filling in patients with acute myocardial infarction. American Heart Journal1999;138(4 Pt 1):710-20. PoulsenSH , JensenSE , EgstrupK . Improvement of exercise capacity and left ventricular diastolic function with metoprolol XL after acute myocardial infarction. American Heart Journal2000;140(1):E6-11. ">Poulsen 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe uncontrolled congestive heart failure. LVEF &lt; 40%, because it appears that all patients had LVEF &gt; 40% at baseline </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0023" title="SchwartzPJ , MotoleseM , PollaviniG , LottoA , RubertiU , TrazziR , et al. Prevention of sudden cardiac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. Journal of Cardiovascular Electrophysiology1992;3(1):2-16. ">Schwartz 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically overt heart failure (NYHA III and IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0024" title="TaylorSH , SilkeB , EbbuttA , SuttonGC , ProutBJ , BurleyDM . A long-term prevention study with oxprenolol in coronary heart disease. New England Journal of Medicine1982;307(21):1293-301. ">Taylor 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac contraindications to beta‐blockade ‐ i.e. radiographic evidence of heart failure (cardiothoracic ratio &gt; 0.50) or pulmonary venous congestion, resting heart rate &lt; 50 beats per minute, or any grade of heart block </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012565-bbs2-0025" title="VedinA , WilhelmssonC , WerköL . Chronic alprenolol treatment of patients with acute myocardial infarction after discharge from hospital. Acta Medica Scandinavica Supplementum1975;575:3-56. WihelmssonC , VedinA , WilhelmsenL , TibblinG , WerköL , WedelH . Deaths and non-fatal reinfarctions during two years' follow-up. Acta Medica Scandinavica Supplementum1975;575:19-24. WilhelmssonC , VedinJA , WilhelmsenL , TibblinG , WerköL . Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet1974;2(7890):1157-60. ">Wilhelmsson 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac decompensation despite treatment with optimum doses of digitalis and diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>LVEF: left ventricular ejection fraction.</p> <p>NR: not reported.</p> <p>NYHA: New York Heart Association.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Detailed description of heart failure in the included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/full#CD012565-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012565-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">All‐cause mortality at maximum follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.74, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 All‐cause mortality ‐ Type of beta‐blocker <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.74, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Alprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.42, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Acebutolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.64, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Atenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.19, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 Carvedilol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.48, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.5 Metoprolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.67, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.6 Oxprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3817</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.49, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.7 Pindolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.67, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.8 Practolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3053</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.46, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.9 Propranolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.63, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.10 Sotalol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.58, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.11 Timolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1884</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.69, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 All‐cause mortality ‐ Different follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.74, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Between 6 months and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.67, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Between 1 year and 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.67, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 3 years or longer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.72, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 All‐cause mortality ‐ Registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.74, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.60, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.74, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.48, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 All‐cause mortality ‐ Industry vs non‐industry funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Industry‐funded trials or unknown funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.68, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Non‐industry‐funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.59, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 All‐cause mortality ‐ Subacute vs non‐acute phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.70, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Beta‐blockers administered within 7 days following acute myocardial infarction (subacute phase) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.50, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Beta‐blockers administered after 7 days following acute myocardial infarction (non‐acute phase) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.69, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 All‐cause mortality ‐ Heart failure vs no heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.74, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Trials specifically excluding heart failure participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.60, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Trials specifically excluding heart failure participants but likely not adhering to this </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.77, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 All‐cause mortality ‐ 'Best‐worst case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.59, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 All‐cause mortality ‐ 'Worst‐best case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.72, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">All‐cause mortality at maximum follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012565-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Major adverse cardiovascular events (MACE) at maximum follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 MACE (major cardiovascular events) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.63, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 MACE (major cardiovascular events) ‐ Type of beta‐blocker <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.69, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Alprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.12, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Acebutolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.22, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Carvedilol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.42, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.4 Metoprolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.48, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.5 Oxprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2076</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.36, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.6 Pindolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.63, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.7 Practolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3053</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.57, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.8 Propranolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.65, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.9 Sotalol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.58, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 MACE (major cardiovascular events) ‐ Different follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.69, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Between 6 months and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.67, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Between 1 year and 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.64, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 3 years or longer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.28, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 MACE (major cardiovascular events) ‐ Registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.69, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.60, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.66, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.42, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 MACE (major cardiovascular events) ‐ Industry vs non‐industry funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.63, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Industry‐funded trials or unknown funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.64, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Non‐industry‐funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.40, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 MACE (major cardiovascular events) ‐ Subacute vs non‐acute phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.63, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Beta‐blockers administered within 7 days following acute myocardial infarction (subacute phase) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.47, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Beta‐blockers administered after 7 days following acute myocardial infarction (non‐acute phase) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.62, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 MACE (major cardiovascular events) ‐ Heart failure vs no heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.69, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Trials specifically excluding heart failure participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.62, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Trials specifically excluding heart failure participants but likely not adhering to this </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.67, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 MACE (major cardiovascular events) ‐ 'Best‐worst case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.50, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 MACE (major cardiovascular events) ‐ 'Worst‐best case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.68, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Major adverse cardiovascular events (MACE) at maximum follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012565-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Angina pectoris at maximum follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Angina pectoris on a dichotomous scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.96, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Angina pectoris on a dichotomous scale ‐ 'Best‐worst case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.83, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Angina pectoris on a dichotomous scale ‐ 'Worst‐best case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [1.11, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Angina pectoris at maximum follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012565-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Cardiovascular mortality at maximum follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.63, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Cardiovascular mortality ‐ Type of beta‐blocker <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.63, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Atenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.19, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Acebutolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.22, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.3 Alprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.02, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.4 Carvedilol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.37, 3.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.5 Metoprolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.67, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.6 Oxprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3817</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.45, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.7 Pindolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.63, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.8 Practolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3053</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.43, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.9 Propranolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.56, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.10 Sotalol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.58, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.11 Timolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1884</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.45, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Cardiovascular mortality ‐ Different follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.63, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Between 6 months and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5778</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.60, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Between 1 year and 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.57, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 3 years or longer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.37, 3.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Cardiovascular mortality ‐ Registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.63, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.60, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.60, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.37, 3.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Cardiovascular mortality ‐ Industry vs non‐industry funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.64, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Industry‐funded trials or unknown funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.65, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Non‐industry‐funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.36, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Cardiovascular mortality ‐ Subacute vs non‐acute phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.60, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Beta‐blockers administered within 7 days following acute myocardial infarction (subacute phase) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.40, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 Beta‐blockers administered after 7 days following acute myocardial infarction (non‐acute phase) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.59, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Cardiovascular mortality ‐ Heart failure vs no heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.63, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Trials specifically excluding heart failure participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.48, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 Trials specifically excluding heart failure participants but likely not adhering to this </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.66, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Cardiovascular mortality ‐ 'Best‐worst case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.60, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Cardiovascular mortality ‐ 'Worst‐best case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.63, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Cardiovascular mortality at maximum follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012565-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Myocardial reinfarction at maximum follow‐up</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.69, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Myocardial infarction ‐ Type of beta‐blocker <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.68, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Alprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.40, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Acebutolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.36, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 Atenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.44, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.4 Carvedilol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.27, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.5 Metoprolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.45, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.6 Oxprenolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3817</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.62, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.7 Pindolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.61, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.8 Practolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3053</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.57, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.9 Propranolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.69, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.10 Sotalol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.36, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.11 Timolol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1884</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.48, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Myocardial infarction ‐ Different follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.68, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Between 6 months and 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.66, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Between 1 year and 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.65, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.3 3 years or longer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.27, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Myocardial infarction ‐ Registration status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.68, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Post‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.64, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 No registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.66, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.3 Pre‐registration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.27, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Myocardial infarction ‐ Industry vs non‐industry funding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.66, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Industry‐funded trials or unknown funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.67, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 Non‐industry‐funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.39, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Myocardial infarction ‐ Subacute vs non‐acute phase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.66, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 Beta‐blockers administered within 7 days following acute myocardial infarction (subacute phase) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.51, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 Beta‐blockers administered after 7 days following acute myocardial infarction (non‐acute phase) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.66, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Myocardial reinfarction ‐ Heart failure vs no heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.68, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.1 Trials specifically excluding heart failure participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.62, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.2 Trials specifically excluding heart failure participants but likely not adhering to this </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.67, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Myocardial infarction ‐ 'Best‐worst case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.54, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Myocardial infarction ‐ 'Worst‐best case scenario' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.71, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Myocardial reinfarction at maximum follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012565.pub2/references#CD012565-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012565.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012565-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012565-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012565-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012565-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012565-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012565-note-0008">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012565-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012565-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012565\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012565\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012565\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012565\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012565\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012565.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012565.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012565.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012565.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012565.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718841765"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012565.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718841769"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012565.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dda2b2b5c935f',t:'MTc0MDcxODg0Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 